"In this multicenter, double-blind, parallel-group study, 218 patients with CHF (New York Heart Association class II or III) with impaired left ventricular function (ejection fraction 40%) and pulmonary capillary wedge pressure 13 mm Hg were randomly assigned to 12 weeks of treatment with placebo (n =44) or candesartan cilexetil (2 mg [n = 45], 4 mg [n = 46], 8 mg [n = 39], or 16 mg [n = 44]) once daily after a 2-week placebo run-in period.",multicenter double-blind parallel-group study 218 patients chf york heart association class ii iii impaired left ventricular function ejection fraction 40% pulmonary capillary wedge pressure 13 mm hg randomly assigned 12 weeks treatment placebo =44 candesartan cilexetil 2 = 45 4 = 46 8 = 39 16 = 44 daily 2-week placebo run-in period,C0439743|C0013072|C2348042|C0557651|C1442061|C0030705|C0018802|G0000000|C0018787|C0004083|C0456387|G0000000|C0439070|C0221099|C0205091|C0018827|C0031843|C0302131|C1264633|C0450371|C0024109|C0006901|C0439639|C0033095|C0450371|G0000000|C0025424|G0000000|C1516050|C0450371|C0439230|C0039798|C0032042|C0450371|C0717550|G0000000|G0000000|G0000000|C0450371|G0000000|G0000000|C0450371|G0000000|G0000000|C0450371|C0450371|G0000000|C0450371|C0332173|C0332174|C0032042|C3274438|C0439531
Three thousand ten patients with operable node-positive breast cancer were randomly assigned to receive adjuvant anthracycline-based chemotherapy with or without docetaxel.,ten patients operable node-positive breast cancer randomly assigned receive adjuvant anthracycline-based chemotherapy docetaxel,C0014518|C0030705|C0205188|C0746319|C0006141|C0006826|G0000000|C1516050|C1514756|C0001551|C0003234|C0013216|C0246415
"Each patient received an infusion of either IVIG or placebo (4% dextrose, 0.18% normal saline) at a dose of 1 g/kg on days 0 and 1 (maximum, 60 g) and then 0.4 mg/kg on days 14 and 28.",patient received infusion ivig placebo 4% dextrose 018% normal saline dose 1 g/kg days 0 1 maximum 60 04 mg/kg days 14 28,C0030705|C1514756|C0574032|C0085297|C0032042|G0000000|C0017725|C1442061|C0205307|C0036082|C0178602|G0000000|C1300563|C0439228|G0000000|G0000000|C0806909|C0450371|C0450371|C0439272|C0439228|C0450371|C0450371
"For patients whose study medications were discontinued either permanently or temporarily, 81 (26.8%) discontinued clopidogrel or aspirin patients received nonstudy warfarin, 94 (55.6%) discontinued warfarin patients received nonstudy aspirin, and 72 (48.0%) discontinued clopidogrel patients received nonstudy aspirin.",patients study medications discontinued permanently temporarily 81 268% discontinued clopidogrel aspirin patients received nonstudy warfarin 94 556% discontinued warfarin patients received nonstudy aspirin 72 480% discontinued clopidogrel patients received nonstudy aspirin,C0030705|C0557651|C0013227|C1444662|G0000000|G0000000|C0450371|C1442061|C1444662|C0070166|C0004057|C0030705|C1514756|G0000000|C0043031|C0450371|C1442061|C1444662|C0043031|C0030705|C1514756|G0000000|C0004057|C0450371|C1442061|C1444662|C0070166|C0030705|C1514756|G0000000|C0004057
"Regarding cardiac toxicity, trastuzumab treatment was stopped if LVEF dropped below 45%, or if LVEF was between 45% and 50% together with a relative decrease of 15% or more.",cardiac toxicity trastuzumab treatment stopped lvef dropped 45% lvef 45% 50% relative decrease 15%,C0018787|C0040539|C0728747|C0039798|C1272691|C0428772|C1705648|C0450371|C0428772|C0450371|C0450371|C0080103|C0392756|C0450371
"A limitation of this study could be that the licensed doses of doxorubicin and epirubin differ; therefore, different (prospectively dened) doses of dexrazoxane had to be administered according to the anthracycline treatment regimen (20:1 dexrazoxane: doxorubicin or 10:1 dexrazoxane:epirubicin dose ratio).",limitation study licensed doses doxorubicin epirubin prospectively dened doses dexrazoxane administered anthracycline treatment regimen 201 dexrazoxane doxorubicin 101 dexrazoxaneepirubicin dose ratio,C0449295|C0557651|C0023636|C0178602|C0013089|G0000000|G0000000|G0000000|C0178602|C0086444|C1521801|C0003234|C0039798|C0040808|C1442061|C0086444|C0013089|C1442061|G0000000|C0178602|C0456603
"Of the 1587 patients randomized, 523 received aspirin, 524 received clopidogrel, and 540 received warfarin.",1587 patients randomized 523 received aspirin 524 received clopidogrel 540 received warfarin,G0000000|C0030705|C0034656|C1442061|C1514756|C0004057|C1442061|C1514756|C0070166|C1442061|C1514756|C0043031
"In a randomized manner, telephone dispatchers gave bystanders at the scene of apparent cardiac arrest instructions in either chest compression alone or chest compression plus mouthto-mouth ventilation.",randomized manner telephone dispatchers bystanders scene apparent cardiac arrest instructions chest compression chest compression mouthto-mouth ventilation,C0034656|G0000000|C0039457|G0000000|G0000000|G0000000|C0750489|C0018787|C0237477|C0302828|C0817096|C0332459|C0817096|C0332459|C0226896|C0035203
The control group received an information session provided by the cardiac rehabilitation coordinator and then follow-up care by either their cardiologist or general practitioner.,control received session provided cardiac rehabilitation coordinator follow-up care cardiologist practitioner,C0243148|C1514756|C1883016|C1999230|C0018787|C0034991|C1711307|C0589120|C1947933|C0175906|C1709627
"The patients were randomly assigned in two groups (N = 10) to receive or not dexrazoxane hydrochloride (Cardioxane, Chiron, Amsterdam, The Netherlands), given intravenously (400 mg/m2) over 15 min, immediately after the cyclophosphamideepirubicin infusion.",patients randomly assigned = 10 receive dexrazoxane hydrochloride cardioxane chiron amsterdam netherlands intravenously 400 mg/m2 15 min cyclophosphamideepirubicin infusion,C0030705|G0000000|C1516050|G0000000|C0450371|C1514756|C0086444|C1512523|C0524711|C1504071|G0000000|C0027778|G0000000|C1442061|C0026410|C0450371|C0702093|G0000000|C0574032
"Either the reversed vein or a stretched thin-walled 6-mm polytetrauoroethylene (W. L. Gore, Flagstaff, Ariz) prosthesis was used.",reversed vein stretched thin-walled 6-mm polytetrauoroethylene gore flagstaff ariz prosthesis,C1555029|C0042449|C1883175|C0205168|G0000000|G0000000|G0000000|G0000000|G0000000|C0175649
A randomized cross-over design was used to determine the effect of a longer KC condition (30 minutes of KC before and throughout heel stick; KC30) and a shorter KC condition (15 minutes of KC before and throughout heel stick; KC15) compared with standard incubator care (IC) during heel stick.,randomized cross-over design determine kc condition 30 minutes kc heel stick kc30 shorter kc condition 15 minutes kc heel stick kc15 compared standard incubator care ic heel stick,C0034656|C0010366|C1707689|G0000000|C0022575|C0012634|C0450371|C0439232|C0022575|C0018870|C1706582|G0000000|C1282927|C0022575|C0012634|C0450371|C0439232|C0022575|C0018870|C1706582|G0000000|C1707455|C1442989|C0021178|C1947933|C0020750|C0018870|C1706582
"The grafts applied were either a 6-mm externally supported thin wall uoropolymer coated knitted polyester (P-EXS) or a 6-mm externally unsupported thin wall knitted polyester (P-non-EXS) (both Fluoropassiv, Sulzer Vascutek, Inchinnan Renfrewshire, Scotland, United Kingdom).",grafts applied 6-mm externally supported thin wall uoropolymer coated knitted polyester p-exs 6-mm externally unsupported thin wall knitted polyester p-non-exs fluoropassiv sulzer vascutek inchinnan renfrewshire scotland united kingdom,C0332835|C4048755|G0000000|C0205101|C1521721|C0205168|C0677535|G0000000|C1522408|C0868977|C0032474|C0369773|G0000000|C0205101|G0000000|C0205168|C0677535|C0868977|C0032474|C0369773|G0000000|G0000000|G0000000|G0000000|G0000000|C0036453|C0166872|C1708611
"20 patients were scheduled to receive 3 g L-carnitine before each chemotherapy cycle, followed by 1 g L-carnitine/day during the following 21 days, while 20 patients received a placebo (randomized controlled trial).",20 patients scheduled receive 3 l-carnitine chemotherapy cycle 1 l-carnitine/day 21 days 20 patients received placebo randomized controlled trial,C0450371|C0030705|C0086960|C1514756|G0000000|C0087163|C0013216|C1511572|G0000000|C0475219|C0450371|C0439228|C0450371|C0030705|C1514756|C0032042|C0034656|C2587213|C0008976
"After the 12-week intervention or control condition, T2 measures were taken at the physical function laboratory, and intervention participants received telephone calls weekly, then bimonthly, and at the end of 3 months to monitor walking progress and or depressive symptoms.",12-week intervention control condition t2 measures physical function laboratory intervention participants received telephone calls weekly bimonthly 3 months monitor walking progress depressive symptoms,C0450371|C0886296|C0243148|C0012634|C0041403|C0079809|C0031809|C0031843|C0022877|C0886296|C0679646|C1514756|C0039457|C0679006|C0332174|C0585337|G0000000|C0439231|C0030695|C0080331|C1272688|G0000000|C0683368
"After 12 weeks, the telephonic feedback was terminated and the patients were advised to continue their training with the heart rate monitor.",12 weeks telephonic feedback terminated patients advised continue training heart rate monitor,C0450371|C0439230|C0039457|C0015744|C1553404|C0030705|G0000000|C0549178|C0040607|C0018787|C0871208|C0030695
"To determine whether dexrazoxane decreases doxorubicin-associated injury of cardiomyocytes, we randomly assigned 101 children with ALL to receive doxorubicin alone (30 mg per square meter of body-surface area every three weeks for 10 doses) and 105 to receive dexrazoxane (300 mg per square meter) followed immediately by doxorubicin.",determine dexrazoxane decreases doxorubicin-associated injury cardiomyocytes randomly assigned 101 children receive doxorubicin 30 square meter body-surface weeks 10 doses 105 receive dexrazoxane 300 square meter doxorubicin,G0000000|C0086444|C0442797|C0013089|C3263722|C0225828|G0000000|C1516050|C1442061|C0008059|C1514756|C0013089|C0450371|C0205120|C0475209|C0489451|C0439230|C0450371|C0178602|C1442061|C1514756|C0086444|C1442061|C0205120|C0475209|C0013089
"In contrast, SSC neonates were placed prone and skin  to skin on their mothers chest in her bed for the rest period.",contrast ssc neonates prone skin skin mothers chest bed rest period,C0009924|C3897657|C0021289|C0033422|C0444099|C0444099|C0026591|C0817096|C0004916|C0035253|C0439531
The 30 patients in group 2 had a reversed L-shaped  ministernotomy from the sternal notch to the 3rd intercostal  space.,30 patients 2 reversed l-shaped ministernotomy sternal notch 3rd intercostal space,C0450371|C0030705|G0000000|C1555029|C0022828|G0000000|C0038293|C1235660|G0000000|G0000000|C1883067
"Patients in the intervention group received an individualized, multidisciplinary 12-week cardiac rehabilitation program, including an individualized exercise component tailored to functional ability and social circumstances.",patients intervention received individualized multidisciplinary 12-week cardiac rehabilitation program including individualized exercise component tailored functional ability social circumstances,C0030705|C0886296|C1514756|C1881197|C0242479|C0450371|C0018787|C0034991|C1709697|C0332257|C1881197|C0015259|C0449432|C0402883|C0205245|C0085732|C0728831|G0000000
"Results: Median dose intensity of epirubicin and paclitaxel was double in group A, as designed, with signicantly less cycles administered at full dose (P < 0.001).",median dose intensity epirubicin paclitaxel double designed signicantly cycles administered dose < 0001,C0549183|C0178602|C0522510|C0014582|C0144576|C0205173|C1707689|G0000000|C1511572|C1521801|C0178602|G0000000|G0000000
"A larger study, the Warfarin Anti-platelet Trial in Chronic Heart Failure (WATCH), comparing warfarin (target INR 3.0), aspirin (160 mg/day), and clopidogrel (75 mg/day), will report soon.23 Clopidogrel exerts its antithrombotic effects through platelet ADP receptors and has no direct effect on prostaglandin synthesis.24 Comparison of aspirin and clopidogrel in this patient population should allow any benet from reducing platelet aggregation to be separated from potential adverse effects of aspirin on vascular wall prostaglandin synthesis.",larger study warfarin anti-platelet trial chronic heart failure watch comparing warfarin target inr 30 aspirin 160 mg/day clopidogrel 75 mg/day report soon23 clopidogrel exerts antithrombotic effects platelet adp receptors direct prostaglandin synthesis24 comparison aspirin clopidogrel patient population benet reducing platelet aggregation separated potential adverse effects aspirin vascular wall prostaglandin synthesis,C0549177|C0557651|C0043031|C0005821|C0008976|C0205191|C0018787|C0231174|C0699864|C1707455|C0043031|C1521840|C0525032|C0450371|C0004057|C1442061|C0439422|C0070166|C0450371|C0439422|C0684224|G0000000|C0070166|C0015264|G0000000|C1280500|C0005821|C0523452|C0597357|C0439851|C0033554|G0000000|C1707455|C0004057|C0070166|C0030705|C0032659|G0000000|C0392756|C0005821|C0332621|C0086972|C3245505|G0000000|C1280500|C0004057|C0005847|C0677535|C0033554|C0220781
"Oral coumarin (Sintrom, Ciba-Geigy) was started the day before the operation and was continued for 6 months, with aim for an international normalized ratio between 2 and 4.",oral coumarin sintrom ciba-geigy started day operation continued 6 months aim international normalized ratio 2 4,C0442027|C0010206|C0919378|C0331935|C1272689|C0332173|C0543467|C0549178|G0000000|C0439231|C1947946|C1512888|C1882115|C0456603|G0000000|G0000000
"Patients were randomly assigned to receive either eprosartan (400 mg daily, given as 200 mg twice daily) or matching placebo.",patients randomly assigned receive eprosartan 400 daily 200 daily matching placebo,C0030705|G0000000|C1516050|C1514756|C0287041|C1442061|C0332173|C1442061|C0332173|C0150103|C0032042
All patients were treated with warfarin.,patients treated warfarin,C0030705|C1522326|C0043031
"Patients,  stratified  for  blocker  use,  were randomly  assigned  losartan  (n=1578) titrated to 50 mg once daily or captopril (n=1574) titrated to  50  mg  three  times  daily.",patients stratified blocker randomly assigned losartan n=1578 titrated 50 daily captopril n=1574 titrated 50 times daily,C0030705|C0205363|G0000000|G0000000|C1516050|C0126174|C0369718|C1883350|C0450371|C0332173|C0006938|C0369718|C1883350|C0450371|C0040223|C0332173
"In general, the program recommended a comprehensive approach to managing the heart condition, that is, using medicines as prescribed, following dietary recommendations, and obtaining adequate exercise.",program recommended comprehensive approach managing heart condition medicines prescribed dietary recommendations obtaining adequate exercise,C1709697|C0034866|C1880156|C0449445|C1273870|C0018787|C0012634|C0013227|C0278329|C0012155|C0034866|C1301820|C0205410|C0015259
"Between January 1999 and July 2001, 80 consecutive patients undergoing elective aortic valve replacement were randomly divided into two groups: group I (n  40 patients) undergoing a ministernotomy approach (reversed-C or reversed-L), and group II (n  40 patients) undergoing conventional sternotomy.",january 1999 july 2001 80 consecutive patients undergoing elective aortic valve replacement randomly divided 40 patients undergoing ministernotomy approach reversed-c reversed-l ii 40 patients undergoing conventional sternotomy,C3829466|G0000000|C3829447|G0000000|C0450371|C1707491|C0030705|G0000000|C0206058|C0003483|C0184252|C0035139|G0000000|C0332849|C0450371|C0030705|G0000000|G0000000|C0449445|C1555029|C1555029|G0000000|C0450371|C0030705|G0000000|C0439858|C0185792
"Accordingly, infants  randomized to the MR group received 0.5, 0.75, and 1 g/kg/min and  those infants randomized to the LEVO group received 0.1, 0.15, and 0.2  g/kg/min, for doses 1, 2, and 3, respectively.",infants randomized received 05 075 1 g/kg/min infants randomized levo received 01 015 02 g/kg/min doses 1 2 3,C0021270|C0034656|C1514756|C0450371|C1442061|G0000000|C1320758|C0021270|C0034656|C0205091|C1514756|C0450371|C1442061|C0450371|C1320758|C0178602|G0000000|G0000000|G0000000
"The RadIal Vs femorAL access for coronary intervention  (RIVAL)  trial was a randomised, parallel group,  multicentre trial.",radial femoral access coronary intervention rival trial randomised parallel multicentre trial,C0442038|C0015811|C0444454|C0018787|C0886296|G0000000|C0008976|G0000000|C2348042|C0439743|C0008976
Methods: We performed a prospective and randomized study in which 408 patients underwent coronary angiography (CAG) and/or percutaneous coronary intervention (PCI) via transradial approach (TRA) and 428 patients underwent CAG and/or PCI via transfemoral approach (TFA).,methods performed prospective randomized study 408 patients underwent coronary angiography cag and/or percutaneous coronary intervention pci transradial approach tra 428 patients underwent cag and/or pci transfemoral approach tfa,C0025663|C0884358|C0023981|C0034656|C0557651|C1442061|C0030705|G0000000|C0018787|C0002978|G0000000|G0000000|C0522523|C0018787|C0886296|C4049621|G0000000|C0449445|C0040845|C1442061|C0030705|G0000000|G0000000|G0000000|C4049621|G0000000|C0449445|C0040982
Above-knee (AK) femoro-popliteal bypass grafting is an effective treatment for either disabling claudication or critical ischaemia.,above-knee ak femoro-popliteal bypass grafting effective treatment disabling claudication critical ischaemia,C1282910|C0001905|C0545765|C0741847|C0332835|C1280519|C0039798|G0000000|C0311395|C1511545|C0022116
"The median chemotherapy duration in our study was 18 weeks, the same in both arms, and the median cumulative dose of all drugs was virtually identical, while, by design, the median DIs of epirubicin and paclitaxel were double in the dose-dense arm.",median chemotherapy duration study 18 weeks arms median cumulative dose drugs virtually identical design median dis epirubicin paclitaxel double dose-dense arm,C0549183|C0013216|C0449238|C0557651|C0450371|C0439230|C0206655|C0549183|C1511559|C0178602|C0013227|G0000000|C0205280|C1707689|C0549183|C0451119|C0014582|C0144576|C0205173|C0178602|C0446516
"Fire-department dispatchers followed a structured interrogation protocol with two basic questions: Is the patient conscious or awake? and Is the patient breathing normally? If the answers to both of these questions were no or equivocal, an emergency-medical-services team was immediately dispatched and the caller was assured that help was on the way; in addition, if there was no one on the scene who was already performing (or intending to perform) CPR , and if the caller was willing to be instructed, the caller was given instructions for performing either chest compression alone or chest compression plus mouth-to-mouth ventilation (Fig. 1), as randomly assigned by a microcomputer located at the dispatchers console.",fire-department dispatchers structured interrogation protocol basic questions patient conscious awake patient breathing answers questions equivocal emergency-medical-services team dispatched caller assured addition scene performing intending perform cpr caller instructed caller instructions performing chest compression chest compression mouth-to-mouth ventilation fig 1 randomly assigned microcomputer located dispatchers console,C0016141|G0000000|C0678594|C0680701|C0442711|C1527178|C1522634|C0030705|C0234421|C0234422|C0030705|C0004048|C1706817|C1522634|C0332241|C0013961|C0871489|G0000000|G0000000|G0000000|C0332287|G0000000|C0884358|G0000000|C0884358|C0007203|G0000000|G0000000|G0000000|C0302828|C0884358|C0817096|C0332459|C0817096|C0332459|C0226896|C0035203|C0349966|G0000000|G0000000|C1516050|C0025971|G0000000|G0000000|C3873699
"69 patients with ST elevation Acute Myocardial Infarction (AMI), <12 hours after symptoms onset, undergoing primary angioplasty, with documented multivessel disease and both culprit lesion and 1 to 3 other lesions suitable for implantation.",69 patients st elevation acute myocardial infarction ami <12 hours symptoms onset undergoing primary angioplasty documented multivessel disease culprit lesion 1 3 lesions suitable implantation,C0450371|C0030705|C0036056|C0439775|C0205178|C0027061|C0021308|G0000000|C0450371|C0439227|C0683368|C0206132|G0000000|C0205225|C0162577|C1301725|G0000000|C0012634|G0000000|C0221198|G0000000|G0000000|C0221198|C3900053|C0021107
"The intervention was standardized with a flip chart so that patients and family members received the same information components, but it was tailored to the patients own past medical experience and unique living situation.",intervention standardized flip chart patients family received components tailored patients medical experience unique living situation,C0886296|G0000000|C1413357|C0007963|C0030705|C0015576|C1514756|C0449432|C0402883|C0030705|C0199168|C0237607|C1710548|C0376558|G0000000
The intervention group also received the study intervention that started before they underwent the PCI procedure and lasted until the sixteenth week after hospital discharge.,intervention received study intervention started underwent pci procedure lasted sixteenth week hospital discharge,C0886296|C1514756|C0557651|C0886296|C1272689|G0000000|C4049621|C0184661|C1517741|G0000000|C0332174|C0019994|C0012621
314 patients were randomly allocated complete revascularisation and 313 individuals were assigned no further invasive treatment.,314 patients randomly allocated complete revascularisation 313 individuals assigned invasive treatment,C1442061|C0030705|G0000000|G0000000|C0205197|C0581603|C1442061|C0027361|C1516050|C0205281|C0039798
"Results were used to develop individualized exercise prescriptions on the basis of established guidelines, and participants were encouraged to accumulate at least 150 minutes of exercise per week at their target heart rate, preferably exercising most days of the week via stationary bicycle/treadmill/walking.",develop individualized exercise prescriptions basis established guidelines participants encouraged accumulate 150 minutes exercise week target heart rate preferably exercising days week stationary bicycle/treadmill/walking,G0000000|C1881197|C0015259|C0033080|C1527178|C0443211|C0162791|C0679646|G0000000|G0000000|C1442061|C0439232|C0015259|C0332174|C1521840|C0018787|C0871208|G0000000|C0015259|C0439228|C0332174|C0439835|C0005375
"They were provided the same education materials as patients attending the supervised models at their initial visit, which was reviewed on the phone with program staff.",provided education materials patients attending supervised models initial visit reviewed phone program staff,C1999230|C0013621|C0520510|C0030705|C1547429|G0000000|C3161035|C0205265|C0545082|C0282443|C1515258|C1709697|C0851286
"All patients had to be in a stable condition on a diuretic plus the ACE inhibitor enalapril 10 mg twice daily for 28 days before randomisation, with or without digoxin.",patients stable condition diuretic ace inhibitor enalapril 10 daily 28 days randomisation digoxin,C0030705|C0205360|C0012634|C0012798|C1452534|C1999216|C0014025|C0450371|C0332173|C0450371|C0439228|C0034656|C0012265
"Calibration measurements using an Alderson-Phantom at a height of 130 cm during uoroscopy revealed that the Stephens 6000 dosimeter underestimated the ambient dose equivalent at depth of 1 cm, i.e., H  (10), by a factor of 7.4.",calibration measurements alderson-phantom height 130 cm uoroscopy revealed stephens 6000 dosimeter underestimated ambient dose equivalent depth 1 cm 10 factor 74,C0006751|C0242485|C0282611|C0489786|C1442061|G0000000|G0000000|C0443289|G0000000|G0000000|C0180488|G0000000|C1879688|C0178602|C0205163|C0205125|G0000000|G0000000|C0450371|C1521761|C0450371
"In the ablation group, patients underwent cavo-tricuspid and left inferior pulmonary vein (PV)-mitral isthmus ablation plus circumferential PV ablation.",ablation patients underwent cavo-tricuspid left inferior pulmonary vein pv-mitral isthmus ablation circumferential pv ablation,C0547070|C0030705|G0000000|C0443327|C0205091|C0542339|C0024109|C0042449|C0032463|C2985476|C0547070|C0205113|C0032463|C0547070
"In the other 30 patients, a full sternotomy was carried out, with cannulation for CPB, and antegrade cold blood cardioplegia for myocardial protection.",30 patients sternotomy carried cannulation cpb antegrade cold blood cardioplegia myocardial protection,C0450371|C0030705|C0185792|C0206243|C0917707|G0000000|C0589502|C0009264|C0005767|C0018791|C0027061|C1545588
"After 6 weeks for optimization of the aerobic portion of the protocol, a resistive training component was added that involved both upper and lower extremity strengthening.",6 weeks optimization aerobic portion protocol resistive training component involved upper lower extremity strengthening,G0000000|C0439230|C2698650|C1510824|C0449719|C0442711|G0000000|C0040607|C0449432|C1314939|C1282910|C0441994|C0015385|G0000000
"Eighty low-to moderate-risk cardiac patients were randomized to a TP (n=42) or a MP (n=38) and were compared over 6 months on program participation, exercise adherence, cardiovascular outcomes, and program costs.",low-to moderate-risk cardiac patients randomized tp n=42 mp n=38 compared 6 months program participation exercise adherence cardiovascular outcomes program costs,C0205251|C0205081|C0018787|C0030705|C0034656|C0036183|C0369718|C0024944|C0369718|C1707455|G0000000|C0439231|C1709697|C0679823|C0015259|C1510802|C0007226|C1274040|C1709697|C0010186
"There were four deaths in the placebo group and 2 and 0 deaths in the enoximone 25 mg three times a day and enoximone 50 mg three times a day groups, respectively.",deaths placebo 2 0 deaths enoximone 25 times day enoximone 50 times day,C0011065|C0032042|G0000000|G0000000|C0011065|C0116190|C0450371|C0040223|C0332173|C0116190|C0450371|C0040223|C0332173
Group B received KC on the rst day and routine IC on the second day.,received kc rst day routine ic day,C1514756|C0022575|C1425219|C0332173|C0205547|C0020750|C0332173
Patients were randomized to undergo MIS-RDAVR through an upper hemisternotomy (n  51) with Edwards Intuity or FS-AVR with a conventional stented valve (n  49) of the investigators preference.,patients randomized undergo mis-rdavr upper hemisternotomy 51 edwards intuity fs-avr conventional stented valve 49 investigators preference,C0030705|C0034656|G0000000|C0687670|C1282910|G0000000|C0450371|G0000000|G0000000|C1517317|C0439858|C0038257|C0184252|C0450371|C0035173|C0558295
"In addition to usual care, those participants randomized to the intervention group also received the PRIDE education program.",addition usual care participants randomized intervention received pride education program,C0332287|C3538928|C1947933|C0679646|C0034656|C0886296|C1514756|C0683296|C0013621|C1709697
The training program involved both aerobic and resistive components.,training program involved aerobic resistive components,C0040607|C1709697|C1314939|C1510824|G0000000|C0449432
"Treatment with pegylated liposomal doxorubicin was withheld if an ANC  500 per microliter, a platelet count  50,000 per microliter, or a transaminase or bilirubin level  5 times the ULN was recorded.",treatment pegylated liposomal doxorubicin withheld anc 500 microliter platelet count 50000 microliter transaminase bilirubin level 5 times uln recorded,C0039798|G0000000|C0023828|C0013089|G0000000|C0948762|C1442061|C0439243|C0005821|C0750480|G0000000|C0439243|C0002594|C0005437|C0441889|G0000000|C0040223|C1519815|C0034869
Only one patient in the radial group required crossover to femoral access because of inability to cannulate the radial artery.,patient radial required crossover femoral access inability cannulate radial artery,C0030705|C0442038|C1514873|C0010366|C0015811|C0444454|G0000000|G0000000|C0442038|C0003842
"Female patients were randomized to 1 of 3 models: (1) supervised mixed-sex, (2) supervised womenonly, or (3) home-based CR (Figure 1).",female patients randomized 1 3 models 1 supervised mixed-sex 2 supervised womenonly 3 home-based cr figure 1,C0015780|C0030705|C0034656|G0000000|G0000000|C3161035|G0000000|G0000000|C0205430|G0000000|G0000000|G0000000|G0000000|C0442519|C0201975|G0000000|G0000000
"They were randomized (by computergenerated randomization) with prior informed consent into two groups: group I, comprising 40 patients who underwent ministernotomy (reversed-C or reversed-L, with a skin incision shorter than 10 cm), and group II, comprising 40 patients who underwent conventional median sternotomy (with a roughly 25-cm incision).",randomized computergenerated randomization prior informed consent comprising 40 patients underwent ministernotomy reversed-c reversed-l skin incision shorter 10 cm ii comprising 40 patients underwent conventional median sternotomy roughly 25-cm incision,C0034656|G0000000|C0034656|C0332152|C1522154|C1511481|C2700400|C0450371|C0030705|G0000000|G0000000|C1555029|C1555029|C0444099|C0184898|C1282927|C0450371|G0000000|G0000000|C2700400|C0450371|C0030705|G0000000|C0439858|C0549183|C0185792|G0000000|C0450371|C0184898
"Participants' recorded time and duration of each walking session, HR, blood pressure, weight, and symptoms in weekly walking logs.",participants recorded time duration walking session hr blood pressure weight symptoms weekly walking logs,C0679646|C0034869|C0040223|C0449238|C0080331|C1883016|G0000000|C0005767|C0033095|C0005910|C0683368|C0332174|C0080331|C1708728
"Patients and Methods: Between 1992 and 1996, 228 AK femoro-popliteal bypass grafts were randomly allocated to either an ePTFE (n Z 114) or a Dacron (n Z 114) vascular graft (6 mm in diameter).",patients methods 1992 1996 228 ak femoro-popliteal bypass grafts randomly allocated eptfe 114 dacron 114 vascular graft 6 mm diameter,C0030705|C0025663|G0000000|G0000000|C1442061|C0001905|C0545765|C0741847|C0332835|G0000000|G0000000|G0000000|C1442061|C0947693|C1442061|C0005847|C0181074|G0000000|G0000000|C1301886
Instructions in chest compression plus mouth-to-mouth ventilation given by dispatchers over the telephone can require 2.4 minutes.,instructions chest compression mouth-to-mouth ventilation dispatchers telephone require 24 minutes,C0302828|C0817096|C0332459|C0226896|C0035203|G0000000|C0039457|G0000000|C0450371|C0439232
"Study 2 (30-min study, N  10) tested 30 min of KC before and throughout the heel stick versus incubator care.",study 2 30-min study 10 tested 30 min kc heel stick versus incubator care,C0557651|G0000000|C0450371|C0557651|C0450371|C0392366|C0450371|C0702093|C0022575|C0018870|C1706582|G0000000|C0021178|C1947933
"A total of 5010 patients with heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned to receive 160 mg of valsartan or placebo twice daily.",total 5010 patients heart failure york heart association nyha class ii iii iv randomly assigned receive 160 valsartan placebo daily,C0439175|G0000000|C0030705|C0018787|C0231174|G0000000|C0018787|C0004083|G0000000|C0456387|G0000000|C0439070|C0022326|G0000000|C1516050|C1514756|C1442061|C0216784|C0032042|C0332173
"In the control condition, the baby was placed in the incubator in a prone position, swaddled with a blanket (with heel accessible), for at least 15 minutes prior to the heel lancing procedure.",control condition baby incubator prone position swaddled blanket heel accessible 15 minutes prior heel lancing procedure,C0243148|C0012634|C0021270|C0021178|C0033422|C0733755|G0000000|C0179330|C0018870|C0814423|C0450371|C0439232|C0332152|C0018870|C0522666|C0184661
ABVE-PC was administered every 21 days.,abve-pc administered 21 days,C1879497|C1521801|C0450371|C0439228
"Those who satised eligibility criteria and provided written informed consent were randomly assigned to the standard ePTFE graft or the FUSION BIOLINE heparin-coated graft (Maquet Cardiovascular, Wayne, NJ).",satised eligibility criteria provided written informed consent randomly assigned standard eptfe graft fusion bioline heparin-coated graft maquet cardiovascular wayne nj,G0000000|C0013893|C0243161|C1999230|C0043266|C1522154|C1511481|G0000000|C1516050|C1442989|G0000000|C0181074|C0332466|G0000000|C0019134|C0181074|G0000000|C0007226|G0000000|C0027971
Recruited patients were randomly assigned to either ablation (CA group) or medical therapy (ADT group) according to a 2:1 blocked randomization list stratied by centre.,recruited patients randomly assigned ablation medical therapy adt 21 blocked randomization list stratied centre,G0000000|C0030705|G0000000|C1516050|C0547070|C0199168|C0039798|C0279492|C0450371|C0028778|C0034656|C0745732|G0000000|C0205099
"In accordance  with standard care, control neonates were placed supine in  their bassinet and taken to the nursery to rest before the injection.",standard care control neonates supine bassinet nursery rest injection,C1442989|C1947933|C0243148|C0021289|C0038846|C0179231|C0028659|C0035253|C0021485
"In the MS group, after a 6- to 10-cm midline skin incision, the chest was opened using a reversed-L sternal incision to the 4th intercostal space.",ms 6- 10-cm midline skin incision chest reversed-l sternal incision 4th intercostal space,C0039676|G0000000|C0450371|C0549183|C0444099|C0184898|C0817096|C1555029|C0038293|C0184898|G0000000|G0000000|C1883067
Nearly 80% of patients (107 patients in the pimobendan group and 111 patients in the placebo group) were treated with 1.25 mg twice daily of pimobendan or the equivalent dose of placebo throughout the entire period of study.,80% patients 107 patients pimobendan 111 patients placebo treated 125 daily pimobendan equivalent dose placebo entire period study,C0450371|C0030705|C1442061|C0030705|C0071071|C1442061|C0030705|C0032042|C1522326|C1442061|C0332173|C0071071|C0205163|C0178602|C0032042|C0439751|C0439531|C0557651
"Patienten:        In  der  kooperativen  Therpiestudie  zur  Behandlung  von  Kindern  mit  akuter  lymphatischer  Leuk  mie  COALL  92  wurden  178  Patienten  randomisiert,  um  in  einem  therapeutischen  Fenster  36   mg / m 2   DNR  als  1-h  (85  Patienten) oder 24-h (93 Patienten) Infusion zu  erhalten.",patienten der kooperativen therpiestudie zur behandlung von kindern mit akuter lymphatischer leuk mie coall 92 wurden 178 patienten randomisiert um einem therapeutischen fenster 36 / 2 dnr als 1-h 85 patienten oder 24-h 93 patienten infusion zu erhalten,G0000000|C1511780|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|G0000000|C1442061|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|G0000000|G0000000|C0011015|G0000000|C0033727|C0450371|G0000000|G0000000|C0450371|C0450371|G0000000|C0574032|C1190825|G0000000
Design Patients were randomly assigned to receive combination AC or sequential treatment with doxorubicin followed by cyclophosphamide (A 3 C).,design patients randomly assigned receive combination ac sequential treatment doxorubicin cyclophosphamide 3,C1707689|C0030705|G0000000|C1516050|C1514756|C0205195|C0003354|C1548958|C0039798|C0013089|C0010583|G0000000
"In the United Kingdom home-based cardiac rehabilitation with a self-help manual supported by a nurse facilitator is a popular method of rehabilitation [14], and was offered to more than 10,000 survivors of acute myocardial infarction in 2004 [16].",united kingdom home-based cardiac rehabilitation self-help manual supported nurse facilitator popular method rehabilitation 14 offered 10000 survivors acute myocardial infarction 2004 16,C0166872|C1708611|C0442519|C0018787|C0034991|C0597431|C0024763|C1521721|C0028661|G0000000|C0679970|C0025663|C0034991|C0450371|C1444648|G0000000|C0206194|C0205178|C0027061|C0021308|G0000000|C0450371
Procedure:        In the cooperative treatment study  COALL-92  for  childhood  ALL  178  patients  were  randomized  to  receive  in  a  therapeutic  window a single dose of 36   mg / m 2  DNR either as a  1-h (85 patients) or 24-h infusion (93 patients).,procedure cooperative treatment study coall-92 childhood 178 patients randomized receive therapeutic window single dose 36 / 2 dnr 1-h 85 patients 24-h infusion 93 patients,C0184661|C0679729|C0039798|C0557651|C0450371|C0231335|C1442061|C0030705|C0034656|C1514756|C0087111|C0557702|C0037179|C0178602|C0450371|G0000000|G0000000|C0011015|C0033727|C0450371|C0030705|C0450371|C0574032|C0450371|C0030705
"Intervention: During 2 separate medically ordered heel lance procedures at least 24 hours apart, infants were held in KC for 30 minutes before and during the procedure with the mother or with the father, and with the other parent in the subsequent session.",intervention 2 separate medically heel lance procedures 24 hours infants held kc 30 minutes procedure mother father parent subsequent session,C0886296|G0000000|C0443299|G0000000|C0018870|C0522666|C0025664|C0450371|C0439227|C0021270|C0675390|C0022575|C0450371|C0439232|C0184661|C0026591|C0015671|C0030551|C0332282|C1883016
"The mean propranolol dosage of 1.660.6 mg / kg / day was slightly lower than the target dose of 2 mg / kg / day propranolol, as two infants developed bradycardia at higher dosages.",propranolol dosage 16606 / / day lower target dose 2 / / day propranolol infants developed bradycardia dosages,C0033497|C0178602|G0000000|G0000000|G0000000|C0332173|C0441994|C1521840|C0178602|G0000000|G0000000|G0000000|C0332173|C0033497|C0021270|G0000000|C0428977|C0178602
"Before completion of a baseline treadmill test, patients exercised at a heart rate of 20 to 30 beats above their resting level (patients prescribed b-blocking agents, 10 to 15 beats above resting levels) and a rating of perceived exertion #13 (somewhat hard).14 Patients were instructed to regulate their exercise intensity via a prescribed heart rate range corresponding to 60% to 85% of their aerobic capacity; additionally, they were encouraged to achieve $5 aerobic exercise sessions/week for $30 minutes.",completion baseline treadmill test patients exercised heart rate 20 30 beats resting level patients prescribed b-blocking agents 10 15 beats resting levels rating perceived exertion #13 hard14 patients instructed regulate exercise intensity prescribed heart rate range 60% 85% aerobic capacity additionally encouraged achieve 5 aerobic exercise sessions/week 30 minutes,C0205197|C0168634|C0184069|C0022885|C0030705|C0015259|C0018787|C0871208|C0450371|C0450371|G0000000|C0035253|C0441889|C0030705|C0278329|C0233660|C0450442|C0450371|C0450371|G0000000|C0035253|C0441889|C0871208|C0030971|C0015264|C0450371|G0000000|C0030705|G0000000|G0000000|C0015259|C0522510|C0278329|C0018787|C0871208|C1514721|C0450371|C0450371|C1510824|C1516240|G0000000|G0000000|G0000000|G0000000|C1510824|C0015259|C1883016|C0450371|C0439232
"After  gathering  all  baseline  observations,  the  patients were  randomly  assigned  to  double-blind  treatment  for  52 weeks with pimobendan, 1.25 mg twice daily, vs matching",gathering baseline observations patients randomly assigned double-blind treatment 52 weeks pimobendan 125 daily matching,G0000000|C0168634|C0302523|C0030705|G0000000|C1516050|C0013072|C0039798|C0450371|C0439230|C0071071|C1442061|C0332173|C0150103
"The neonates were then assigned to one of the following three groups in a randomized manner: group 1 (incubator, n = 33), group 2 (kangaroo, n = 31), and group 3 (glucose, n = 31) (Fig. 1).",neonates assigned randomized manner 1 incubator = 33 2 kangaroo = 31 3 glucose = 31 fig 1,C0021289|C1516050|C0034656|G0000000|G0000000|C0021178|G0000000|C0450371|G0000000|C0022494|G0000000|C0450371|G0000000|C0017725|G0000000|C0450371|C0349966|G0000000
"Study Procedures and Follow-up After the completion of PCI in the infarct artery,  eligible patients were randomly assigned to undergo no further PCI procedures or to undergo  immediate preventive PCI in noninfarct arteries  with more than 50% stenoses (preventive PCI).",study procedures follow-up completion pci infarct artery eligible patients randomly assigned undergo pci procedures undergo preventive pci noninfarct arteries 50% stenoses preventive pci,C0557651|C0025664|C0589120|C0205197|C4049621|C0021308|C0003842|C1548635|C0030705|G0000000|C1516050|G0000000|C4049621|C0025664|G0000000|C0445202|C4049621|G0000000|C0003842|C0450371|C1261287|C0445202|C4049621
"On study entry and every 12 months, all patients underwent a cardiopulmonary exercise test (CPET), an echo-Doppler study, and quality of life (QOL) assessment.",study entry 12 months patients underwent cardiopulmonary exercise test cpet echo-doppler study quality life qol assessment,C0557651|C1705654|C0450371|C0439231|C0030705|G0000000|C0553534|C0015259|C0022885|C0055954|C0058928|C0557651|C0332306|C0376558|C0518214|C1261322
Patients were given a written prescription to follow that included exercise sessions 4 times weekly with increasing session durations until they were walking a continuous 45 minutes.,patients written prescription follow included exercise sessions 4 times weekly increasing session durations walking continuous 45 minutes,C0030705|C0043266|C0033080|C0332283|C0332257|C0015259|C1883016|G0000000|C0040223|C0332174|C0442808|C1883016|C0449238|C0080331|C0549178|C0450371|C0439232
Mediated  patients  participated  fully  by  agreeing  to  accept  telephone  calls  from  LifeMasters  nurse DM staff and measuring and reporting  to  LifeMasters  their  vi    tal  signs  and  symptoms.,mediated patients participated agreeing accept telephone calls lifemasters nurse dm staff measuring reporting lifemasters vi tal signs symptoms,C0086597|C0030705|G0000000|C3641827|C1272684|C0039457|C0679006|G0000000|C0028661|C3250443|C0851286|C0444706|C0700287|G0000000|C0205999|C1428449|C0220912|C0683368
"In group 2 (kangaroo), the neonates were placed in skin-to-skin contact on the mothers chest 10 min before the painful stimulus, with the mother sitting comfortably at an angle of 4560.",2 kangaroo neonates skin-to-skin contact mothers chest 10 min painful stimulus mother sitting comfortably angle 4560,G0000000|C0022494|C0021289|C0444099|C0332158|C0026591|C0817096|C0450371|C0702093|C0030193|C0234402|C0026591|C0277814|G0000000|C0205143|G0000000
"Patients in the HT group exercised 61 min per training session, of which they exercised 42 min in the prescribed exercise intensity zone (70 85% of maximal heart rate).",patients ht exercised 61 min training session exercised 42 min prescribed exercise intensity zone 70 85% maximal heart rate,C0030705|C0018510|C0015259|C0450371|C0702093|C0040607|C1883016|C0015259|C0450371|C0702093|C0278329|C0015259|C0522510|C1710706|C0450371|C0450371|C0205289|C0018787|C0871208
All patients received antibiotic prophylaxis,patients received antibiotic prophylaxis,C0030705|C1514756|C0003232|C0033107
"From 850 patients with ST-segment elevation myocardial infarction, 296 were randomized to receive complete (150) or culprit lesiononly (146) revascularization.",850 patients st-segment elevation myocardial infarction 296 randomized receive complete 150 culprit lesiononly 146 revascularization,C1442061|C0030705|C0429029|C0439775|C0027061|C0021308|C1442061|C0034656|C1514756|C0205197|C1442061|G0000000|G0000000|C1442061|C0581603
"Continuous intravenous infusion of the study drug through  a separate central line was started intraoperatively and was increased  stepwise: dose 1, starting immediately after the central lines were placed  and maintained for the duration of the surgical procedure; dose 2, upon  NICU admission, providing the infant was in stable hemodynamic condition; and dose 3, starting after 2 h of stability with dose 2, and maintained up to 48 h after the infusion of IND started.",continuous intravenous infusion study drug separate central started intraoperatively increased stepwise dose 1 starting central lines maintained duration surgical procedure dose 2 nicu admission providing infant stable hemodynamic condition dose 3 starting 2 stability dose 2 maintained 48 infusion ind started,C0549178|C0348016|C0574032|C0557651|C0013227|C0443299|C0205099|C1272689|G0000000|C0205217|G0000000|C0178602|G0000000|C0439659|C0205099|C0205132|C1314677|C0449238|C0543467|C0184661|C0178602|G0000000|C0021709|C0184666|C1999230|C0021270|C0205360|C0019010|C0012634|C0178602|G0000000|C0439659|G0000000|C0205360|C0178602|G0000000|C1314677|C0450371|C0574032|C4049864|C1272689
"Patients and Methods One thousand ten women with axillary nodepositive or high-risk node-negative breast cancer were randomly assigned to receive three cycles of docetaxel or vinorelbine, followed in both groups by three cycles of uorouracil, epirubicin, and cyclophosphamide (FEC).",patients methods ten women axillary nodepositive high-risk node-negative breast cancer randomly assigned receive cycles docetaxel vinorelbine cycles uorouracil epirubicin cyclophosphamide fec,C0030705|C0025663|C0014518|C0043210|C0004454|G0000000|C0332167|C0678034|C0006141|C0006826|G0000000|C1516050|C1514756|C1511572|C0246415|C0078257|C1511572|G0000000|C0014582|C0010583|C0060133
"Immediately  after  the  initial  primary  PCI  procedure,  we randomly assigned patients in an open-label manner  to  either  FFR-guided  complete  revascularisation  or  no  further invasive treatment (ie, PCI of the infarct-related  artery only).",initial primary pci procedure randomly assigned patients open-label manner ffr-guided complete revascularisation invasive treatment pci infarct-related artery,C0205265|C0205225|C4049621|C0184661|G0000000|C1516050|C0030705|C1709323|G0000000|C1412871|C0205197|C0581603|C0205281|C0039798|C4049621|C0021308|C0003842
"This was followed by a second doubleblind treatment period using placebo or candesartan cilexetil, 8 mg once daily, for 6 months.",doubleblind treatment period placebo candesartan cilexetil 8 daily 6 months,C0013072|C0039798|C0439531|C0032042|C0717550|G0000000|G0000000|C0332173|G0000000|C0439231
"Cyclophosphamide  (600  mg/m),  methotrexate(40  mg/m),  and  uorouracil  (600  mg/m)  were  then  given  on  days  1  and  8  every  4  weeks  for  three  cycles.",cyclophosphamide 600 mg/m methotrexate40 mg/m uorouracil 600 mg/m days 1 8 4 weeks cycles,C0010583|C1442061|C0026410|G0000000|C0026410|G0000000|C1442061|C0026410|C0439228|G0000000|G0000000|G0000000|C0439230|C1511572
"The  Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial was designed to  compare the efficacy and safety of warfarin with  those of aspirin among a substantially larger number of patients, with the use of a double-blind,  randomized design.17",warfarin versus aspirin reduced cardiac ejection fraction warcef trial designed compare efficacy safety warfarin aspirin larger patients double-blind randomized design17,C0043031|G0000000|C0004057|C0392756|C0018787|C0302131|C1264633|G0000000|C0008976|C1707689|C1707455|C1280519|C0036043|C0043031|C0004057|C0549177|C0030705|C0013072|C0034656|G0000000
"For adults, continuous infusions are less cardiotoxic than bolus infusions, when effects are assessed during or shortly after therapy.1-5 Such continuous infusions allow the cumulative doxorubicin dose to be increased by a factor of at least two and do not attenuate the oncologic effect of the drug.1-5",adults continuous infusions cardiotoxic bolus infusions effects assessed shortly therapy1-5 continuous infusions cumulative doxorubicin dose increased factor attenuate oncologic drug1-5,C0001675|C0549178|C0574032|C0876994|C1511237|C0574032|C1280500|C1516048|G0000000|G0000000|C0549178|C0574032|C1511559|C0013089|C0178602|C0205217|C1521761|C0599946|C0205478|G0000000
All  Previous inclusion in this study either for a contrapatients were treated with heparin perioperatively lateral bypass or an earlier ipsilateral one (sim(dosage and type of administration not standardised).,previous inclusion study contrapatients treated heparin perioperatively lateral bypass earlier ipsilateral simdosage type administration standardised,C0205156|C0007637|C0557651|G0000000|C1522326|C0019134|G0000000|C0205093|C0741847|C1279919|C0441989|G0000000|C0332307|C0001554|G0000000
"We randomised 141 patients (mean 68 years, 74% males) with stable mild/moderate heart failure and left ventricular ejection fraction 0.45 or less, to valsartan 160 mg q.d. (n=70) or enalapril 10 mg b.i.d. (n=71) for 12 weeks.",randomised 141 patients 68 74% males stable mild/moderate heart failure left ventricular ejection fraction 045 valsartan 160 qd n=70 enalapril 10 bid n=71 12 weeks,G0000000|C1442061|C0030705|C0450371|C0450371|C0086582|C0205360|C1299392|C0018787|C0231174|C0205091|C0018827|C0302131|C1264633|C1442061|C0216784|C1442061|C0332173|C0369718|C0014025|C0450371|G0000000|C0369718|C0450371|C0439230
Forty-eight patients with symptomatic HRPCA were randomized to receive pegylated liposomal doxorubicin at either 25 mg/m2 every 2 weeks for 12 cycles (Group A) or 50 mg/m2 every 4 weeks for 6 cycles (Group B).,forty-eight patients symptomatic hrpca randomized receive pegylated liposomal doxorubicin 25 mg/m2 2 weeks 12 cycles 50 mg/m2 4 weeks 6 cycles,C3816449|C0030705|C0231220|G0000000|C0034656|C1514756|G0000000|C0023828|C0013089|C0450371|C0026410|G0000000|C0439230|C0450371|C1511572|C0450371|C0026410|G0000000|C0439230|G0000000|C1511572
"Infants were assigned randomly to either being held by their mothers in whole body, skin-toskin contact or to no intervention (swaddled in crib) during a standard heel lance procedure.",infants assigned randomly held mothers body skin-toskin contact intervention swaddled crib standard heel lance procedure,C0021270|C1516050|G0000000|C0675390|C0026591|C0242821|C0444099|C0332158|C0886296|G0000000|C0010317|C1442989|C0018870|C0522666|C0184661
The antiarrhythmic drug preferentially administered was amiodarone.,antiarrhythmic drug preferentially administered amiodarone,C0003195|C0013227|G0000000|C1521801|C0002598
"According to the random codes, infants were assigned to two groups, determined by the sequence of the KC and current standard of care  routine incubator care (IC) conditions.",random codes infants assigned determined sequence kc current standard care routine incubator care ic conditions,C0034656|C0919279|C0021270|C1516050|G0000000|C0004793|C0022575|C0521116|C1442989|C1947933|C0205547|C0021178|C1947933|C0020750|C0012634
"Interventions Patients were randomized in a 1:1:1 ratio to twice-daily dosing with placebo, low-dose carvedilol (0.2 mg/kg per dose if weight 62.5 kg or 12.5 mg per dose if weight 62.5 kg), or high-dose carvedilol (0.4 mg/kg per dose if weight 62.5 kg or 25 mg per dose if weight 62.5 kg) and were stratified according to whether each patients systemic ventricle was a left ventricle or not.",interventions patients randomized 111 ratio twice-daily dosing placebo low-dose carvedilol 02 mg/kg dose weight 625 125 dose weight 625 high-dose carvedilol 04 mg/kg dose weight 625 25 dose weight 625 stratified patients systemic ventricle left ventricle,C0886296|C0030705|C0034656|C1442061|C0456603|C0585361|G0000000|C0032042|C0445550|C0054836|C0450371|C0439272|C0178602|C0005910|C1442061|C1442061|C0178602|C0005910|C1442061|C0444956|C0054836|C0450371|C0439272|C0178602|C0005910|C1442061|C0450371|C0178602|C0005910|C1442061|C0205363|C0030705|C0205373|C0018827|C0205091|C0018827
"Those receiving coenzyme Q10 had the agent given at a dose of 2 milligram/kilogram/day in 2 or 3 divided doses, these being increased to the maximum dose of 10 milligram/kilogram/day according to tolerance or the appearance of side effects.",receiving coenzyme q10 agent dose 2 milligram/kilogram/day 2 3 divided doses increased maximum dose 10 milligram/kilogram/day tolerance appearance effects,C1514756|C0009235|G0000000|C0450442|C0178602|G0000000|C3665414|G0000000|G0000000|C0332849|C0178602|C0205217|C0806909|C0178602|C0450371|C3665414|C0013220|C0233426|C1280500
"For this study, we prospectively collected data from high-risk patients who had been randomly assigned to receive continuous (over 48 hours) or bolus (over 1 hour) infusions of doxorubicin (30 mg/m2 every 3 weeks).",study prospectively collected data high-risk patients randomly assigned receive continuous 48 hours bolus 1 hour infusions doxorubicin 30 mg/m2 3 weeks,C0557651|G0000000|C1516695|C1511726|C0332167|C0030705|G0000000|C1516050|C1514756|C0549178|C0450371|C0439227|C1511237|G0000000|C0439227|C0574032|C0013089|C0450371|C0026410|G0000000|C0439230
"This protocol included more intense postremission therapy than previous protocols, dexamethasone was substituted for prednisone, and intensied asparaginase administration was prolonged from 20 to 30 weeks.8",protocol included intense postremission therapy previous protocols dexamethasone substituted prednisone intensied asparaginase administration prolonged 20 30 weeks8,C0442711|C0332257|C0522510|G0000000|C0039798|C0205156|C0442711|C0011777|G0000000|C0032952|G0000000|C0003993|C0001554|C0439590|C0450371|C0450371|G0000000
"Patients attended the House of Education at least 6 times: within the first month after discharge and then at months 2, 3, 6, 9, and 12.",patients attended house education 6 times month discharge months 2 3 6 9 12,C0030705|C1456498|C0442519|C0013621|G0000000|C0040223|C0332177|C0012621|C0439231|G0000000|G0000000|G0000000|G0000000|C0450371
Group A received routine IC on the rst day of the study and KC on the second day.,received routine ic rst day study kc day,C1514756|C0205547|C0020750|C1425219|C0332173|C0557651|C0022575|C0332173
"After three supervised training sessions, patients in the HT group started training at home and received coaching from their therapist through weekly telephone calls.",supervised training sessions patients ht started training received coaching therapist weekly telephone calls,G0000000|C0040607|C1883016|C0030705|C0018510|C1272689|C0040607|C1514756|C0557773|C0871525|C0332174|C0039457|C0679006
This is a multi-centre randomised controlled clinical trial in which patients in the intervention group received periodic postal reminders to see their general practitioner every three months during a 3-year follow-up.,multi-centre randomised controlled clinical trial patients intervention received periodic postal reminders practitioner months 3-year follow-up,C0439743|G0000000|C2587213|C0205210|C0008976|C0030705|C0886296|C1514756|C0332182|C1514253|C1709896|C1709627|C0439231|C0439234|C0589120
"Radiation therapy (RT) and/or hormonal therapy were given after completion of chemotherapy, when indicated.",radiation therapy rt and/or hormonal therapy completion chemotherapy,C0034519|C0039798|C0230425|G0000000|C0458083|C0039798|C0205197|C0013216
"Patients in Arm A received liposomal doxorubicin (dissolved in 250 mL 5% glucose) at a dose of 25 mg/m2 administered as a 60-minute intravenous infusion every 2 weeks for 12 consecutive cycles, whereas Patients in Arm B received the same formulation at a dose of 50 mg/m2 administered as a 60-minute intravenous infusion every 4 weeks for 6 consecutive cycles.",patients arm received liposomal doxorubicin dissolved 250 5% glucose dose 25 mg/m2 administered 60-minute intravenous infusion 2 weeks 12 consecutive cycles patients arm received formulation dose 50 mg/m2 administered 60-minute intravenous infusion 4 weeks 6 consecutive cycles,C0030705|C0446516|C1514756|C0023828|C0013089|C1549535|C1442061|G0000000|C0017725|C0178602|C0450371|C0026410|C1521801|C0450371|C0348016|C0574032|G0000000|C0439230|C0450371|C1707491|C1511572|C0030705|C0446516|C1514756|C0524527|C0178602|C0450371|C0026410|C1521801|C0450371|C0348016|C0574032|G0000000|C0439230|G0000000|C1707491|C1511572
"In a randomized study, children with high-risk acute lymphoblastic leukemia received doxorubicin 360 mg/m2 in 30-mg/m2 doses every 3 weeks either by bolus (within 1 hour, n  57) or by continuous infusion (over 48 hours, n  64).",randomized study children high-risk acute lymphoblastic leukemia received doxorubicin 360 mg/m2 30-mg/m2 doses 3 weeks bolus 1 hour 57 continuous infusion 48 hours 64,C0034656|C0557651|C0008059|C0332167|C0205178|C0229613|C0023418|C1514756|C0013089|C1442061|C0026410|C0450371|C0178602|G0000000|C0439230|C1511237|G0000000|C0439227|C0450371|C0549178|C0574032|C0450371|C0439227|C0450371
"Between October 2009 and February 2012, 707 patients with an STEMI were randomly assigned to PCI via the radial (n  348) or femoral (n  359) approach within 12 h of symptoms onset",october 2009 february 2012 707 patients stemi randomly assigned pci radial 348 femoral 359 approach 12 symptoms onset,C3828732|G0000000|C3830166|G0000000|C1442061|C0030705|C3538872|G0000000|C1516050|C4049621|C0442038|C1442061|C0015811|C1442061|C0449445|C0450371|C0683368|C0206132
The aim of this study was to compare the effects on patency of externally supported thin wall knitted polyester (P-EXS) and externally unsupported thin wall knitted polyester (P-non-EXS) for AK femoro-popliteal bypass grafting.,aim study compare effects patency externally supported thin wall knitted polyester p-exs externally unsupported thin wall knitted polyester p-non-exs ak femoro-popliteal bypass grafting,C1947946|C0557651|C1707455|C1280500|C0175566|C0205101|C1521721|C0205168|C0677535|C0868977|C0032474|C0369773|C0205101|G0000000|C0205168|C0677535|C0868977|C0032474|C0369773|C0001905|C0545765|C0741847|C0332835
"The 12-month intervention comprised an initial consultation with a community pharmacist to review appropriateness of therapy, compliance, lifestyle, social and support issues.",12-month intervention comprised initial consultation community pharmacist review appropriateness therapy compliance lifestyle social support issues,C0450371|C0886296|C2700400|C0205265|C0009818|C0009462|C0031323|C0282443|C0814634|C0039798|C0009563|C0023676|C0728831|C0183683|C0033213
a complete profile as a known case of idiopathic dilated cardiomyoapathy according to the definition of World Health Organization classification aged less than 18 years old stability of at least 1 month in medications received for treatment of cardiac failure > presence of a normal sinus rhythm.,complete profile idiopathic dilated cardiomyoapathy definition health organization classification aged 18 stability 1 month medications received treatment cardiac failure presence normal sinus rhythm,C0205197|C1979963|C0332240|C0700124|G0000000|C1550452|C0018684|C0029237|C0008902|C0001779|C0450371|C0205360|G0000000|C0332177|C0013227|C1514756|C0039798|C0018787|C0231174|C0150312|C0205307|C0016169|C0871269
"Infants were randomly assigned to two sequences (sequence A: day 1 heel stick in Kangaroo Care [after 30 min of prone skin contact upright between maternal breasts] and day 2 heel stick in incubator [inclined, nested and prone]; or sequence B: opposite of sequence A) was conducted.",infants randomly assigned sequences sequence day 1 heel stick kangaroo care 30 min prone skin contact upright maternal breasts day 2 heel stick incubator inclined nested prone sequence opposite sequence conducted,C0021270|G0000000|C1516050|C0162326|C0004793|C0332173|G0000000|C0018870|C1706582|C0022494|C1947933|C0450371|C0702093|C0033422|C0444099|C0332158|C0522015|C2347083|C0006141|C0332173|G0000000|C0018870|C1706582|C0021178|G0000000|G0000000|C0033422|C0004793|C1521805|C0004793|C0004927
Patients were treated depending on physicians choice and according to current guidelines.3 Discontinuation of the antiarrhythmic treatment was not required before inclusion in the ADT group.,patients treated depending physicians choice current guidelines3 discontinuation antiarrhythmic treatment required inclusion adt,C0030705|C1522326|C0725813|C0031831|C0008300|C0521116|G0000000|C0457454|C0003195|C0039798|C1514873|C0007637|C0279492
"Patients in the warfarin group did not receive the  randomly assigned medication (and instead received open-label therapy) for 34% of the total  follow-up time, and patients in the aspirin group  did not receive the assigned medication for 32%  of the time.",patients warfarin receive randomly assigned medication received open-label therapy 34% total follow-up time patients aspirin receive assigned medication 32% time,C0030705|C0043031|C1514756|G0000000|C1516050|C0013227|C1514756|C1709323|C0039798|C0450371|C0439175|C0589120|C0040223|C0030705|C0004057|C1514756|C1516050|C0013227|C0450371|C0040223
"The results of this trial indicate that enoximone at doses of 25 mg three times a day and 50 mg three times a day increases maximal exercise capacity compared with placebo, as assessed by the protocol-specied method of end point analysis (last observation carried-forward at 12 weeks).",trial enoximone doses 25 times day 50 times day increases maximal exercise capacity compared placebo assessed protocol-specied method analysis observation carried-forward 12 weeks,C0008976|C0116190|C0178602|C0450371|C0040223|C0332173|C0450371|C0040223|C0332173|C0205217|C0205289|C0015259|C1516240|C1707455|C0032042|C1516048|C0442711|C0025663|C0002778|C0302523|C0206243|C0450371|C0439230
"Resistance training was prescribed at 80% of one repetition maximum, which is the maximal weight lifted one time, for 2 sets of 10 repetitions using seated biceps curls to strengthen the arms and seated lateral raises to strengthen shoulders.",resistance training prescribed 80% repetition maximum maximal weight lifted time 2 sets 10 repetitions seated biceps curls strengthen arms seated lateral raises strengthen shoulders,C0237834|C0040607|C0278329|C0450371|C0205341|C0806909|C0205289|C0005910|C0206244|C0040223|G0000000|C0036849|C0450371|C0205341|C0277814|C0559499|C0887883|G0000000|C0206655|C0277814|C0205093|G0000000|G0000000|C0037004
"In first stage of  study,  we  used  PIPP  score,  heart  rate,  and  oxygen saturations to assess whether removal of adhesive tape in VLBW  neonates  is  a  painful  procedure  or  not.",stage study pipp score heart rate oxygen saturations assess removal adhesive tape vlbw neonates painful procedure,C0205390|C0557651|C0070798|C0449820|C0018787|C0871208|C0030054|C0522534|C1516048|C0015252|C0001516|C0183828|C0282666|C0021289|C0030193|C0184661
"Radial versus femoral access for coronary angiography and  intervention in patients with acute coronary syndromes  (RIVAL): a randomised, parallel group, multicentre trial",radial versus femoral access coronary angiography intervention patients acute coronary syndromes rival randomised parallel multicentre trial,C0442038|G0000000|C0015811|C0444454|C0018787|C0002978|C0886296|C0030705|C0205178|C0018787|C0039082|G0000000|G0000000|C2348042|C0439743|C0008976
One neonate in the  milrinone group with total anomalous  venous connection repair required prolonged mechanical ventilation (28 days)  due to bilateral diaphragmatic paralysis.,neonate milrinone total anomalous venous connection repair required prolonged mechanical ventilation 28 days bilateral diaphragmatic paralysis,C0021289|C0128513|C0439175|C3277934|C0042449|C0449379|C0043240|C1514873|C0439590|C0443254|C0035203|C0450371|C0439228|C0238767|C0011980|C0522224
"In the experimental condition, the infant was held in KMC for 15 minutes prior to and throughout heel lance procedure.",experimental condition infant held kmc 15 minutes prior heel lance procedure,C1517586|C0012634|C0021270|C0675390|G0000000|C0450371|C0439232|C0332152|C0018870|C0522666|C0184661
"We enrolled 4128 patients who were at least 60 years of age and had New York Heart  Association class II, III, or IV heart failure and an ejection fraction of at least 45%  and randomly assigned them to receive 300 mg of irbesartan or placebo per day.",enrolled 4128 patients 60 age york heart association class ii iii iv heart failure ejection fraction 45% randomly assigned receive 300 irbesartan placebo day,G0000000|G0000000|C0030705|C0450371|C0001779|G0000000|C0018787|C0004083|C0456387|G0000000|C0439070|C0022326|C0018787|C0231174|C0302131|C1264633|C0450371|G0000000|C1516050|C1514756|C1442061|C0288171|C0032042|C0332173
"In the second treatment arm, patients with idiopathic dilated cardiomyopathy (DCM) were randomised to receive either W or placebo (P).",treatment arm patients idiopathic dilated cardiomyopathy dcm randomised receive placebo,C0039798|C0446516|C0030705|C0332240|C0700124|C0878544|G0000000|G0000000|C1514756|C0032042
"Intravenous solutions of the study INDs were prepared in identical  opaque syringes, and the concentration was adjusted to deliver the corresponding dose for each IND at the same infusion rate.",intravenous solutions study inds prepared identical opaque syringes concentration adjusted deliver dose ind infusion rate,C0348016|C0037633|C0557651|C4049864|C4082130|C0205280|C0029053|C0039142|C0004268|C0456081|C0308779|C0178602|C4049864|C0574032|C0871208
"Thirty-six patients with stable New York Heart Association class II-IV CHF receiving ACE inhibitor therapy were randomly assigned in a double-blind manner to receive either eprosartan, a specific competitive AT1 receptor antagonist (400 to 800 mg daily, n = 18) or placebo (n = 18) for 8 weeks.",thirty-six patients stable york heart association class ii-iv chf receiving ace inhibitor therapy randomly assigned double-blind manner receive eprosartan specific competitive at1 receptor antagonist 400 800 daily = 18 placebo = 18 8 weeks,C3816446|C0030705|C0205360|G0000000|C0018787|C0004083|C0456387|C0022326|C0018802|C1514756|C1452534|C1999216|C0039798|G0000000|C1516050|C0013072|G0000000|C1514756|C0287041|C0205369|C0679932|C1414408|C0597357|C0231491|C1442061|C1442061|C0332173|G0000000|C0450371|C0032042|G0000000|C0450371|G0000000|C0439230
"Eligible patients were randomly assigned to AC (60/600 mg/m2) followed by: paclitaxel (80 mg/m2; control arm, arm A); paclitaxel followed by trastuzumab (4 mg/kg loading dose, then 2 mg/kg for 52 weeks; sequential arm, arm B); or paclitaxel plus trastuzumab followed by trastuzumab alone (concurrent arm, arm C; Fig 1).",eligible patients randomly assigned ac 60/600 mg/m2 paclitaxel 80 mg/m2 control arm arm paclitaxel trastuzumab 4 mg/kg loading dose 2 mg/kg 52 weeks sequential arm arm paclitaxel trastuzumab trastuzumab concurrent arm arm fig 1,C1548635|C0030705|G0000000|C1516050|C0003354|C0450371|C0026410|C0144576|C0450371|C0026410|C0243148|C0446516|C0446516|C0144576|C0728747|G0000000|C0439272|C1708715|C0178602|G0000000|C0439272|C0450371|C0439230|C1548958|C0446516|C0446516|C0144576|C0728747|C0728747|C0205420|C0446516|C0446516|C0349966|G0000000
Intervention  educational programme with telephone follow-up Participants in the intervention group received the information routinely delivered by the institution at discharge plus an educational programme with telephone follow-up.,intervention educational programme telephone follow-up participants intervention received routinely delivered institution discharge educational programme telephone follow-up,C0886296|C0587721|C1709697|C0039457|C0589120|C0679646|C0886296|C1514756|G0000000|C1705822|C0018704|C0012621|C0587721|C1709697|C0039457|C0589120
"During  the  next  three  heel  sticks,  the  infants  in Kangaroo  Mother  Care  group  received  heel  sticks  during Kangaroo  Mother  Care,  while  infants  in  the  incubator group  received  heel  sticks  in  incubator.",heel sticks infants kangaroo mother care received heel sticks kangaroo mother care infants incubator received heel sticks incubator,C0018870|C1706582|C0021270|C0022494|C0026591|C1947933|C1514756|C0018870|C1706582|C0022494|C0026591|C1947933|C0021270|C0021178|C1514756|C0018870|C1706582|C0021178
"The infant was held in KMC with the addition of rocking, singing and sucking or the infant was held in KMC without additional stimulation.",infant held kmc addition rocking singing sucking infant held kmc additional stimulation,C0021270|C0675390|G0000000|C0332287|C0005899|C0234857|C0233927|C0021270|C0675390|G0000000|C1524062|C1292856
Thirty-three patients undergoing rescue PCI and 17 patients undergoing primary PCI were randomized to either radial (n = 25) or femoral (n = 25) arterial access.,thirty-three patients undergoing rescue pci 17 patients undergoing primary pci randomized radial = 25 femoral = 25 arterial access,C3816446|C0030705|G0000000|G0000000|C4049621|C0450371|C0030705|G0000000|C0205225|C4049621|C0034656|C0442038|G0000000|C0450371|C0015811|G0000000|C0450371|C0003842|C0444454
"Neonates undergoing surgical repair for congenital  heart defects received stepwise dose increases of milrinone  (MR; 0.51 g/kg/min, n = 9) or LeVO (0.10.2 g/kg/min, n =  11) as an i.v.",neonates undergoing surgical repair congenital heart defects received stepwise dose increases milrinone 051 g/kg/min = 9 levo 0102 g/kg/min = 11 iv,C0021289|G0000000|C0543467|C0043240|C0009678|C0018787|C0243067|C1514756|G0000000|C0178602|C0205217|C0128513|C1442061|C1320758|G0000000|G0000000|C0205091|G0000000|C1320758|G0000000|C0450371|C0022326
"An intervention that has been proposed as an alternative for patients that are unwilling or unable to attend the hospital for supervised CR is home-based exercise training.79 A meta-analysis of 12 studies showed comparable short-term improvement in exercise capacity and mortality rates after home-based as compared to centre-based CR.10 However, the long-term eects of home-based CR are not well established.",intervention proposed alternative patients unwilling unable attend hospital supervised cr home-based exercise training79 meta-analysis 12 studies comparable short-term improvement exercise capacity mortality rates home-based compared centre-based cr10 long-term eects home-based cr established,C0886296|C1553874|C1523987|C0030705|C0558080|C1299582|C1999232|C0019994|G0000000|C0201975|C0442519|C0015259|G0000000|C0282458|C0450371|C0947630|G0000000|C0443303|C2986411|C0015259|C1516240|C0026565|C0871208|C0442519|C1707455|C0205099|G0000000|C0443252|G0000000|C0442519|C0201975|C0443211
"The hypotheses were that a) women assigned to an individualized (self-directed) format would exhibit the same or improved healthrelated quality of life outcomes, including physical and psychosocial functioning, frequency and severity of symptoms, ambulation, and weight loss as women assigned to a group format, b) women in both formats would achieve better outcomes than the control group and c) differences in program participants by format would be evident.",hypotheses women assigned individualized self-directed format exhibit improved healthrelated quality life outcomes including physical psychosocial functioning frequency severity symptoms ambulation weight loss women assigned format women formats achieve outcomes control differences program participants format evident,C1512571|C0043210|C1516050|C1881197|C0036588|C1301627|C0015272|C0184511|G0000000|C0332306|C0376558|C1274040|C0332257|C0031809|C0542298|C0205245|C0376249|C0439793|C0683368|C0080331|C0005910|C1517945|C0043210|C1516050|C1301627|C0043210|C1301627|G0000000|C1274040|C0243148|C1705241|C1709697|C0679646|C1301627|C3887511
"The trial patients also participated in the Dutch BOA-trial,13 comparing the effect of coumarin derivatives and acetylsalysilic acid after infra-inguinal bypass surgery.",trial patients participated dutch boa-trial13 comparing coumarin derivatives acetylsalysilic acid infra-inguinal bypass surgery,C0008976|C0030705|G0000000|C0013331|C0006506|C1707455|C0010206|C0243072|G0000000|C0001128|C0542339|C0741847|C0038894
The intervention was designed to encourage patients to personalize the message to seek care quickly in the face of ACS symptoms and to counter emotional coping mechanisms such as denial that might lead to prolonged prehospital delay time.,intervention designed encourage patients personalize message seek care acs symptoms counter emotional coping mechanisms denial lead prolonged prehospital delay time,C0886296|C1707689|G0000000|C0030705|G0000000|C0470166|G0000000|C1947933|G0000000|C0683368|C0677601|C0013987|C0009967|C0441712|C0011317|C0023175|C0439590|G0000000|C0205421|C0040223
"After  local  regional  therapy  (surgery  with  or  without  radiotherapy),  patients  were  randomly  assigned  to  one  of three groups: observation only, 8 mg/kg trastuzumab  given intravenously by 90 minute infusion as a loading  dose followed by 6 mg/kg every 3 weeks for 1 year, or the  same schedule of trastuzumab for 2 years (not reported   here).",local regional therapy surgery radiotherapy patients randomly assigned observation 8 mg/kg trastuzumab intravenously 90 minute infusion loading dose 6 mg/kg 3 weeks 1 schedule trastuzumab 2 reported,C0205276|C0205147|C0039798|C0038894|C0034619|C0030705|G0000000|C1516050|C0302523|G0000000|C0439272|C0728747|G0000000|C0450371|C0439232|C0574032|C1708715|C0178602|G0000000|C0439272|G0000000|C0439230|G0000000|C0086960|C0728747|G0000000|C0684224
"They were reminded quarterly to measure blood pressure and weight and to provide patients in the intervention group with recommendations on healthy lifestyle, including materials about the traditional Mediterranean diet (pulses, fruits, vegetables, fish, and olive oil), physical exercise (GPs offered various options, such as walking and cycling), hypo-caloric diet, and counselling to quit smoking if applicable.",reminded quarterly measure blood pressure weight provide patients intervention recommendations healthy lifestyle including materials traditional mediterranean diet pulses fruits vegetables fish olive oil physical exercise gps offered options walking cycling hypo-caloric diet counselling quit smoking applicable,C0557033|C0332179|C0079809|C0005767|C0033095|C0005910|C1999230|C0030705|C0886296|C0034866|C3898900|C0023676|C0332257|C0520510|C0443324|C0240321|C0012155|C0034107|C0016767|C0042440|C0016163|C0228539|C0028908|C0031809|C0015259|C0272302|C1444648|C1518601|C0080331|C1511572|G0000000|C0012155|C0010210|C0748223|C0037369|C1272460
Further consultations were provided according to pharmacist-determined patient need.,consultations provided pharmacist-determined patient,C0009818|C1999230|C0031323|C0030705
"In the first treatment arm, patients with CHF and a previous history of myocardial infarction were randomised to receive either aspirin (ASA) or warfarin (W).",treatment arm patients chf previous history myocardial infarction randomised receive aspirin asa warfarin,C0039798|C0446516|C0030705|C0018802|C0205156|C0019664|C0027061|C0021308|G0000000|C1514756|C0004057|C0004057|C0043031
"In patients with persistent AF, cardioversion was performed under a new ADT to maintain the sinus rhythm.",patients persistent af cardioversion performed adt maintain sinus rhythm,C0030705|C0205322|C0344434|C0013778|C0884358|C0279492|C0024501|C0016169|C0871269
"Each team included a cardiac rehabilitation nurse, physiotherapist, or exercise therapist, with input from a psychologist or occupational therapist, pharmacist and dietician.",team included cardiac rehabilitation nurse physiotherapist exercise therapist input psychologist occupational therapist pharmacist dietician,C0871489|C0332257|C0018787|C0034991|C0028661|C2362565|C0015259|C0871525|C1708517|C0033908|C0521127|C0871525|C0031323|C3536818
"Before PCI, patients were pretreated by either an intravenous bolus of heparin as follows: unfractionated heparin 50 IU/kg with an upper limit of 4000 IU in patients more than 75 years old, or low molecular weight heparin (enoxaparin) 30 mg intravenously and 1 mg/kg subcutaneously in patients aged less than 75 years, and a bolus of aspirin (250 mg intravenously).",pci patients pretreated intravenous bolus heparin unfractionated heparin 50 iu/kg upper limit 4000 iu patients 75 low molecular weight heparin enoxaparin 30 intravenously 1 mg/kg subcutaneously patients aged 75 bolus aspirin 250 intravenously,C4049621|C0030705|G0000000|C0348016|C1511237|C0019134|G0000000|C0019134|C0450371|C0439463|C1282910|C0439801|G0000000|C0049272|C0030705|C0450371|C0205251|C1521991|C0005910|C0019134|C0206460|C0450371|G0000000|G0000000|C0439272|G0000000|C0030705|C0001779|C0450371|C1511237|C0004057|C1442061|G0000000
"Tailored care plans for practices (practice based training in prescribing and behaviour change, administrative support, quarterly newsletter), and tailored care plans for patients (motivational interviewing, goal identification, and target setting for lifestyle change) with reviews every four months at the practices.",tailored care plans practices practice based training prescribing behaviour change administrative support quarterly newsletter tailored care plans patients motivational interviewing goal identification target setting lifestyle change reviews months practices,C0402883|C1947933|C0270724|C0237607|C0237607|C1527178|C0040607|C0278329|C0004927|C0392747|C1292785|C0183683|C0332179|C0027988|C0402883|C1947933|C0270724|C0030705|C0026605|C0021822|C0018017|C0020792|C1521840|C0542559|C0023676|C0392747|C0282443|C0439231|C0237607
"At this visit, goals were negotiated, strategies were developed for compliance (including provision of behavioral prompts, fridge magnets, diaries, and educational literature), and an individualized exercise program was designed to interface with a home-based self-management program.",visit goals negotiated strategies developed compliance including provision behavioral prompts fridge magnets diaries educational literature individualized exercise program designed interface home-based self-management program,C0545082|C0018017|C0680727|C0679199|G0000000|C0009563|C0332257|C1549071|C0004927|C0871157|G0000000|C0024483|C0376660|C0587721|C0023866|C1881197|C0015259|C1709697|C1707689|C1708533|C0442519|C0086969|C1709697
Slow early responders received 2 additional ABVE-PC cycles before 21 Gy radiation.,slow responders received 2 additional abve-pc cycles 21 gy radiation,C0439834|G0000000|C1514756|G0000000|C1524062|C1879497|C1511572|C0450371|C0018408|C0034519
The cardiac rehabilitation nurse made a home visit in the first week after discharge followed up by telephone calls over six weeks.,cardiac rehabilitation nurse visit week discharge telephone calls weeks,C0018787|C0034991|C0028661|C0545082|C0332174|C0012621|C0039457|C0679006|C0439230
"This consists of bed/chair rest in hospital for 2 weeks, oral penicillin for 2 weeks or until discharge, and then 4 weekly administrations of intramuscular benzathine (long-acting) penicillin.",consists bed/chair rest hospital 2 weeks oral penicillin 2 weeks discharge 4 weekly administrations intramuscular benzathine long-acting penicillin,C0332529|C0004916|C0035253|C0019994|G0000000|C0439230|C0442027|C0030827|G0000000|C0439230|C0012621|G0000000|C0332174|C0001554|C0021492|C0053153|C0205166|C0030827
"Infants at 12 to 72 hours of life were assigned randomly to receive an intramuscular injection of hepatitis B vaccine in the right thigh according to 4 analgesia groups, that is, no analgesia (routine); oral 25% dextrose treatment, given 2 minutes before the injection; skin-to-skin contact, initiated 2 minutes before the injection and persisting throughout the procedure; and a combination of the oral dextrose treatment and skinto-skin contact strategies.",infants 12 72 hours life assigned randomly receive intramuscular injection hepatitis vaccine thigh 4 analgesia analgesia routine oral 25% dextrose treatment 2 minutes injection skin-to-skin contact initiated 2 minutes injection persisting procedure combination oral dextrose treatment skinto-skin contact strategies,C0021270|C0450371|C0450371|C0439227|C0376558|C1516050|G0000000|C1514756|C0021492|C0021485|C0019158|C0042210|C0039866|G0000000|C0002766|C0002766|C0205547|C0442027|C0450371|C0017725|C0039798|G0000000|C0439232|C0021485|C0444099|C0332158|C1548602|G0000000|C0439232|C0021485|G0000000|C0184661|C0205195|C0442027|C0017725|C0039798|C0444099|C0332158|C0679199
"These 3,010 patients were randomly assigned to either six courses of uorouracil 500 mg/m2, epirubicine 100 mg/m2, and cyclophosphamide 500 mg/m2 (FE100C) or epirubicin 75 mg/m2 and docetaxel 75 mg/m2 (ED75) every 3 weeks.",3010 patients randomly assigned courses uorouracil 500 mg/m2 epirubicine 100 mg/m2 cyclophosphamide 500 mg/m2 fe100c epirubicin 75 mg/m2 docetaxel 75 mg/m2 ed75 3 weeks,G0000000|C0030705|G0000000|C1516050|C0750729|G0000000|C1442061|C0026410|G0000000|C1442061|C0026410|C0010583|C1442061|C0026410|G0000000|C0014582|C0450371|C0026410|C0246415|C0450371|C0026410|G0000000|G0000000|C0439230
"Between  March,  1999,  and  July,  2000,  we randomly  assigned  3023  patients  candesartan  (n=1514, target  dose  32  mg  once  daily)  or  matching  placebo (n=1509).",march 1999 july 2000 randomly assigned 3023 patients candesartan n=1514 target dose 32 daily matching placebo n=1509,C3829202|G0000000|C3829447|G0000000|G0000000|C1516050|G0000000|C0030705|C0717550|C0369718|C1521840|C0178602|C0450371|C0332173|C0150103|C0032042|C0369718
"Of the 520 cases randomly assigned to treatment and included in the analysis, 279 were assigned to chest compression plus mouth-tomouth ventilation and 241 to chest compression alone (P=0.10).",520 randomly assigned treatment included analysis 279 assigned chest compression mouth-tomouth ventilation 241 chest compression p=010,C1442061|G0000000|C1516050|C0039798|C0332257|C0002778|C1442061|C1516050|C0817096|C0332459|C0226896|C0035203|C1442061|C0817096|C0332459|C0369773
"Individual education was provided before and during exercise sessions and included exercise training principles, cardiovascular risk factors, nutrition principles, pharmacologic therapy, and identifying target outcomes.",individual education provided exercise sessions included exercise training principles cardiovascular risk factors nutrition principles pharmacologic therapy identifying target outcomes,C0027361|C0013621|C1999230|C0015259|C1883016|C0332257|C0015259|C0040607|G0000000|C0007226|C0035647|C1521761|C0028707|G0000000|C0031330|C0039798|G0000000|C1521840|C1274040
"After 6 months, 38 mg acetylsalicylic acid was given daily.",6 months 38 acetylsalicylic acid daily,G0000000|C0439231|C0450371|G0000000|C0001128|C0332173
"In  a  study  of  52  ambulatory  patients  in  NYHA  functional class IIIIV heart failure, adding 5 or 10 mg/day of pimobendan  to  a  conventional  drug  regimen  for  4  weeks was associated with a signicant increase in maximal exercise  duration  and  peak  oxygen  uptake  compared  with placebo.11 Furthermore, in a multicenter randomized trial of pimobendan,  2.5,  5.0  or  10 mg/day  vs  placebo  for  12 weeks,  including  nearly  200  patients  with  moderate  heart failure,  active  therapy  significantly  increased  exercise capacity and QOL, and was associated with fewer hospitalizations  for  heart  failure  than  placebo.12 It  is  noteworthy that  the  effects  of  pimobendan  did  not  follow  a  simple dose  response  relationship,  as  maximum  efficacy  was associated  with  the  5 mg/day  dose,  and  a  lesser  efcacy was observed with the 10 mg/day dose.",study 52 ambulatory patients nyha functional class iiiiv heart failure adding 5 10 mg/day pimobendan conventional drug regimen 4 weeks signicant increase maximal exercise duration peak oxygen uptake compared placebo11 multicenter randomized trial pimobendan 25 50 10 mg/day placebo 12 weeks including 200 patients moderate heart failure active therapy increased exercise capacity qol fewer hospitalizations heart failure placebo12 noteworthy effects pimobendan follow simple dose response relationship maximum efficacy 5 mg/day dose lesser efcacy observed 10 mg/day dose,C0557651|C0450371|C0439841|C0030705|G0000000|C0205245|C0456387|G0000000|C0018787|C0231174|C1883712|G0000000|C0450371|C0439422|C0071071|C0439858|C0013227|C0040808|G0000000|C0439230|G0000000|C0442805|C0205289|C0015259|C0449238|C0444505|C0030054|C0243144|C1707455|G0000000|C0439743|C0034656|C0008976|C0071071|C0450371|C0450371|C0450371|C0439422|C0032042|C0450371|C0439230|C0332257|C1442061|C0030705|C0205081|C0018787|C0231174|C0205177|C0039798|C0205217|C0015259|C1516240|C0518214|C0205388|C0019993|C0018787|C0231174|G0000000|G0000000|C1280500|C0071071|C0332283|C0205352|C0178602|C0871261|C0439849|C0806909|C1280519|G0000000|C0439422|C0178602|C0547044|G0000000|C1441672|C0450371|C0439422|C0178602
"This prospective, randomized clinical trial of open-label warfarin (target international normalized ratio of 2.5 to 3.0) and double-blind treatment with either aspirin (162 mg once daily) or clopidogrel (75 mg once daily) had a 30-month enrollment period and a minimum of 12 months of treatment.",prospective randomized clinical trial open-label warfarin target international normalized ratio 25 30 double-blind treatment aspirin 162 daily clopidogrel 75 daily 30-month enrollment period minimum 12 months treatment,C0023981|C0034656|C0205210|C0008976|C1709323|C0043031|C1521840|C1512888|C1882115|C0456603|C0450371|C0450371|C0013072|C0039798|C0004057|C1442061|C0332173|C0070166|C0450371|C0332173|C0450371|C1516879|C0439531|C1524031|C0450371|C0439231|C0039798
Investigators were encouraged to use warfarin in patients who developed atrial brillation and were encouraged to reduce the dose of aspirin or use any appropriate antidyspeptic medication if dyspepsia occurred.,investigators encouraged warfarin patients developed atrial brillation encouraged reduce dose aspirin antidyspeptic medication dyspepsia occurred,C0035173|G0000000|C0043031|C0030705|G0000000|C0018792|G0000000|G0000000|G0000000|C0178602|C0004057|G0000000|C0013227|C0013395|C1709305
"At the time of weaning from cardiopulmonary bypass in the levosimendan group, a  continuous infusion of 0.1 g/kg/min of levosimendan and in the milrionone group a  continuous infusion of 0.5 g/kg/min of milrinone for the first postoperative 24 hrs were  initiated.",time weaning cardiopulmonary bypass levosimendan continuous infusion 01 g/kg/min levosimendan milrionone continuous infusion 05 g/kg/min milrinone postoperative 24 hrs initiated,C0040223|C0043084|C0553534|C0741847|C0246904|C0549178|C0574032|C0450371|C1320758|C0246904|G0000000|C0549178|C0574032|C0450371|C1320758|C0128513|C0032790|C0450371|G0000000|C1548602
"In patients with a history of side-effects or intolerance to amiodarone, a class IC antiarrhythmic drug was administered.",patients history side-effects intolerance amiodarone class ic antiarrhythmic drug administered,C0030705|C0019664|C0001688|C0231199|C0002598|C0456387|C0020750|C0003195|C0013227|C1521801
"Patients were randomized to 300 mg of aspirin, to warfarin with a target international normalized ratio (INR) of 2.5 (range 23), or to no antithrombotic therapy.",patients randomized 300 aspirin warfarin target international normalized ratio inr 25 range 23 antithrombotic therapy,C0030705|C0034656|C1442061|C0004057|C0043031|C1521840|C1512888|C1882115|C0456603|C0525032|C0450371|C1514721|C0450371|G0000000|C0039798
"After approval by the local ethics committee and registration in ClinicalTrials.gov  (Identifier: NCT00549107), 78 patients were  assessed for eligibility, and 40 infants undergoing repair of their congenital heart defect  were randomized in a prospective, singlecenter, double-blind trial, 20 allocated to  each group.",approval local ethics committee registration clinicaltrialsgov identifier nct00549107 78 patients assessed eligibility 40 infants undergoing repair congenital heart defect randomized prospective singlecenter double-blind trial 20 allocated,C0205540|C0205276|C0015000|C2699414|C1514821|G0000000|C0600091|G0000000|C0450371|C0030705|C1516048|C0013893|C0450371|C0021270|G0000000|C0043240|C0009678|C0018787|C1457869|C0034656|C0023981|G0000000|C0013072|C0008976|C0450371|G0000000
"The study consisted of three phases: a pilot trial  comprising 17 patients (7 receiving progenitor cells  derived from bone marrow [BMC] and 10 receiving progenitor cells derived from circulating blood  [CPC]); a second phase, in which 75 patients were  randomly assigned to receive intracoronary infusion of BMC (28 patients) or CPC (24) or no cell  infusion (23); and a third phase, in which the 75  randomly assigned patients crossed over to one  of the active treatments if they had originally been  in the control group or to the alternate cell type if  they had initially received intracoronary cell infusion (Fig. 1).",study consisted phases pilot trial comprising 17 patients 7 receiving progenitor cells derived bone marrow bmc 10 receiving progenitor cells derived circulating blood cpc phase 75 patients randomly assigned receive intracoronary infusion bmc 28 patients cpc 24 cell infusion 23 phase 75 randomly assigned patients crossed active treatments originally control alternate cell type initially received intracoronary cell infusion fig 1,C0557651|C0332529|C0585064|C0473169|C0008976|C2700400|C0450371|C0030705|G0000000|C1514756|C0870134|C0007634|C1441547|C0262950|C0086590|C0065839|C0450371|C1514756|C0870134|C0007634|C1441547|C0175630|C0005767|C0431109|C0205390|C0450371|C0030705|G0000000|C1516050|C1514756|C0595454|C0574032|C0065839|C0450371|C0030705|C0431109|C0450371|C0007634|C0574032|C0450371|C0205390|C0450371|G0000000|C1516050|C0030705|C0205203|C0205177|C0087111|G0000000|C0243148|C0332270|C0007634|C0332307|C0205265|C1514756|C0595454|C0007634|C0574032|C0349966|G0000000
Comparator Intervention Patients in the control group attended appointments with their primary care physician and primary care cardiologist within 1 month of discharge.,comparator intervention patients control attended appointments primary care physician primary care cardiologist 1 month discharge,C1707454|C0886296|C0030705|C0243148|C1456498|C0003629|C0205225|C1947933|C0031831|C0205225|C1947933|C0175906|G0000000|C0332177|C0012621
"For  the  rst  heel  stick,  preterm  infants  in  each  group received  no  intervention  (routinely  stayed  in  incubator).",rst heel stick preterm infants received intervention routinely stayed incubator,C1425219|C0018870|C1706582|C0151526|C0021270|C1514756|C0886296|G0000000|G0000000|C0021178
"It comprised a nurse who was specialized in smoking cessation counseling, a dietician who had received training in physical activity counseling, and an administrative coordinator who offered individual consultations 5 days per week, with a telephone hotline available from 9 AM to 6 PM if patients needed information about cardiovascular risk factors and therapeutic education.",comprised nurse specialized smoking cessation counseling dietician received training physical activity counseling administrative coordinator offered individual consultations 5 days week telephone hotline 9 6 pm patients cardiovascular risk factors therapeutic education,C2700400|C0028661|C0205555|C0037369|C1880019|C0010210|C3536818|C1514756|C0040607|C0031809|C0205177|C0010210|C1292785|C1711307|C1444648|C0027361|C0009818|G0000000|C0439228|C0332174|C0039457|C0020042|G0000000|G0000000|C0030266|C0030705|C0007226|C0035647|C1521761|C0087111|C0013621
Before the rst angioplasty patients were randomly assigned to three different strategies: culprit vessel angioplasty-only (COR group); staged revascularisation (SR group) and simultaneous treatment of non-IRA (CR group).,rst angioplasty patients randomly assigned strategies culprit vessel angioplasty-only cor staged revascularisation sr simultaneous treatment non-ira cr,C1425219|C0162577|C0030705|G0000000|C1516050|C0679199|G0000000|C0005847|C0162577|C0018787|C3846398|C0581603|C3813610|C0205420|C0039798|C1518422|C0201975
"Secondary prevention recommendations involve lifestyle changes such as: tobacco cessation, blood pressure control, lipid management, physical activity, weight management, diabetes management, correct use of medication, inuenza vaccination, treatment of depression and participation in cardiac rehabilitation programmes (Smith et al.",secondary prevention recommendations involve lifestyle tobacco cessation blood pressure control lipid management physical activity weight management diabetes management correct medication inuenza vaccination treatment depression participation cardiac rehabilitation programmes smith al,C0027627|C0199176|C0034866|G0000000|C0023676|C0040329|C1880019|C0005767|C0033095|C0243148|C0023779|C0001554|C0031809|C0205177|C0005910|C0001554|C0011847|C0001554|C2349182|C0013227|G0000000|C0042196|C0039798|C0011570|C0679823|C0018787|C0034991|G0000000|C0554249|C0202311
"From January 2005 to September 2006, 70 patients with a diagnosis of DM2 and paroxysmal (n = 29) or persistent (n = 41) AF were randomized to receive either pulmonary vein isolation or a new antiarrhythmic drug treatment (ADT) with a 1-year follow-up.",january 2005 september 2006 70 patients diagnosis dm2 paroxysmal = 29 persistent = 41 af randomized receive pulmonary vein isolation antiarrhythmic drug treatment adt 1-year follow-up,C3829466|G0000000|C3828193|G0000000|C0450371|C0030705|C0011900|G0000000|C0205311|G0000000|C0450371|C0205322|G0000000|C0450371|C0344434|C0034656|C1514756|C0024109|C0042449|C0204727|C0003195|C0013227|C0039798|C0279492|C0439234|C0589120
"Warfarin therapy, which was managed by either the investigative team or an anticoagulation clinic, was initiated at 4 mg daily except in subjects 70 years of age or taking amiodarone; they were started at 3 mg daily.",warfarin therapy managed investigative team anticoagulation clinic initiated 4 daily subjects 70 age amiodarone started 3 daily,C0043031|C0039798|C1273870|C0220825|C0871489|C0003281|C0002424|C1548602|G0000000|C0332173|C0681850|C0450371|C0001779|C0002598|C1272689|G0000000|C0332173
"In  KMC  group,  the  baby  was  kept  in  Kangaroo Mother Care for 15 minutes before the removal of the adhesive tape.",kmc baby kangaroo mother care 15 minutes removal adhesive tape,G0000000|C0021270|C0022494|C0026591|C1947933|C0450371|C0439232|C0015252|C0001516|C0183828
Treatment schedule for INT-0137 is shown schematically with doxorubicin in blue and cyclophosphamide in yellow.,treatment schedule int-0137 schematically doxorubicin blue cyclophosphamide yellow,C0039798|C0086960|C0063789|G0000000|C0013089|C1260957|C0010583|C0221205
"WATCH was a multinational, prospective, randomized trial in which patients were assigned to 1 of 3 treatment arms: aspirin 162 mg or clopidogrel 75 mg daily provided in a double blind, double-dummy manner or open-label warfarin titrated to a target INR of 2.5 to 3.0 with a designated acceptable range of 2.0 to 3.5.",watch multinational prospective randomized trial patients assigned 1 3 treatment arms aspirin 162 clopidogrel 75 daily provided double blind double-dummy manner open-label warfarin titrated target inr 25 30 designated acceptable range 20 35,C0699864|G0000000|C0023981|C0034656|C0008976|C0030705|C1516050|G0000000|G0000000|C0039798|C0206655|C0004057|C1442061|C0070166|C0450371|C0332173|C1999230|C0205173|C0150108|C0205173|G0000000|C1709323|C0043031|C1883350|C1521840|C0525032|C0450371|C0450371|C1524084|C1879533|C1514721|C0450371|C0450371
"In group 1 (incubator), the neonates were placed in the prone position at 3045 elevation, 10 min before the painful stimulus.",1 incubator neonates prone position 3045 elevation 10 min painful stimulus,G0000000|C0021178|C0021289|C0033422|C0733755|G0000000|C0439775|C0450371|C0702093|C0030193|C0234402
Rapid early responders (RERs) to 3 ABVE-PC cycles received 21 Gy radiation to involved regions; RER was documented in 63% of patients.,rapid responders rers 3 abve-pc cycles received 21 gy radiation involved regions rer documented 63% patients,C0456962|G0000000|C0230779|G0000000|C1879497|C1511572|C1514756|C0450371|C0018408|C0034519|C1314939|C0017446|C0230779|C1301725|C0450371|C0030705
"In the double-blind, double-dummy design, patients who were assigned to active warfarin received warfarin and placebo aspirin, and patients  assigned to active aspirin received aspirin and placebo warfarin.18 The statistical analysis center fabricated clinically plausible INR results for patients  in the aspirin group and provided these results to  the sites, along with the actual INR results for the  patients in the warfarin group, so that all the patients were treated as if they were receiving active  warfarin.",double-blind double-dummy design patients assigned active warfarin received warfarin placebo aspirin patients assigned active aspirin received aspirin placebo warfarin18 statistical analysis center fabricated clinically plausible inr patients aspirin provided sites actual inr patients warfarin patients treated receiving active warfarin,C0013072|C0205173|C1707689|C0030705|C1516050|C0205177|C0043031|C1514756|C0043031|C0032042|C0004057|C0030705|C1516050|C0205177|C0004057|C1514756|C0004057|C0032042|G0000000|C0038215|C0002778|C0205099|G0000000|G0000000|G0000000|C0525032|C0030705|C0004057|C1999230|C0205145|C0237400|C0525032|C0030705|C0043031|C0030705|C1522326|C1514756|C0205177|C0043031
"The STEMI-RADIAL (ST Elevation Myocardial Infarction treated by RADIAL or femoral approach) trial was a randomized, national, multicenter, parallel group trial.",stemi-radial st elevation myocardial infarction treated radial femoral approach trial randomized national multicenter parallel trial,C3538872|C0036056|C0439775|C0027061|C0021308|C1522326|C0442038|C0015811|C0449445|C0008976|C0034656|C3245503|C0439743|C2348042|C0008976
"Among the 528 patients, 268 were randomly assigned to the observation arm and 260 to the trastuzumab arm; 279 and 249 were previously randomly assigned to receive six cycles of FE100C and ED75,",528 patients 268 randomly assigned observation arm 260 trastuzumab arm 279 249 randomly assigned receive cycles fe100c ed75,C1442061|C0030705|C1442061|G0000000|C1516050|C0302523|C0446516|C1442061|C0728747|C0446516|C1442061|C1442061|G0000000|C1516050|C1514756|C1511572|G0000000|G0000000
"Within the 2 years reporting period 3 (1.1%) grafts, 2 P-EXS and 1 P-non-EXS, had been removed because of an infection.",2 reporting period 3 11% grafts 2 p-exs 1 p-non-exs removed infection,G0000000|C0700287|C0439531|G0000000|C0450371|C0332835|G0000000|C0369773|G0000000|C0369773|C0849355|C0009450
OBJECTIVE To examine the effect of a lifestyle-focused semipersonalized support program delivered by mobile phone text message on cardiovascular risk factors.,objective examine lifestyle-focused semipersonalized support program delivered mobile phone text message cardiovascular risk factors,C0018017|G0000000|C0023676|G0000000|C0183683|C1709697|C1705822|C0231435|C1515258|C1527021|C0470166|C0007226|C0035647|C1521761
Major graft reinterventions occurred in 17 FUSION BIOLINE patients (16.2%) vs 31 patients (30.7%) treated with standard ePTFE (P  .033).,major graft reinterventions occurred 17 fusion bioline patients 162% 31 patients 307% treated standard eptfe 033,C0205082|C0181074|G0000000|C1709305|C0450371|C0332466|G0000000|C0030705|C1442061|C0450371|C0030705|C1442061|C1522326|C1442989|G0000000|C1442061
"During weeks 18 to 25, patients were asked to further reduce their on-site exercise to 1 session every 2 weeks.",weeks 18 25 patients reduce on-site exercise 1 session 2 weeks,C0439230|C0450371|C0450371|C0030705|G0000000|C1720176|C0015259|G0000000|C1883016|G0000000|C0439230
Patients with Dilated Cardiomyopathy (DCM) were randomised to receive either warfarin or placebo.,patients dilated cardiomyopathy dcm randomised receive warfarin placebo,C0030705|C0700124|C0878544|G0000000|G0000000|C1514756|C0043031|C0032042
"The educational programme consisted of three booklets entitled Percutaneous Transluminal Coronary Angioplasty, Going home after your coronary angioplasty, and How to take care of your heart and your health, and telephone follow-up.",educational programme consisted booklets entitled percutaneous transluminal coronary angioplasty coronary angioplasty care heart health telephone follow-up,C0587721|C1709697|C0332529|C0030258|G0000000|C0522523|C0522520|C0018787|C0162577|C0018787|C0162577|C1947933|C0018787|C0018684|C0039457|C0589120
Eligible patients were randomly assigned by computer generation (in 2 blocks in a 1:1 ratio) to either transfemoral or transradial catheterization.,eligible patients randomly assigned computer generation 2 blocks 11 ratio transfemoral transradial catheterization,C1548635|C0030705|G0000000|C1516050|C0009622|C0079411|G0000000|C0028778|C0450371|C0456603|G0000000|G0000000|C0007430
"Hospital-based exercise sessions included a warm-up, 30 to 40 minutes of aerobic exercise with continuous ECG monitoring, and a cooldown.",hospital-based exercise sessions included warm-up 30 40 minutes aerobic exercise continuous ecg monitoring cooldown,C0019994|C0015259|C1883016|C0332257|C2350169|C0450371|C0450371|C0439232|C1510824|C0015259|C0549178|C1623258|C0150369|G0000000
"The current study was an open-label, randomized, controlled trial comparing no antithrombotic therapy, aspirin (300 mg/day), and warfarin (target international normalized ratio 2.5) in patients with heart failure and left ventricular systolic dysfunction requiring diuretic therapy.",current study open-label randomized controlled trial comparing antithrombotic therapy aspirin 300 mg/day warfarin target international normalized ratio 25 patients heart failure left ventricular systolic dysfunction requiring diuretic therapy,C0521116|C0557651|C1709323|C0034656|C2587213|C0008976|C1707455|G0000000|C0039798|C0004057|C1442061|C0439422|C0043031|C1521840|C1512888|C1882115|C0456603|C0450371|C0030705|C0018787|C0231174|C0205091|C0018827|C0039155|C0031847|G0000000|C0012798|C0039798
"The objective measures were selected on the basis of the following additional criteria: They (a) provided valid, reproducible data on physical mobility, (b) were appropriate for women over 60 years of age with heart disease, (c)  entailed  minimal  risk  to  participants,  (d)  did  not  place unreasonable demands on professional staff at the hospital sites, and (e) were relatively low in cost.",objective measures selected basis additional criteria provided valid reproducible data physical mobility women 60 age heart disease entailed minimal risk participants unreasonable demands professional staff hospital sites low cost,C0018017|C0079809|C1707391|C1527178|C1524062|C0243161|C1999230|C2349099|C1514863|C1511726|C0031809|C0425245|C0043210|C0450371|C0001779|C0018787|C0012634|G0000000|C0547040|C0035647|C0679646|G0000000|C0441516|C0679924|C0851286|C0019994|C0205145|C0205251|C0010186
"In the carvedilol group, 12.5 mg once-daily oral carvedilol was given during 6 months.",carvedilol 125 once-daily oral carvedilol 6 months,C0054836|C1442061|C0332173|C0442027|C0054836|G0000000|C0439231
Sixty  patients were randomized into 2 groups of 30 each: group 1 had a full sternotomy  and group 2 had a ministernotomy.,sixty patients randomized 2 30 1 sternotomy 2 ministernotomy,C3816724|C0030705|C0034656|G0000000|C0450371|G0000000|C0185792|G0000000|G0000000
"During this period patients continued with their background therapy and either telmisartan 10, 20, 40, or 80 mg once daily instead of enalapril, or continued enalapril 10 mg twice daily.",period patients continued background therapy telmisartan 10 20 40 80 daily enalapril continued enalapril 10 daily,C0439531|C0030705|C0549178|C1706907|C0039798|C0248719|C0450371|C0450371|C0450371|C0450371|C0332173|C0014025|C0549178|C0014025|C0450371|C0332173
"In addition to treatment with conventional heart failure medications, patients were assigned to receive placebo or carvedilol.",addition treatment conventional heart failure medications patients assigned receive placebo carvedilol,C0332287|C0039798|C0439858|C0018787|C0231174|C0013227|C0030705|C1516050|C1514756|C0032042|C0054836
Therefore a   therapeutic window   was chosen and patients received a single dose of DNR either as 1-h or  24-h  infusion  one  week  before  the  start  of  induction  therapy.,therapeutic window chosen patients received single dose dnr 1-h 24-h infusion week start induction therapy,C0087111|C0557702|C1707391|C0030705|C1514756|C0037179|C0178602|C0011015|C0033727|C0450371|C0574032|C0332174|C0439659|C0205263|C0039798
Patients were randomized to placebo or enoximone at 25 or 50 mg orally three times a day.,patients randomized placebo enoximone 25 50 orally times day,C0030705|C0034656|C0032042|C0116190|C0450371|C0450371|C0442027|C0040223|C0332173
"In EBM group, a swab soaked in EBM was kept in the babys mouth for 2 minutes before the removal of  the intervention.",ebm swab soaked ebm babys mouth 2 minutes removal intervention,C0795974|C0183753|C0204774|C0795974|G0000000|C0226896|G0000000|C0439232|C0015252|C0886296
"We randomly assigned 1010 women with axillary-nodepositive or high-risk nodenegative cancer to receive three cycles of docetaxel or vinorelbine, followed by (in  both groups) three cycles of fluorouracil, epirubicin, and cyclophosphamide.",randomly assigned 1010 women axillary-nodepositive high-risk nodenegative cancer receive cycles docetaxel vinorelbine cycles fluorouracil epirubicin cyclophosphamide,G0000000|C1516050|G0000000|C0043210|C0004454|C0332167|G0000000|C0006826|C1514756|C1511572|C0246415|C0078257|C1511572|C0016360|C0014582|C0010583
We enrolled 25 patients each in the carvedilol and control groups.,enrolled 25 patients carvedilol control,G0000000|C0450371|C0030705|C0054836|C0243148
"In line with current recommendations [5] patients were also encouraged to exercise at home, building up to five sessions a week.",current recommendations 5 patients encouraged exercise building sessions week,C0521116|C0034866|G0000000|C0030705|G0000000|C0015259|C1547706|C1883016|C0332174
"In 2 of 7 PCI patients with a complication, a glycoprotein IIa IIIb inhibitor had been used, while glycoprotein IIa IIIb inhibitors were used in 9/72 patients without access site complication (P 5 n.s.).",2 7 pci patients complication glycoprotein iia iiib inhibitor glycoprotein iia iiib inhibitors 9/72 patients access site complication 5 ns,G0000000|G0000000|C4049621|C0030705|C0009566|C0017968|G0000000|G0000000|C1999216|C0017968|G0000000|G0000000|C0243077|C0450371|C0030705|C0444454|C0205145|C0009566|G0000000|C0038944
"Patients fulfilling all entry criteria were randomized to twice-daily dosing with placebo, low-dose carvedilol (target dose of 0.2 mg/kg per dose if weight 62.5 kg or 12.5 mg per dose if weight 62.5 kg) or high-dose carvedilol (target dose of 0.4 mg/kg per dose if weight 62.5 kg or 25 mg per dose if weight 62.5 kg) in a double-blind manner following a ratio of 1:1:1.",patients fulfilling entry criteria randomized twice-daily dosing placebo low-dose carvedilol target dose 02 mg/kg dose weight 625 125 dose weight 625 high-dose carvedilol target dose 04 mg/kg dose weight 625 25 dose weight 625 double-blind manner ratio 111,C0030705|C1550543|C1705654|C0243161|C0034656|C0585361|G0000000|C0032042|C0445550|C0054836|C1521840|C0178602|C0450371|C0439272|C0178602|C0005910|C1442061|C1442061|C0178602|C0005910|C1442061|C0444956|C0054836|C1521840|C0178602|C0450371|C0439272|C0178602|C0005910|C1442061|C0450371|C0178602|C0005910|C1442061|C0013072|G0000000|C0456603|C1442061
"Between March 2013March 2014 a total of 55 patients agreed to participate in the study, of which 26 were allocated to the CT group and 29 to the HT group.",march 2013march 2014 total 55 patients agreed participate study 26 allocated ct 29 ht,C3829202|G0000000|G0000000|C0439175|C0450371|C0030705|C3641827|G0000000|C0557651|C0450371|G0000000|C0007673|C0450371|C0018510
"Intervention The text messagebased prevention program involved delivery of regular semipersonalized text messages (some messages personally addressed through a mail-mergetype function with the participants preferred name) providing advice, motivation, and information that aimed to improve diet, increase physical activity, and encourage smoking cessation (if relevant).",intervention text messagebased prevention program involved delivery regular semipersonalized text messages messages personally addressed mail-mergetype function participants preferred providing advice motivation aimed improve diet increase physical activity encourage smoking cessation relevant,C0886296|C1527021|G0000000|C0199176|C1709697|C1314939|C0011209|C0205272|G0000000|C1527021|C0470166|C0470166|G0000000|C0376649|C0024492|C0031843|C0679646|C0558295|C1999230|C0150600|C0026605|C1947946|G0000000|C0012155|C0442805|C0031809|C0205177|G0000000|C0037369|C1880019|C2347946
This could be due to staff encouragement of patients to exercise at their target heart rate for the full prescribed duration in the supervised setting.,staff encouragement patients exercise target heart rate prescribed duration supervised setting,C0851286|C0870494|C0030705|C0015259|C1521840|C0018787|C0871208|C0278329|C0449238|G0000000|C0542559
Patients with Ischaemic Heart Disease were randomised to receive either aspirin 325 mg or warfarin.,patients ischaemic heart disease randomised receive aspirin 325 warfarin,C0030705|C0475224|C0018787|C0012634|G0000000|C1514756|C0004057|C1442061|C0043031
"Patients and methods: From October 2000 until June 2005, 1121 node-positive patients were randomized to sequential dose-dense epirubicin 110 mg/m2 and paclitaxel (Taxol, Bristol Myers-Squibb, Princeton, New Jersey, USA) 250 mg/m2 (group A), or concurrent epirubicin 83 mg/m2 and paclitaxel 187 mg/m2 (group B), both followed by three cycles of intensied combination chemotherapy with cyclophosphamide, methotrexate and uorouracil (CMF).",patients methods october 2000 june 2005 1121 node-positive patients randomized sequential dose-dense epirubicin 110 mg/m2 paclitaxel taxol bristol myers-squibb princeton jersey usa 250 mg/m2 concurrent epirubicin 83 mg/m2 paclitaxel 187 mg/m2 cycles intensied combination chemotherapy cyclophosphamide methotrexate uorouracil cmf,C0030705|C0025663|C3828732|G0000000|C3829443|G0000000|G0000000|C0746319|C0030705|C0034656|C1548958|C0178602|C0014582|C1442061|C0026410|C0144576|C0678133|G0000000|C0331904|C0331889|C0454673|C0041703|C1442061|C0026410|C0205420|C0014582|C0450371|C0026410|C0144576|C1442061|C0026410|C1511572|G0000000|C0205195|C0013216|C0010583|C0025677|G0000000|C0950521
"As part of the routine management, all  infants received three doses of methylprednisolone, 8 h apart, starting  the night before surgery.",routine management infants received doses methylprednisolone 8 starting night surgery,C0205547|C0001554|C0021270|C1514756|C0178602|C0025815|G0000000|C0439659|C0240526|C0038894
"Radial artery cannulation was performed as previously described. To summarise, the right radial puncture was performed under local anaesthesia (subcutaneous 1 ml of 2% lidocaine) using a 20-gauge needle and a 0.022 inch hydrophilic guide-wire.",radial artery cannulation performed summarise radial puncture performed local anaesthesia subcutaneous 1 2% lidocaine 20-gauge needle 0022 inch hydrophilic guide-wire,C0442038|C0003842|C0917707|C0884358|G0000000|C0442038|C0033119|C0884358|C0205276|C0002903|C0443315|G0000000|G0000000|C0023660|C0450371|C0027551|G0000000|C0439204|C0475370|C0181089
"intervention  components  include patient assessment, care planning,  routine nurse monitoring, patient self-monitoring,  education,  care  coordination,  and  service  arrangement.",intervention components patient assessment care planning routine nurse monitoring patient self-monitoring education care coordination service arrangement,C0886296|C0449432|C0030705|C1261322|C1947933|C0032074|C0205547|C0028661|C0150369|C0030705|C0588436|C0013621|C1947933|C0242414|C0557854|C0449830
Amifostine was administered to 15 patients (740 mg/m2/dose) as a 15-min intravenous infusion immediately prior to any cisplatin administration.,amifostine administered 15 patients 740 mg/m2/dose 15-min intravenous infusion prior cisplatin administration,C0015020|C1521801|C0450371|C0030705|C1442061|C0026410|C0450371|C0348016|C0574032|C0332152|C0008838|C0001554
Regimens consisted of either doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) every 21 days for four cycles followed by paclitaxel (175 mg/m2) every 3 weeks for four cycles (arm 1) or the same chemotherapy plus weekly trastuzumab starting with the rst dose of paclitaxel at a loading dose of 4 mg/kg followed by 2 mg/kg for 51 weeks (arm 2).,regimens consisted doxorubicin 60 mg/m2 cyclophosphamide 600 mg/m2 21 days cycles paclitaxel 175 mg/m2 3 weeks cycles arm 1 chemotherapy weekly trastuzumab starting rst dose paclitaxel loading dose 4 mg/kg 2 mg/kg 51 weeks arm 2,C2945654|C0332529|C0013089|C0450371|C0026410|C0010583|C1442061|C0026410|C0450371|C0439228|C1511572|C0144576|C1442061|C0026410|G0000000|C0439230|C1511572|C0446516|G0000000|C0013216|C0332174|C0728747|C0439659|C1425219|C0178602|C0144576|C1708715|C0178602|G0000000|C0439272|G0000000|C0439272|C0450371|C0439230|C0446516|G0000000
"In  the  UKALL  X  trial  the  patients  received  daunorubicin  as  a  bolus injection, and in the UKALL XI trial in a 6   h infusion with  the same cumulative dose.",ukall trial patients received daunorubicin bolus injection ukall xi trial 6 infusion cumulative dose,G0000000|C0008976|C0030705|C1514756|C0011015|C1511237|C0021485|G0000000|C1720296|C0008976|G0000000|C0574032|C1511559|C0178602
"During these three sessions, patients received instructions on how to use a wearable heart rate monitor (Garmin Forerunner 70) and how to upload the recorded exercise data to a web application (Garmin Connect) through the Internet.",sessions patients received instructions wearable heart rate monitor garmin forerunner 70 upload recorded exercise data web application garmin connect internet,C1883016|C0030705|C1514756|C0302828|G0000000|C0018787|C0871208|C0030695|G0000000|G0000000|C0450371|C1710578|C0034869|C0015259|C1511726|C0282111|C0185125|G0000000|C2986575|C0282111
"Patients were randomly assigned to receive either (arm I) AC given in combination (AC) doxorubicin 54 mg/m2 and cyclophosphamide 1.2 g/m2 intravenously (IV) every 3 weeks for six cycles or (arm II) in sequence (A 3 C) doxorubicin 40.5 mg/m2 IV days 1 and 2 of a 21-day cycle for four cycles, followed by cyclophosphamide 2.4 gm/m2 IV every 2 weeks for three cycles.",patients randomly assigned receive arm ac combination ac doxorubicin 54 mg/m2 cyclophosphamide 12 g/m2 intravenously iv 3 weeks cycles arm ii sequence 3 doxorubicin 405 mg/m2 iv days 1 2 21-day cycle cycles cyclophosphamide 24 gm/m2 iv 2 weeks cycles,C0030705|G0000000|C1516050|C1514756|C0446516|C0003354|C0205195|C0003354|C0013089|C0450371|C0026410|C0010583|C0450371|C0439267|G0000000|C0022326|G0000000|C0439230|C1511572|C0446516|G0000000|C0004793|G0000000|C0013089|C1442061|C0026410|C0022326|C0439228|G0000000|G0000000|C0450371|C1511572|C1511572|C0010583|C0450371|C0017480|C0022326|G0000000|C0439230|C1511572
"We  randomly  assigned  patients  candesartan (n=1276,  target  dose  32  mg  once  daily)  or  placebo (n=1272).",randomly assigned patients candesartan n=1276 target dose 32 daily placebo n=1272,G0000000|C1516050|C0030705|C0717550|C0369718|C1521840|C0178602|C0450371|C0332173|C0032042|C0369718
Patients and Methods High-risk node-negative or low-risk node-positive breast cancer patients received AC given: (arm I) concurrently (AC) doxorubicin 54 mg/m2 and cyclophosphamide 1.2 g/m2 intravenously (IV) every 3 weeks for six cycles; or (arm II) in sequence (A 3 C) doxorubicin 40.5 mg/m2 IV days 1 and 2 every 3 weeks for four cyles followed by cyclophosphamide 2.4 gm/m2 IV every 2 weeks for three cycles.,patients methods high-risk node-negative low-risk node-positive breast cancer patients received ac arm concurrently ac doxorubicin 54 mg/m2 cyclophosphamide 12 g/m2 intravenously iv 3 weeks cycles arm ii sequence 3 doxorubicin 405 mg/m2 iv days 1 2 3 weeks cyles cyclophosphamide 24 gm/m2 iv 2 weeks cycles,C0030705|C0025663|C0332167|C0678034|C3272281|C0746319|C0006141|C0006826|C0030705|C1514756|C0003354|C0446516|G0000000|C0003354|C0013089|C0450371|C0026410|C0010583|C0450371|C0439267|G0000000|C0022326|G0000000|C0439230|C1511572|C0446516|G0000000|C0004793|G0000000|C0013089|C1442061|C0026410|C0022326|C0439228|G0000000|G0000000|G0000000|C0439230|G0000000|C0010583|C0450371|C0017480|C0022326|G0000000|C0439230|C1511572
"All patients received the same intravenous neoadjuvant  chemotherapy regimen, consisting of several non-crossresistant cytotoxic agents: doxorubicin 60 mg/m (given  rst)  plus  paclitaxel  150  mg/m  infused  during  3  h,  every  3  weeks  for  three  cycles,  followed  by  paclitaxel  175  mg/m  administered  every  3  weeks  for  four  cycles.",patients received intravenous neoadjuvant chemotherapy regimen consisting non-crossresistant cytotoxic agents doxorubicin 60 mg/m rst paclitaxel 150 mg/m infused 3 3 weeks cycles paclitaxel 175 mg/m administered 3 weeks cycles,C0030705|C1514756|C0348016|C0600558|C0013216|C0040808|C0332529|C1518422|C0677881|C0450442|C0013089|C0450371|C0026410|C1425219|C0144576|C1442061|C0026410|G0000000|G0000000|G0000000|C0439230|C1511572|C0144576|C1442061|C0026410|C1521801|G0000000|C0439230|C1511572
"After reaching the target dose (digoxin: serum level .0.9 nmol / l; propranolol: a mean heart rate of 110  120 / min) heart failure score, hemodynamic measurements by echocardiography, 24 h Holter ECG and clinical laboratory were determined.",reaching target dose digoxin serum level 09 nmol / propranolol heart rate 110 120 / min heart failure score hemodynamic measurements echocardiography 24 holter ecg clinical laboratory determined,C2584321|C1521840|C0178602|C0012265|C0229671|C0441889|C0450371|C0439191|G0000000|C0033497|C0018787|C0871208|C1442061|C1442061|G0000000|C0702093|C0018787|C0231174|C0449820|C0019010|C0242485|C0013516|C0450371|G0000000|C1623258|C0205210|C0022877|G0000000
"In the second stage of the study, the effect of KMC and  EBM  on  pain  during  removal  of  adhesive  tape  in VLBW  neonates  was  assessed.",stage study kmc ebm pain removal adhesive tape vlbw neonates assessed,C0205390|C0557651|G0000000|C0795974|C0030193|C0015252|C0001516|C0183828|C0282666|C0021289|C1516048
"Twenty-four-h Holter recordings using two-channel recorders were obtained at trial entry, after the run in phase and in those patients, who received propranolol at the end of the titration period.",twenty-four-h holter recordings two-channel recorders trial entry phase patients received propranolol titration period,C3715070|G0000000|G0000000|C0205448|C0182913|C0008976|C1705654|C0205390|C0030705|C1514756|C0033497|C0162621|C0439531
"Study 1 (80-min study, N  18) tested the effect of 80 min of KC before and throughout the heel stick procedure versus incubator care.",study 1 80-min study 18 tested 80 min kc heel stick procedure versus incubator care,C0557651|G0000000|C0450371|C0557651|C0450371|C0392366|C0450371|C0702093|C0022575|C0018870|C1706582|C0184661|G0000000|C0021178|C1947933
Patients  were  randomly  assigned  candesartan  (target  dose 32 mg once daily) or matching placebo.,patients randomly assigned candesartan target dose 32 daily matching placebo,C0030705|G0000000|C1516050|C0717550|C1521840|C0178602|C0450371|C0332173|C0150103|C0032042
Patients in the control group received usual care.,patients control received usual care,C0030705|C0243148|C1514756|C3538928|C1947933
"Nurse case managers provide education  to patients on the recognition of signs and  symptoms of their disease; how to monitor  vital  signs;  the  cause  of  diseases;  how  to  better adhere to diet, exercise, and medication regimens; and strategies to cope with  chronic illness.",nurse managers provide education patients recognition signs symptoms disease monitor vital signs diseases adhere diet exercise medication regimens strategies cope chronic illness,C0028661|C0335141|C1999230|C0013621|C0030705|C0524637|C0220912|C0683368|C0012634|C0030695|C0442732|C0220912|C0012634|C3714578|C0012155|C0015259|C0013227|C2945654|C0679199|C0009967|C0205191|C0221423
"Interventions: At weaning from cardiopulmonary bypass, either  a 24-hr infusion of 0.1 g/kg/min levosimendan or of 0.5 g/kg/min   milrinone were administered.",interventions weaning cardiopulmonary bypass 24-hr infusion 01 g/kg/min levosimendan 05 g/kg/min milrinone administered,C0886296|C0043084|C0553534|C0741847|C0450371|C0574032|C0450371|C1320758|C0246904|C0450371|C1320758|C0128513|C1521801
Psychiatric clinical nurse specialists or clinical psychology doctoral students administered the CBT intervention; all received additional training in Beck's CBT and participated in mock patient sessions prior to enrolling participants described in detail below.,psychiatric clinical nurse specialists clinical psychology doctoral students administered cbt intervention received additional training becks cbt participated mock patient sessions prior enrolling participants detail,C0205487|C0205210|C0028661|C0087009|C0205210|C0033909|C0031831|C0038492|C1521801|C0009244|C0886296|C1514756|C1524062|C0040607|G0000000|C0009244|G0000000|C0562577|C0030705|C1883016|C0332152|G0000000|C0679646|C1522508
The final study group was n=979 in the Pinard arm and n=992 in the Doppler arm.,final study n=979 pinard arm n=992 doppler arm,C0205088|C0557651|C0369718|G0000000|C0446516|C0369718|C0554756|C0446516
"Each session lasted approximately 1 h, beginning with a warm-up phase of calisthenics and stretching for 15 to 20 min, followed by 40 min of aerobic activity on a cycle ergometer, a treadmill, or both.",session lasted 1 warm-up phase calisthenics stretching 15 20 min 40 min aerobic activity cycle ergometer treadmill,C1883016|C1517741|G0000000|C2350169|C0205390|C0006759|C0600080|C0450371|C0450371|C0702093|C0450371|C0702093|C1510824|C0205177|C1511572|C0180748|C0184069
Participation in the BOA-trial did not interfere with the present study because patients were randomized to either coumarin derivates or acetylsalysilic acid.,participation boa-trial interfere study patients randomized coumarin derivates acetylsalysilic acid,C0679823|C0006506|C0521102|C0557651|C0030705|C0034656|C0010206|G0000000|G0000000|C0001128
"MAIN OUTCOMES AND MEASURES The primary outcome was a composite that included at least 1 of the following: smoking cessation, at least 3 hours per week of physical activity, at least 5% reduction in weight, and at least 4% reduction in waist circumference.",main outcomes measures primary outcome composite included 1 smoking cessation 3 hours week physical activity 5% reduction weight 4% reduction waist circumference,C0205225|C1274040|C0079809|C0205225|C1274040|C0205199|C0332257|G0000000|C0037369|C1880019|G0000000|C0439227|C0332174|C0031809|C0205177|G0000000|C0301630|C0005910|G0000000|C0301630|C0230097|C0332520
Antiarrhythmic drugs were discontinued 5 half-life periods (or 1 week for amiodarone) before ablation; antiarrhythmics were re-initiated immediately after CA for the 3-month blanking period.,antiarrhythmic drugs discontinued 5 half-life periods 1 week amiodarone ablation antiarrhythmics re-initiated 3-month blanking period,C0003195|C0013227|C1444662|G0000000|C0018517|C0439531|G0000000|C0332174|C0002598|C0547070|C0003195|C0556581|C0332177|C0750479|C0439531
"Post-operatively, patients were randomized to lifelong treatment with either acid (Aspirin) 80 mg daily or coumarin derivates (Sintrom) [target INR ratio 3.0e4.5], in accordance to local",post-operatively patients randomized lifelong treatment acid aspirin 80 daily coumarin derivates sintrom target inr ratio 30e45 local,C0687676|C0030705|C0034656|G0000000|C0039798|C0001128|C0004057|C0450371|C0332173|C0010206|G0000000|C0919378|C1521840|C0525032|C0456603|G0000000|C0205276
"Methods: Using a randomized crossover design, preterm neonates (n = 18) between 28 and 37 weeks gestational age within 10 days of life from two university-afliated level III NICUs undergoing routine heel lance were assigned to receive KC 30 min before and during the procedure from either their mother (MKC) or an unrelated woman.",methods randomized crossover design preterm neonates = 18 28 37 weeks gestational age 10 days life university-afliated level iii nicus undergoing routine heel lance assigned receive kc 30 min procedure mother mkc unrelated woman,C0025663|C0034656|C0010366|C1707689|C0151526|C0021289|G0000000|C0450371|C0450371|C0450371|C0439230|C0439671|C0001779|C0450371|C0439228|C0376558|C0041740|C0441889|C0439070|C0021709|G0000000|C0205547|C0018870|C0522666|C1516050|C1514756|C0022575|C0450371|C0702093|C0184661|C0026591|G0000000|C0445356|C0043210
Control practices provided usual care.,control practices provided usual care,C0243148|C0237607|C1999230|C3538928|C1947933
"In addition, all patients received vitamin B6 at a dose of 300 mg per day throughout the study to prevent PPE.",addition patients received vitamin b6 dose 300 day study prevent ppe,C0332287|C0030705|C1514756|C0042890|C0005558|C0178602|C1442061|C0332173|C0557651|C0309872|G0000000
"During month 1, patients followed identical regimens, including 3 ECG-monitored exercise sessions/ week, with encouragement to achieve >5 thirty-minute sessions/week.",month 1 patients identical regimens including 3 ecg-monitored exercise sessions/ week encouragement achieve 5 thirty-minute sessions/week,C0332177|G0000000|C0030705|C0205280|C2945654|C0332257|G0000000|C0180580|C0015259|C1883016|C0332174|C0870494|G0000000|G0000000|C3816446|C1883016
"All patients received heparin intra-operatively, and, in 224 limbs, the anastomoses of the bypass grafts were performed with prolene.",patients received heparin intra-operatively 224 limbs anastomoses bypass grafts performed prolene,C0030705|C1514756|C0019134|C0347985|C1442061|C0015385|C0332853|C0741847|C0332835|C0884358|C0917843
The  babies  were randomized to receive either KMC or EBM.,babies randomized receive kmc ebm,C0021270|C0034656|C1514756|G0000000|C0795974
Interventions: Patients were assigned to have minimal sternotomy access (ministernotomy) or conventional median total sternotomy.,interventions patients assigned minimal sternotomy access ministernotomy conventional median total sternotomy,C0886296|C0030705|C1516050|C0547040|C0185792|C0444454|G0000000|C0439858|C0549183|C0439175|C0185792
Control patients received standard care.,control patients received standard care,C0243148|C0030705|C1514756|C1442989|C1947933
Intervention: Intermittent FHR monitoring using Doppler.,intervention intermittent fhr monitoring doppler,C0886296|C0205267|G0000000|C0150369|C0554756
"To achieve LDL cholesterol levels of Õ130 mg/dl, the pravastatin dosage was increased to 40 mg/day, and nicotinic acid (1.5 to 6 g/day) and/or cholestyramine (4 to 32 g/day) were added if necessary.",achieve ldl cholesterol levels 130 mg/dl pravastatin dosage increased 40 mg/day nicotinic acid 1 5 6 g/day and/or cholestyramine 4 32 g/day,G0000000|G0000000|C0008377|C0441889|C1442061|C0439269|C0085542|C0178602|C0205217|C0450371|C0439422|C0028040|C0001128|G0000000|G0000000|G0000000|C0439417|G0000000|C0008402|G0000000|C0450371|C0439417
Women randomised to vaginal misoprostol had the tablet placed by the resident or attending physician in the vaginal vault.,women randomised vaginal misoprostol tablet resident attending physician vaginal vault,C0043210|G0000000|C0042232|C0085174|C0039225|C1320928|C1547429|C0031831|C0042232|C1550319
"Methods The women were randomised to receive 50 mg of misoprostol orally or vaginally every 6 h until the cervix was favourable for amniotomy, spontaneous rupture of membranes, or active labour occurred.",methods women randomised receive 50 misoprostol orally vaginally 6 cervix favourable amniotomy spontaneous rupture membranes active labour occurred,C0025663|C0043210|G0000000|C1514756|C0450371|C0085174|C0442027|G0000000|G0000000|C0007874|C3640814|G0000000|C0205359|C1881712|C0025255|C0205177|C0022864|C1709305
Sample size was calculated with a two-tailed alpha of 0.05 and a power of 95% to detect a 5 h difference in induction-to-delivery time.,sample size calculated two-tailed alpha 0 05 power 95% detect 5 difference induction-to-delivery time,C0370003|C0456389|C0444686|C0205448|C0439095|G0000000|C0450371|C0032863|C0450371|C0442726|G0000000|C1705241|C0205263|C0040223
All women had electronic fetal heart rate monitoring for 45 minutes prior to and following administration of each misoprostol dose.,women electronic fetal heart rate monitoring 45 minutes prior administration misoprostol dose,C0043210|C0013850|C0015965|C0018787|C0871208|C0150369|C0450371|C0439232|C0332152|C0001554|C0085174|C0178602
The vitamin C tablet was nearly identical in appearance with the misoprostol tablet and has no known effect on labor.,vitamin tablet identical appearance misoprostol tablet labor,C0042890|C0039225|C0205280|C0233426|C0085174|C0039225|C0022864
"An initial continuous CTG for 1 h was recorded, followed by intermittent CTG or continuous CTG once in active labor.",initial continuous ctg 1 recorded intermittent ctg continuous ctg active labor,C0205265|C0549178|G0000000|G0000000|C0034869|C0205267|G0000000|C0549178|G0000000|C0205177|C0022864
At the time of recruitment the women received one of the tablets and both groups re-Å½ ceived again the same drug as before misoprostol .,time recruitment women received tablets re- ceived drug misoprostol,C0040223|C2949735|C0043210|C1514756|C0039225|C0556581|G0000000|C0013227|C0085174
Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide with (143 women) or without trastuzumab (138 women).,patients received adjuvant postoperative therapy anthracycline treated doxorubicin epirubicin 36 women cyclophosphamide 143 women trastuzumab 138 women,C0030705|C1514756|C0001551|C0032790|C0039798|C0003234|C1522326|C0013089|C0014582|C0450371|C0043210|C0010583|C1442061|C0043210|C0728747|C1442061|C0043210
"Trastuzumab was administered intravenously in a loading dose of 4 mg per kilogram of body weight, followed by a dose of 2 mg per kilogram once a week, until there was evidence of disease progression.",trastuzumab administered intravenously loading dose 4 kilogram body weight dose 2 kilogram week evidence disease progression,C0728747|C1521801|G0000000|C1708715|C0178602|G0000000|C0439209|C0242821|C0005910|C0178602|G0000000|C0439209|C0332174|C3887511|C0012634|C0242656
paclitaxel as an initial therapy for metastatic breast cancer.,paclitaxel initial therapy metastatic breast cancer,C0144576|C0205265|C0039798|C0036525|C0006141|C0006826
Patients were randomly assigned to receive either chemotherapy alone or chemotherapy plus trastuzumab.,patients randomly assigned receive chemotherapy chemotherapy trastuzumab,C0030705|G0000000|C1516050|C1514756|C0013216|C0013216|C0728747
"Between 24 and 96 hours after hospital admission, eligible patients were randomly assigned with stratification by center to double-blind treatment with atorvastatin (80 mg/d) or matching placebo for 16 weeks.",24 96 hours hospital admission eligible patients randomly assigned stratification center double-blind treatment atorvastatin 80 mg/d matching placebo 16 weeks,C0450371|C0450371|C0439227|C0019994|C0184666|C1548635|C0030705|G0000000|C1516050|C1514983|C0205099|C0013072|C0039798|C0286651|C0450371|C0439422|C0150103|C0032042|C0450371|C0439230
"Between May 1997 and September 1999, 3086 patients were enrolled; 1538 were randomly assigned to receive atorvastatin and 1548 to receive placebo (FIGURE 1).",1997 september 1999 3086 patients enrolled 1538 randomly assigned receive atorvastatin 1548 receive placebo figure 1,G0000000|C3828193|G0000000|G0000000|C0030705|G0000000|G0000000|G0000000|C1516050|C1514756|C0286651|G0000000|C1514756|C0032042|G0000000|G0000000
"If a diagnosis of labour was made or the cervical Bishop's score was 8 or more, she was transferred to labour ward for artiÂ®cial rupture of membranes.",diagnosis labour cervical bishops score 8 transferred labour ward articial rupture membranes,C0011900|C0022864|C0027530|C0649610|C0449820|G0000000|C0348011|C0022864|C1305702|G0000000|C1881712|C0025255
"The women were also asked to state their preference for the route of administration of the induction agent (oral or vaginal), if they were to have another induction.",women preference route administration induction agent oral vaginal induction,C0043210|C0558295|C0013153|C0001554|C0205263|C0450442|C0442027|C0042232|C0205263
"Two of the women who had a failed induction with oral misoprostol eventually went into labour with PGE 2 vaginal gel, but underwent caesarean sections for inadequate progress in labour.",women failed induction oral misoprostol eventually labour pge 2 vaginal gel underwent caesarean sections inadequate progress labour,C0043210|C0231175|C0205263|C0442027|C0085174|G0000000|C0022864|C0033559|G0000000|C0042232|C0017243|G0000000|C3841297|C0152060|C0205412|C1272688|C0022864
"Three others in the oral group did not respond to PGE 2 , and had abdominal deliveries, along with the three women who opted for caesarean sections since they did not want to try PGE 2 .",oral respond pge 2 abdominal deliveries women opted caesarean sections pge 2,C0442027|G0000000|C0033559|G0000000|C0000726|C0011209|C0043210|C1412930|C3841297|C0152060|C0033559|G0000000
Methods The women were randomly assigned to receive 50mgm of misoprostol orally or vaginally four hourly to a maximum of Â®ve doses.,methods women randomly assigned receive 50mgm misoprostol orally vaginally hourly maximum ve doses,C0025663|C0043210|G0000000|C1516050|C1514756|G0000000|C0085174|C0442027|G0000000|C0558292|C0806909|C0042469|C0178602
"All patients received 3 sessions â week of systemic PUVA therapy in the form of oral 8-methoxypsoralen (0.6 mg â kg) followed after 2 h by UVA exposure (300-400 nm, Waldmann, Schwenningen, Germany) according to the United States Cooperative Clinical Trial protocol, and all patients completed the 3-month therapy period.",patients received 3 sessions week systemic puva therapy form oral 8-methoxypsoralen 0 6 2 uva exposure 300-400 nm waldmann schwenningen germany united cooperative clinical trial protocol patients completed 3-month therapy period,C0030705|C1514756|G0000000|C1883016|C0332174|C0205373|C0853073|C0039798|C0348078|C0442027|C0025684|G0000000|G0000000|G0000000|G0000000|C0274281|C1442061|C0312860|G0000000|G0000000|C0017480|C0166872|C0679729|C0205210|C0008976|C0442711|C0030705|C0205197|C0332177|C0039798|C0439531
Patients with psoriasis (n Â¼ 15) treated identically and healthy subjects not receiving any therapy (n Â¼ 15) served as controls.,patients psoriasis 15 treated identically healthy subjects receiving therapy 15 served controls,C0030705|C0033860|C0450371|C1522326|G0000000|C3898900|C0681850|C1514756|C0039798|C0450371|G0000000|C0243148
Vitiligo Area Scoring Index (VASI) and Psoriasis Area Severity Index (PASI) scores were simultaneously evaluated.,vitiligo scoring vasi psoriasis severity pasi scores simultaneously evaluated,C0042900|C0449820|G0000000|C0033860|C0439793|G0000000|C0449820|C0521115|C0220825
"ET-1 was sequentially assessed (using ELISA) in patients with nonsegmental vitiligo treated with PUVA (n Â¼ 20), at 8, 16 and 24 h following the PUVA session.",et-1 sequentially assessed elisa patients nonsegmental vitiligo treated puva 20 8 16 24 puva session,G0000000|G0000000|C1516048|C0014441|C0030705|G0000000|C0042900|C1522326|C0853073|C0450371|G0000000|C0450371|C0450371|C0853073|C1883016
Control patients were recommended to perform basic daily mild physical activities but to avoid any physical training.,control patients recommended perform basic daily mild physical activities avoid physical training,C0243148|C0030705|C0034866|C0884358|C1527178|C0332173|C2945599|C0031809|C0441655|G0000000|C0031809|C0040607
The program lasted six months and consisted of three exercise sessions per week at an intensity of 60% of peak oxygen uptake (V Ë O 2 ).,program lasted months consisted exercise sessions week intensity 60% peak oxygen uptake 2,C1709697|C1517741|C0439231|C0332529|C0015259|C1883016|C0332174|C0522510|C0450371|C0444505|C0030054|C0243144|G0000000
Group T (n Ï­ 59) was exercised three times a week for six months at 60% of peak V Ë O 2.,59 exercised times week months 60% peak 2,C0450371|C0015259|C0040223|C0332174|C0439231|C0450371|C0444505|G0000000
"After a 15-min phase of stretching and calisthenics, patients pedaled on an electronically braked cycle ergometer at the target work rate for 30 min.",15-min phase stretching calisthenics patients pedaled electronically braked cycle ergometer target rate 30 min,C0450371|C0205390|C0600080|C0006759|C0030705|C0016504|G0000000|C0337108|C1511572|C0180748|C1521840|C0871208|C0450371|C0702093
The medication regimens could be re-administered every 6 hours for a total of six doses.,medication regimens re-administered 6 hours total doses,C0013227|C2945654|C0556581|G0000000|C0439227|C0439175|C0178602
"Cervical ripening was performed in the antepartum unit adjacent to the labor suite, and continuous fetal heart rate and uterine activity were monitored in all patients.",cervical ripening performed antepartum unit adjacent labor suite continuous fetal heart rate uterine activity monitored patients,C0027530|C1160534|C0884358|C0456336|C0439148|C0205117|C0022864|C1553446|C0549178|C0015965|C0018787|C0871208|C0042149|C0205177|C0030695|C0030705
Ngai et al 23 noted one of his patients underwent an emergency cesarean delivery for late decelerations after 15 minutes from taking an oral 200-â®g dose.,ngai al 23 patients underwent emergency cesarean delivery late decelerations 15 minutes oral 200-g dose,G0000000|C0202311|C0450371|C0030705|G0000000|C0013956|C3841297|C0011209|C0205087|C0011100|C0450371|C0439232|C0442027|C1442061|C0178602
"In the vaginal group, after the first two doses of 50 â®g, the dose was increased to 100 â®g for the duration of the study (up to a total of 500 â®g).",vaginal doses 50 dose increased 100 duration study total 500,C0042232|C0178602|C0450371|C0178602|C0205217|C1442061|C0449238|C0557651|C0439175|C1442061
"In the oral group, after the first two doses of 200 â®g, the dose was increased to 300 â®g for the duration of the study (up to a total of 1600 â®g).",oral doses 200 dose increased 300 duration study total 1600,C0442027|C0178602|C1442061|C0178602|C0205217|C1442061|C0449238|C0557651|C0439175|G0000000
"The indications for cesarean delivery were similar between the groups, the most frequent indication being fetal distress in 70 (14%) and 58 (12%) oral versus vaginal, respectively (P Ï­ .27, â¹ 2 ).",indications cesarean delivery frequent indication fetal distress 70 14% 58 12% oral versus vaginal 27 2,C0392360|C3841297|C0011209|C0332183|C0392360|C0015965|C0231303|C0450371|C0450371|C0450371|C0450371|C0442027|G0000000|C0042232|C0450371|G0000000
We therefore designed the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial to compare the efficacy and safety of the early and long-term use of clopidogrel plus aspirin with those of aspirin alone in patients with acute coronary syndromes and no ST-segment elevation.,designed clopidogrel unstable angina prevent recurrent events cure trial compare efficacy safety long-term clopidogrel aspirin aspirin patients acute coronary syndromes st-segment elevation,C1707689|C0070166|C0443343|C0002962|C0309872|C2945760|C0441471|C1880198|C0008976|C1707455|C1280519|C0036043|C0443252|C0070166|C0004057|C0004057|C0030705|C0205178|C0018787|C0039082|C0429029|C0439775
"Methods We randomly assigned 12,562 patients who had presented within 24 hours after the onset of symptoms to receive clopidogrel (300 mg immediately, followed by 75 mg once daily) (6259 patients) or placebo (6303 patients) in addition to aspirin for 3 to 12 months.",methods randomly assigned 12 562 patients 24 hours onset symptoms receive clopidogrel 300 75 daily 6259 patients placebo 6303 patients addition aspirin 3 12 months,C0025663|G0000000|C1516050|C0450371|C1442061|C0030705|C0450371|C0439227|C0206132|C0683368|C1514756|C0070166|C1442061|C0450371|C0332173|G0000000|C0030705|C0032042|G0000000|C0030705|C0332287|C0004057|G0000000|C0450371|C0439231
Our study demonstrates the benefit of adding clopidogrel to the regimen of treatment for patients with acute coronary syndromes without ST-segment elevation who are receiving aspirin and other medications.,study demonstrates benefit adding clopidogrel regimen treatment patients acute coronary syndromes st-segment elevation receiving aspirin medications,C0557651|C3687625|C0814225|C1883712|C0070166|C0040808|C0039798|C0030705|C0205178|C0018787|C0039082|C0429029|C0439775|C1514756|C0004057|C0013227
They were randomly assigned monitoring with cardiotocography plus ST analysis (CTG+ST group) or cardiotocography only (CTG group).,randomly assigned monitoring cardiotocography st analysis ctg+st cardiotocography ctg,G0000000|C1516050|C0150369|C0007208|C0036056|C0002778|C0036056|C0007208|G0000000
"This instrument uses digital signalprocessing techniques and automatic assessment of ST changes by means of an ""expert system"", 16 and has been assessed in observational clinical studies.",instrument digital signalprocessing techniques automatic assessment st expert system 16 assessed observational clinical studies,C0348000|C0442015|G0000000|C0025664|C0205554|C1261322|C0036056|G0000000|C0449913|C0450371|C1516048|C1518527|C0205210|C0947630
Women were randomly assigned fetal monitoring by cardiotocography (CTG group) or cardiotocography with ST-waveform analysis (CTG+ST group).,women randomly assigned fetal monitoring cardiotocography ctg cardiotocography st-waveform analysis ctg+st,C0043210|G0000000|C1516050|C0015965|C0150369|C0007208|G0000000|C0007208|C0036056|C0002778|C0036056
"Because the study had two primary objectives, it was to be considered positive only if enalapril was more effective than nifedipine for both LV mass reduction and normalization of LV diastolic filling at a value of PÏ½0.05 or if one comparison had a value of PÏ½0.025.",study primary objectives considered positive enalapril effective nifedipine lv mass reduction normalization lv diastolic filling p0 05 comparison p0 025,C0557651|C0205225|C0018017|C0750591|C0439178|C0014025|C1280519|C0028066|C0023128|C0577559|C0301630|C1882115|C0023128|C0012000|G0000000|C0332132|C0450371|C1707455|C0332132|C1442061
"Blinded study medication was titrated and then maintained for 1 year, with echocardiograms performed after 6 and 12 months, after which double-blinded therapy was continued during ""clean-up"" of measurements and clinical event ascertainment to prevent knowledge of treatment assignment from influencing data adjudication.",blinded study medication titrated maintained 1 echocardiograms performed 6 12 months double-blinded therapy continued clean-up measurements clinical event ascertainment prevent knowledge treatment assignment influencing data adjudication,C0150108|C0557651|C0013227|C1883350|C1314677|G0000000|C0013516|C0884358|G0000000|C0450371|C0439231|C0205173|C0039798|C0549178|C3841937|C0242485|C0205210|C0441471|G0000000|C0309872|C0376554|C0039798|C1516050|C4054723|C1511726|C0680730
Methods and Results-An ethnically diverse population of 303 men and women with essential hypertension and increased LV mass at screening echocardiography were enrolled at clinical centers on 4 continents and studied by echocardiog-raphy at baseline and after 6-and 12-month randomized therapy.,methods results-an ethnically diverse population 303 women essential hypertension increased lv mass screening echocardiography enrolled clinical centers 4 continents studied echocardiog-raphy baseline 6-and 12-month randomized therapy,C0025663|C1274040|G0000000|C1880371|C0032659|C1442061|C0043210|C0205224|C0020538|C0205217|C0023128|C0577559|C0220908|C0013516|G0000000|C0205210|C0205099|G0000000|C0454690|C0557651|G0000000|C0168634|G0000000|C0450371|C0034656|C0039798
"If the contractions became inadequate, augmentation of the active phase of labour was attempted with hourly titrated oral misoprostol (1mg/mL solution) escalating the dose from 5ml to 10ml and, 20ml (maximum).",contractions inadequate augmentation active phase labour attempted hourly titrated oral misoprostol 1mg/ml solution escalating dose 5ml 10ml 20ml maximum,C1140999|C0205412|C1293122|C0205177|C0205390|C0022864|C1516084|C0558292|C1883350|C0442027|C0085174|C0439526|C0037633|G0000000|C0178602|C1707981|G0000000|G0000000|C0806909
Vaginal delivery within 24 hours was not achieved in 38% of women in the oral misoprostol group and 36% in the vaginal dinoprostone group (RR 1.08; 95% CI 0.89-1.31).,vaginal delivery 24 hours achieved 38% women oral misoprostol 36% vaginal dinoprostone rr 1 08 95% ci 0 89-1 31,C0042232|C0011209|C0450371|C0439227|G0000000|C0450371|C0043210|C0442027|C0085174|C0450371|C0042232|C0012472|G0000000|G0000000|C0450371|C0450371|C0008107|G0000000|C0450371|C0450371
"Hyperstimulation with fetal heart rate changes occurred in 4% of women in the oral misoprostol group and 3% after vaginal dinoprostone (RR 1.32, 95% CI 0.59Â±2.98).",hyperstimulation fetal heart rate occurred 4% women oral misoprostol 3% vaginal dinoprostone rr 1 32 95% ci 0 592 98,G0000000|C0015965|C0018787|C0871208|C1709305|G0000000|C0043210|C0442027|C0085174|G0000000|C0042232|C0012472|G0000000|G0000000|C0450371|C0450371|C0008107|G0000000|C1442061|C0450371
"Methods Women undergoing induction of labour after 34 weeks of pregnancy were allocated by randomised, sealed opaque envelopes, to induction of labour with titrated oral misoprostol solution, or two doses of vaginal dinoprostone (2mg) administered six hours apart.",methods women undergoing induction labour 34 weeks pregnancy allocated randomised sealed opaque envelopes induction labour titrated oral misoprostol solution doses vaginal dinoprostone 2mg administered hours,C0025663|C0043210|G0000000|C0205263|C0022864|C0450371|C0439230|C0032961|G0000000|G0000000|C0036492|C0029053|C1622204|C0205263|C0022864|C1883350|C0442027|C0085174|C0037633|C0178602|C0042232|C0012472|G0000000|C1521801|C0439227
"STUDY METHODS: In this double-blind randomized trial, 126 women received misoprostol (50 Âµg) either orally every 3 hours or vaginally every 6 hours for induction of labor.",study methods double-blind randomized trial 126 women received misoprostol 50 orally 3 hours vaginally 6 hours induction labor,C0557651|C0025663|C0013072|C0034656|C0008976|C1442061|C0043210|C1514756|C0085174|C0450371|C0442027|G0000000|C0439227|G0000000|G0000000|C0439227|C0205263|C0022864
"Each envelope contained 2 packages of identically appearing pills, 1 labeled oral medication (either placebo or misoprostol, 50 Âµg) and 1 labeled vaginal medication (either placebo or misoprostol, 50 Âµg).",envelope contained 2 packages identically appearing pills 1 labeled oral medication placebo misoprostol 50 1 labeled vaginal medication placebo misoprostol 50,C1622204|C0332256|G0000000|C0013194|G0000000|C0700364|C0994475|G0000000|C1708632|C0442027|C0013227|C0032042|C0085174|C0450371|G0000000|C1708632|C0042232|C0013227|C0032042|C0085174|C0450371
Each patient received an oral tablet every 3 hours and a vaginal tablet every 6 hours (administered concurrently with an oral tablet) to a maximum of 48 hours.,patient received oral tablet 3 hours vaginal tablet 6 hours administered concurrently oral tablet maximum 48 hours,C0030705|C1514756|C0442027|C0039225|G0000000|C0439227|C0042232|C0039225|G0000000|C0439227|C1521801|G0000000|C0442027|C0039225|C0806909|C0450371|C0439227
"As per our center's usual protocol for cervical ripening, those women not in labor at 48 hours were reassessed and their Bishop score repeated.",centers usual protocol cervical ripening women labor 48 hours reassessed bishop score repeated,C0205099|C3538928|C0442711|C0027530|C1160534|C0043210|C0022864|C0450371|C0439227|G0000000|C1551458|C0449820|C0205341
"Data included baseline characteristics of the pregnant women, doses and route of misoprostol administration, adverse effects, further methods used after failure, mean interval between initiation of termination and delivery time (fetal expulsion time), estimated blood loss, analgesia and oxytocin requirement, and serious complications such as excessive blood loss and uterine rupture.",data included baseline characteristics pregnant women doses route misoprostol administration adverse effects methods failure interval initiation termination delivery time fetal expulsion time estimated blood loss analgesia oxytocin requirement complications excessive blood loss uterine rupture,C1511726|C0332257|C0168634|C1521970|C0549206|C0043210|C0178602|C0013153|C0085174|C0001554|G0000000|C1280500|C0025663|C0231174|C1272706|C0589507|C1549081|C0011209|C0040223|C0015965|C1293107|C0040223|C0750572|C0005767|C1517945|C0002766|C0030095|C1514873|C0009566|C0442802|C0005767|C1517945|C0042149|C1881712
Women received additional doses of misoprostol in case of failure to insert the modified condom balloon.,women received additional doses misoprostol failure insert modified condom balloon,C0043210|C1514756|C1524062|C0178602|C0085174|C0231174|C0441587|C0392747|C0009653|C0336867
"Additionally, some women received additional doses of misoprostol instead of modified condom balloon as per the physician's choice.",additionally women received additional doses misoprostol modified condom balloon physicians choice,G0000000|C0043210|C1514756|C1524062|C0178602|C0085174|C0392747|C0009653|C0336867|C0031831|C0008300
The longest abortion time was 247.88 h. This was a nulliparous woman with a live fetus (22 weeks of gestation).,abortion time 247 88 nulliparous woman live fetus 22 weeks gestation,C0156543|C0040223|C1442061|C0450371|C0425979|C0043210|C1548795|C0015965|C0450371|C0439230|C0032961
Fifty-two (76.5%) women required oxytocin infusion and 37 (54.4%) women received analgesia.,fifty-two 76 5% women required oxytocin infusion 37 54 4% women received analgesia,C3816723|C0450371|G0000000|C0043210|C1514873|C0030095|C0574032|C0450371|C0450371|G0000000|C0043210|C1514756|C0002766
Modified condom balloon was used as a primary technique in 33.8% of women who failed to abort.,modified condom balloon primary technique 33 8% women failed abort,C0392747|C0009653|C0336867|C0205225|C0449851|C0450371|G0000000|C0043210|C0231175|C1611646
"Inclusion criteria were any women having induction of labor with a singleton cephalic fetus of 34 weeks or more in whom the membranes were unruptured, cardiotocography showed no fetal distress, and there were no painful contractions.",inclusion criteria women induction labor singleton cephalic fetus 34 weeks membranes unruptured cardiotocography fetal distress painful contractions,C0007637|C0243161|C0043210|C0205263|C0022864|C0481462|C0205096|C0015965|C0450371|C0439230|C0025255|G0000000|C0007208|C0015965|C0231303|C0030193|C1140999
"A total of 573 women admitted for induction of labor were randomized to receive oral misoprostol, vaginal misoprostol, or the control, dinoprostone.",total 573 women admitted induction labor randomized receive oral misoprostol vaginal misoprostol control dinoprostone,C0439175|C1442061|C0043210|C0184666|C0205263|C0022864|C0034656|C1514756|C0442027|C0085174|C0042232|C0085174|C0243148|C0012472
There were twice as many women randomized into the dinoprostone group.,women randomized dinoprostone,C0043210|C0034656|C0012472
"We also measured serum and plasma concentrations, in two central laboratories, of haemoglobin, creatinine, alanine aminotransferase, glucose, uric acid, sodium, potassium, total and HDL cholesterol, and urine concentrations of albumin and creatinine.",measured serum plasma concentrations central laboratories haemoglobin creatinine alanine aminotransferase glucose uric acid sodium potassium total hdl cholesterol urine concentrations albumin creatinine,C0444706|C0229671|C0032105|C0086045|C0205099|C0022877|C0019046|C0010294|C0001898|C0002594|C0017725|G0000000|C0001128|C0037473|C0032821|C0439175|C3715113|C0008377|C0042036|C0086045|C0001924|C0010294
We followed up patients for at least 4 years with regular visits and increases in drug doses to reach a target blood pressure of less than 140/90 mm Hg (figure 1).,patients 4 regular visits increases drug doses reach target blood pressure 140/90 mm hg figure 1,C0030705|G0000000|C0205272|C0545082|C0205217|C0013227|C0178602|C2584321|C1521840|C0005767|C0033095|C1442061|G0000000|C0025424|G0000000|G0000000
"We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke).",assigned participants daily losartan-based atenolol-based antihypertensive treatment 4 1040 patients primary cardiovascular event death myocardial infarction stroke,C1516050|C0679646|C0332173|C0126174|C0004147|C0003364|C0039798|G0000000|G0000000|C0030705|C0205225|C0007226|C0441471|C0011065|C0027061|C0021308|C0038454
"We randomly assigned participants losartanbased or atenolol-based regimens after 1-2 weeks of placebo if trough sitting blood pressures were 160-200 mm Hg systolic, 95Ïª115 mm Hg diastolic, or both.",randomly assigned participants losartanbased atenolol-based regimens 1-2 weeks placebo trough sitting blood pressures 160-200 mm hg systolic 95115 mm hg diastolic,G0000000|C1516050|C0679646|G0000000|C0004147|C2945654|G0000000|C0439230|C0032042|C0444506|C0277814|C0005767|C0033095|C1442061|G0000000|C0025424|C0039155|G0000000|G0000000|C0025424|C0012000
"After the end date, patients had a follow-up clinic visit or at least a vital status check within 6 weeks.",patients follow-up clinic visit vital status check 6 weeks,C0030705|C0589120|C0002424|C0545082|C0442732|C0449438|C1283174|G0000000|C0439230
"Parous women in the higher dose group received 50 mgs as their first dose, subsequent doses being 100 mgs.",parous women dose received 50 mgs dose subsequent doses 100 mgs,G0000000|C0043210|C0178602|C1514756|C0450371|C0024467|C0178602|C0332282|C0178602|C1442061|C0024467
A reassuring CTG recording for about 30 min prior to the start of the induction and a cervical Bishop's score (8) of 7 or less were the other requirements.,reassuring ctg recording 30 min prior start induction cervical bishops score 8 7 requirements,C0557055|G0000000|G0000000|C0450371|C0702093|C0332152|C0439659|C0205263|C0027530|C0649610|C0449820|G0000000|G0000000|C1514873
Comparison of outcomes in labor in women randomly allocated to 50 or 100 mgs of misoprostol.,comparison outcomes labor women randomly allocated 50 100 mgs misoprostol,C1707455|C1274040|C0022864|C0043210|G0000000|G0000000|C0450371|C1442061|C0024467|C0085174
"Of the 16 women in the low dose group who did not respond to the misoprostol, 11 had a favorable cervix following Prostin A gel administration (10 of whom went on to have a vaginal delivery), while three did not respond to the PGE2.",16 women low dose respond misoprostol 11 favorable cervix prostin gel administration 10 vaginal delivery respond pge2,C0450371|C0043210|C0205251|C0178602|G0000000|C0085174|C0450371|C3640814|C0007874|C1367517|C0017243|C0001554|C0450371|C0042232|C0011209|G0000000|G0000000
"Because of safety concerns with the 100 mgs dose in parous women, we started with an initial dose of 50 mgs, subsequent doses being 100 mgs.",safety concerns 100 mgs dose parous women started initial dose 50 mgs subsequent doses 100 mgs,C0036043|C2699424|C1442061|C0024467|C0178602|G0000000|C0043210|C1272689|C0205265|C0178602|C0450371|C0024467|C0332282|C0178602|C1442061|C0024467
"In the 100 mgs group, of the six women with failed inductions, two patients opted for caesarean sections, two responded to Prostin A gel and the other two had no response to the vaginal gel and eventually had to be delivered abdominally.",100 mgs women failed inductions patients opted caesarean sections responded prostin gel response vaginal gel eventually delivered abdominally,C1442061|C0024467|C0043210|C0231175|C0857127|C0030705|C1412930|C3841297|C0152060|G0000000|C1367517|C0017243|C0871261|C0042232|C0017243|G0000000|C1705822|G0000000
"Women were asked to complete a questionnaire postnatally, to assess their satisfaction with their inductions and their preference for the route of administration (oral or vaginal) of the inducing agent, were they to have another induction.",women complete questionnaire postnatally assess satisfaction inductions preference route administration oral vaginal inducing agent induction,C0043210|C0205197|C0034394|G0000000|C1516048|C0242428|C0857127|C0558295|C0013153|C0001554|C0442027|C0042232|C0205263|C0450442|C0205263
"This was repeated every 3-4 hours until the occurrence of progressive labor (as evidenced by a Bishop score of 7 or more), a contraction pattern of three every 10 minutes, and evidence of fetal intolerance or delivery.",repeated 3-4 hours occurrence progressive labor evidenced bishop score 7 contraction pattern 10 minutes evidence fetal intolerance delivery,C0205341|G0000000|C0439227|C0243132|C0205329|C0022864|C3887511|C1551458|C0449820|G0000000|C1140999|C0449774|C0450371|C0439232|C3887511|C0015965|C0231199|C0011209
"If cervical ripening or active labor did not occur, repeated doses of oral (100-200 â®g) or vaginal (25-50 â®g) were given until labor was established.",cervical ripening active labor occur repeated doses oral 100-200 vaginal 25-50 labor established,C0027530|C1160534|C0205177|C0022864|C1709305|C0205341|C0178602|C0442027|C1442061|C0042232|C0450371|C0022864|C0443211
Doses of 100 â®g of oral or 25 â®g of vaginal misoprostol were given every 3-4 hours.,doses 100 oral 25 vaginal misoprostol 3-4 hours,C0178602|C1442061|C0442027|C0450371|C0042232|C0085174|G0000000|C0439227
"Between April 1996 and October 1998, a total of 1677 patients were recruited and were randomly assigned to receive either fluvastatin (n = 844) or placebo (n = 833) (FIGURE 1).",april 1996 october 1998 total 1677 patients recruited randomly assigned receive fluvastatin = 844 placebo = 833 figure 1,C3715024|G0000000|C3828732|G0000000|C0439175|G0000000|C0030705|G0000000|G0000000|C1516050|C1514756|C0082608|G0000000|C1442061|C0032042|G0000000|C1442061|G0000000|G0000000
"Interventions Patients were randomly assigned to receive treatment with fluvastatin, 80 mg/d (n = 844), or matching placebo (n = 833) at hospital discharge for 3 to 4 years.",interventions patients randomly assigned receive treatment fluvastatin 80 mg/d = 844 matching placebo = 833 hospital discharge 3 4,C0886296|C0030705|G0000000|C1516050|C1514756|C0039798|C0082608|C0450371|C0439422|G0000000|C1442061|C0150103|C0032042|G0000000|C1442061|C0019994|C0012621|G0000000|G0000000
"Until the time of the first MACE or up to completion of follow-up for patients without MACE, 19.3% of the patients in the fluvastatin group were taking less than 80% of the study treatment regimen while not taking other lipidlowering drugs.",time mace completion follow-up patients mace 19 3% patients fluvastatin 80% study treatment regimen lipidlowering drugs,C0040223|C0349381|C0205197|C0589120|C0030705|C0349381|C0450371|G0000000|C0030705|C0082608|C0450371|C0557651|C0039798|C0040808|G0000000|C0013227
"During the study, 97% of patients in the fluvastatin group and 98% in the placebo group were taking aspirin.",study 97% patients fluvastatin 98% placebo aspirin,C0557651|C0450371|C0030705|C0082608|C0450371|C0032042|C0004057
"Patients were randomly assigned, in a double-blind manner, to receive losartan or atenolol (50 mg once daily) for 36 weeks (Fig.",patients randomly assigned double-blind manner receive losartan atenolol 50 daily 36 weeks fig,C0030705|G0000000|C1516050|C0013072|G0000000|C1514756|C0126174|C0004147|C0450371|C0332173|C0450371|C0439230|C0349966
"We studied 30 untreated hypertensive patients, aged 28-55 years, who were rotated through six 6-week periods of daily treatment with amlodipine 5 mg, doxazosin 4 mg, lisinopril 10 mg, bisoprolol 5 mg, bendrofluazide 2.5 mg or placebo.",studied 30 untreated hypertensive patients aged 28-55 rotated 6-week periods daily treatment amlodipine 5 doxazosin 4 lisinopril 10 bisoprolol 5 bendrofluazide 2 5 placebo,C0557651|C0450371|C0332155|C0857121|C0030705|C0001779|C0450371|C0231458|C0332174|C0439531|C0332173|C0039798|C0051696|G0000000|C0114873|G0000000|C0065374|C0450371|C0053799|G0000000|C0004975|G0000000|G0000000|C0032042
"Based on a 3Ï«2 factorial design, participants were randomized equally to a usual mean arterial pressure goal of 102 to 107 mm Hg or to a lower mean arterial pressure goal of 92 mm Hg or lower, and to treatment with 1 of 3 antihypertensive drugs (a sustainedrelease â¤-blocker, metoprolol, 50 to 200 mg/d; an angiotensin-converting enzyme inhibitor, ramipril, 2.5 to 10 mg/d; or a dihydropyridine calcium channel blocker, amlodipine, 5 to 10 mg/d).",based 32 factorial design participants randomized equally usual arterial pressure goal 102 107 mm hg lower arterial pressure goal 92 mm hg lower treatment 1 3 antihypertensive drugs sustainedrelease -blocker metoprolol 50 200 mg/d angiotensin-converting enzyme inhibitor ramipril 2 5 10 mg/d dihydropyridine calcium channel blocker amlodipine 5 10 mg/d,C1527178|C0450371|C2826344|C1707689|C0679646|C0034656|G0000000|C3538928|C0003842|C0033095|C0018017|C1442061|C1442061|G0000000|C0025424|C0441994|C0003842|C0033095|C0018017|C0450371|G0000000|C0025424|C0441994|C0039798|G0000000|G0000000|C0003364|C0013227|G0000000|G0000000|C0025859|C0450371|C1442061|C0439422|C0003018|C0014442|C1999216|C0072973|G0000000|G0000000|C0450371|C0439422|C0012315|C0006675|C0439799|G0000000|C0051696|G0000000|C0450371|C0439422
"The study's visit schedule, including GFR measurements, was continued and patients in all 3 drug groups remained on their randomly assigned BP goals through the end of the trial.",studys visit schedule including gfr measurements continued patients 3 drug remained randomly assigned bp goals trial,G0000000|C0545082|C0086960|C0332257|C0017654|C0242485|C0549178|C0030705|G0000000|C0013227|G0000000|G0000000|C1516050|C0037623|C0018017|C0008976
The relationships of the treatment comparisons with baseline proteinuria were investigated by adding con- tinuous interaction terms between ln (urinary protein to creatinine ratio) and the treatment groups.,relationships treatment comparisons baseline proteinuria investigated adding con- tinuous interaction terms ln urinary protein creatinine ratio treatment,C0439849|C0039798|C1707455|C0168634|C0033687|C1292732|C1883712|G0000000|G0000000|C1704675|C0233324|C0861352|C0042027|C0033684|C0010294|C0456603|C0039798
"Three primary treatment comparisons were specified: lower vs usual BP goal, ramipril vs metoprolol, and amlodipine vs metoprolol.",primary treatment comparisons lower usual bp goal ramipril metoprolol amlodipine metoprolol,C0205225|C0039798|C1707455|C0441994|C3538928|C0037623|C0018017|C0072973|C0025859|C0051696|C0025859
"A number of patients in the fluvastatin and placebo groups was also receiving ACE inhibitors (38% and 36%, respectively) and calcium channel blockers (17% and 15%, respectively).",patients fluvastatin placebo receiving ace inhibitors 38% 36% calcium channel blockers 17% 15%,C0030705|C0082608|C0032042|C1514756|C1452534|C0243077|C0450371|C0450371|C0006675|C0439799|G0000000|C0450371|C0450371
"At baseline, beta-blockers were used in 91% of the patients in each treatment group.",baseline beta-blockers 91% patients treatment,C0168634|C0001645|C0450371|C0030705|C0039798
"At 1 year, 40.0% (n=4645), 44.0% (n=3017), and 43.8% (n = 2764) of participants assigned to chlorthalidone, amlodipine, and lisinopril, respectively, still taking their disease; MI, myocardial infarction; HDL-C, high-density lipoprotein cholesterol; LVH, left ventricular hypertrophy; and CHD, coronary heart disease.",1 40 0% n=4645 44 0% n=3017 43 8% = 2764 participants assigned chlorthalidone amlodipine lisinopril disease mi myocardial infarction hdl-c high-density lipoprotein cholesterol lvh left ventricular hypertrophy chd coronary heart disease,G0000000|C0450371|G0000000|C0369718|C0450371|G0000000|C0369718|C0450371|G0000000|G0000000|G0000000|C0679646|C1516050|C0008294|C0051696|C0065374|C0012634|C3810814|C0027061|C0021308|C3715113|C0205250|C0023820|C0008377|C0149721|C0205091|C0018827|C0020564|C0280604|C0018787|C0018787|C0012634
"Other drugs, including low doses of open-label step 1 drug classes, were permitted if clinically indicated.",drugs including low doses open-label step 1 drug classes permitted clinically,C0013227|C0332257|C0205251|C0178602|C1709323|C1261552|G0000000|C0013227|C0456387|C0329040|G0000000
"Since a large proportion of participants required more than 1 drug to control their BP, it is reasonable to infer that a diuretic be included in all multidrug regimens, if possible.",proportion participants required 1 drug control bp reasonable infer diuretic included multidrug regimens,C1709707|C0679646|C1514873|G0000000|C0013227|C0243148|C0037623|G0000000|C0679201|C0012798|C0332257|G0000000|C2945654
"Among participants in the chlorthalidone group who were contacted in the clinic or by telephone within 12 months of annual scheduled visits, 87.1% were taking chlorthalidone or another diuretic at 1 year, decreasing to 80.5% at 5 years; 67.5% (n=4387) were taking a diuretic without a CCB or an ACE inhibitor; and 13.2% were taking a diuretic with a CCB (5.8% [n = 399]) or an ACE inhibitor (9.3% [n=641]).",participants chlorthalidone contacted clinic telephone 12 months annual scheduled visits 87 1% chlorthalidone diuretic 1 decreasing 80 5% 5 67 5% n=4387 diuretic ccb ace inhibitor 13 2% diuretic ccb 5 8% = 399 ace inhibitor 9 3% n=641,C0679646|C0008294|C0332158|C0002424|C0039457|C0450371|C0439231|C0332181|C0086960|C0545082|C0450371|G0000000|C0008294|C0012798|G0000000|C0442797|C0450371|G0000000|G0000000|C0450371|G0000000|C0369718|C0012798|C0006684|C1452534|C1999216|C0450371|G0000000|C0012798|C0006684|G0000000|G0000000|G0000000|C1442061|C1452534|C1999216|G0000000|G0000000|C0369718
"Among participants with available medication information at 1 year, 26.7%, 25.9%, and 32.6% of those assigned to chlorthalidone, amlodipine, and lisinopril, respectively, were taking a step 2 or step 3 drug.",participants medication 1 26 7% 25 9% 32 6% assigned chlorthalidone amlodipine lisinopril step 2 step 3 drug,C0679646|C0013227|G0000000|C0450371|G0000000|C0450371|G0000000|C0450371|G0000000|C1516050|C0008294|C0051696|C0065374|C1261552|G0000000|C1261552|G0000000|C0013227
"Of those achieving a vaginal delivery, 72% of the active group did so within 24 hours of the prelabour rupture of membranes as compared with 26.9% of the conservative group (RR 2.7, 95% CI 1.4 to 5.3, P Â¼ 0.002).",achieving vaginal delivery 72% active 24 hours prelabour rupture membranes compared 26 9% conservative rr 2 7 95% ci 1 4 5 3 0 002,G0000000|C0042232|C0011209|C0450371|C0205177|C0450371|C0439227|G0000000|C1881712|C0025255|C1707455|C0450371|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|C0008107|G0000000|G0000000|G0000000|G0000000|G0000000|C1442061
"Results 93.3% of the active group and 54.8% of the conservative group were in spontaneous labour within 24 hours of the prelabour rupture of membranes (RR 1.7, 95% CI 1.2 to 2.4).",93 3% active 54 8% conservative spontaneous labour 24 hours prelabour rupture membranes rr 1 7 95% ci 1 2 2 4,C0450371|G0000000|C0205177|C0450371|G0000000|G0000000|C0205359|C0022864|C0450371|C0439227|G0000000|C1881712|C0025255|G0000000|G0000000|G0000000|C0450371|C0008107|G0000000|G0000000|G0000000|G0000000
Three women in either group had pyrexia of 38jC noted in active labour and received prophylactic antibiotic cover.,women pyrexia 38jc active labour received prophylactic antibiotic cover,C0043210|C0015967|G0000000|C0205177|C0022864|C1514756|C0355642|C0003232|C0180153
"Methods The women were randomised to 50 Ag of oral misoprostol repeated every 4 hours, if required, to a maximum of five doses (active group), or to induction of labour with PGE 2 gel or oxytocin only if not in spontaneous labour 24 hours after prelabour rupture of membranes (conservative group).",methods women randomised 50 ag oral misoprostol repeated 4 hours required maximum doses active induction labour pge 2 gel oxytocin spontaneous labour 24 hours prelabour rupture membranes conservative,C0025663|C0043210|G0000000|C0450371|C0002037|C0442027|C0085174|C0205341|G0000000|C0439227|C1514873|C0806909|C0178602|C0205177|C0205263|C0022864|C0033559|G0000000|C0017243|C0030095|C0205359|C0022864|C0450371|C0439227|G0000000|C1881712|C0025255|G0000000
"In those women randomised to the conservative arm, if labour had not set in by 24 hours of the prelabour rupture of membranes, a vaginal examination was performed to evaluate the cervical score (modified Bishop's score).",women randomised conservative arm labour set 24 hours prelabour rupture membranes vaginal examination performed evaluate cervical score modified bishops score,C0043210|G0000000|G0000000|C0446516|C0022864|C0036849|C0450371|C0439227|G0000000|C1881712|C0025255|C0042232|G0000000|C0884358|C0220825|C0027530|C0449820|C0392747|C0649610|C0449820
"However, oxytocin requirement and spontaneous rupture of membranes were found more in the 6 hour group.",oxytocin requirement spontaneous rupture membranes 6 hour,C0030095|C1514873|C0205359|C1881712|C0025255|G0000000|C0439227
These women were then offered a choice of being delivered by cesarean section (CS) or having 50 m g misoprostol vaginally after the resting period of 6-24 hours.,women offered choice delivered cesarean cs 50 misoprostol vaginally resting period 6-24 hours,C0043210|C1444648|C0008300|C1705822|C3841297|C0010182|C0450371|C0085174|G0000000|C0035253|C0439531|C0450371|C0439227
All subjects were randomly assigned to receive 100 m g misoprostol orally every 3 or 6 hours by means of blocked randomization.,subjects randomly assigned receive 100 misoprostol orally 3 6 hours blocked randomization,C0681850|G0000000|C1516050|C1514756|C1442061|C0085174|C0442027|G0000000|G0000000|C0439227|C0028778|C0034656
"While 50 m g oral misoprostol used every 4-6 hours was less effective than 200 m g, with the interval from induction to vaginal delivery varied from 17.86 Â± 9.88 hours to 37.9 Â± 41 hours, the hyperstimulation syndrome was reported to be from 0% to 13%.",50 oral misoprostol 4-6 hours effective 200 interval induction vaginal delivery varied 17 86 9 88 hours 37 9 41 hours hyperstimulation syndrome reported 0% 13%,C0450371|C0442027|C0085174|G0000000|C0439227|C1280519|C1442061|C1272706|C0205263|C0042232|C0011209|G0000000|C0450371|C0450371|G0000000|C0450371|C0439227|C0450371|G0000000|C0450371|C0439227|G0000000|C0039082|C0684224|G0000000|C0450371
"The medication was repeated every 3 or 6 hours until adequate uterine contraction ( â¥ 3 contractions in 10 min), favorable change of cervix (Bishop score > 4 and favorable enough for amniotomy) or spontaneous rupture of the membranes occurred.",medication repeated 3 6 hours adequate uterine contraction 3 contractions 10 min favorable change cervix bishop score 4 favorable amniotomy spontaneous rupture membranes occurred,C0013227|C0205341|G0000000|G0000000|C0439227|C0205410|C0042149|C1140999|G0000000|C1140999|C0450371|C0702093|C3640814|C0392747|C0007874|C1551458|C0449820|G0000000|C3640814|G0000000|C0205359|C1881712|C0025255|C1709305
"All pregnant women were randomly assigned to receive 100 m g oral misoprostol every 3 hours or 6 hours until the cervix was favorable for amniotomy, spontaneous rupture of membranes or active labor occurred.",pregnant women randomly assigned receive 100 oral misoprostol 3 hours 6 hours cervix favorable amniotomy spontaneous rupture membranes active labor occurred,C0549206|C0043210|G0000000|C1516050|C1514756|C1442061|C0442027|C0085174|G0000000|C0439227|G0000000|C0439227|C0007874|C3640814|G0000000|C0205359|C1881712|C0025255|C0205177|C0022864|C1709305
"In the intervention group, subjects participated in an outpatient phase III CR and exercise training program, whereas the control group were followed up with standard care as an outpatients.",intervention subjects participated outpatient phase iii cr exercise training program control standard care outpatients,C0886296|C0681850|G0000000|C0029921|C0205390|C0439070|C0201975|C0015259|C0040607|C1709697|C0243148|C1442989|C1947933|C0029921
"In the intervention group, patients participated in CR for 6 months, whereas in the control group, they received standard care.",intervention patients participated cr 6 months control received standard care,C0886296|C0030705|G0000000|C0201975|G0000000|C0439231|C0243148|C1514756|C1442989|C1947933
"In the intervention group, patients participated in an outpatient phase III CR program for 6 months.",intervention patients participated outpatient phase iii cr program 6 months,C0886296|C0030705|G0000000|C0029921|C0205390|C0439070|C0201975|C1709697|G0000000|C0439231
"The weekly supervised exercise session at the clinic consisted of approximately 20 min of warm-up exercises including stretching and calisthenics, followed by 20-30 min of continuous upright aerobic and dynamic exercise (various combinations of walking, bicycling, jogging, and other activities) quantitatively and light isometric exercise, such as hand weights, and approximately 20 min of cool-down stretching and calisthenics.",weekly supervised exercise session clinic consisted 20 min warm-up exercises including stretching calisthenics 20-30 min continuous upright aerobic dynamic exercise combinations walking bicycling jogging activities quantitatively light isometric exercise hand weights 20 min cool-down stretching calisthenics,C0332174|G0000000|C0015259|C1883016|C0002424|C0332529|C0450371|C0702093|C2350169|C0015259|C0332257|C0600080|C0006759|C0450371|C0702093|C0549178|C0522015|C1510824|C0729333|C0015259|C0453882|C0080331|C0005377|C0022400|C0441655|G0000000|C0023693|G0000000|C0015259|C0018563|C0043100|C0450371|C0702093|C1548792|C0600080|C0006759
"In the vaginal dinoprostone group, a 2-mg gel was administered twice, 6 hours apart.",vaginal dinoprostone 2-mg gel administered 6 hours,C0042232|C0012472|C0026410|C0017243|C1521801|G0000000|C0439227
"For women allocated to misoprostol, capsules of 20 Âµg prepared by the pharmacy and dissolved in 20 mL of water were administered orally every 2 hours.",women allocated misoprostol capsules 20 prepared pharmacy dissolved 20 water administered orally 2 hours,C0043210|G0000000|C0085174|C0006935|C0450371|C4082130|C0031321|C1549535|C0450371|C0043047|C1521801|C0442027|G0000000|C0439227
"The allocation to the oral misoprostol group (20 Âµg given every 2 hours increased to 40 Âµg depending on uterine contractions) or to the vaginal dinoprostone group (2 mg twice, 6 hours apart) was contained in a sealed, opaque, and consecutively numbered envelope.",allocation oral misoprostol 20 2 hours increased 40 depending uterine contractions vaginal dinoprostone 2 6 hours contained sealed opaque consecutively numbered envelope,C1706778|C0442027|C0085174|C0450371|G0000000|C0439227|C0205217|C0450371|C0725813|C0042149|C1140999|C0042232|C0012472|G0000000|G0000000|C0439227|C0332256|C0036492|C0029053|G0000000|C0449788|C1622204
"A first dose of 5 Âµg misoprostol was doubled every hour with a maximum of 40 Âµg, repeated up to five times, as long as contractions were inadequate.",dose 5 misoprostol doubled hour maximum 40 repeated times contractions inadequate,C0178602|G0000000|C0085174|C0205173|C0439227|C0806909|C0450371|C0205341|C0040223|C1140999|C0205412
"For the analysis of cardiovascular end points, patients were followed to initiation of treatment for end-stage renal failure (dialysis or renal transplantation), reaching a serum creatinine level of 530.4 â®mol/L (6.0 mg/dL) or higher, death, or administrative censoring in December 2000.",analysis cardiovascular patients initiation treatment end-stage renal failure dialysis renal transplantation reaching serum creatinine level 530 4 mol/l 6 0 mg/dl death administrative censoring december 2000,C0002778|C0007226|C0030705|C0589507|C0039798|C0205088|C0022646|C0231174|C0011945|C0022646|C0040732|C2584321|C0229671|C0010294|C0441889|C1442061|G0000000|C0347982|G0000000|G0000000|C0439269|C0011065|C1292785|C3889990|C3830550|G0000000
"Patients were randomly assigned centrally by computer to receive treatment with irbesartan, 300 mg/d (Avapro, Bristol-Myers Squibb, Princeton, New Jersey); amlodipine, 10 mg/d (Norvasc, Pfizer, New York); or matched placebo.",patients randomly assigned centrally computer receive treatment irbesartan 300 mg/d avapro bristol-myers squibb princeton jersey amlodipine 10 mg/d norvasc pfizer york matched placebo,C0030705|G0000000|C1516050|G0000000|C0009622|C1514756|C0039798|C0288171|C1442061|C0439422|C0595301|C0331797|C0331904|C0331889|C0454673|C0051696|C0450371|C0439422|C0162712|C0331888|G0000000|C0150103|C0032042
"All patients had blood pressure controlled to the same blood pressure goal of less than 135/85 mm Hg by using antihypertensive agents other than ACE inhibitors, angiotensin II receptor blocking agents, or calcium-channel blockers.",patients blood pressure controlled blood pressure goal 135/85 mm hg antihypertensive agents ace inhibitors angiotensin ii receptor blocking agents calcium-channel blockers,C0030705|C0005767|C0033095|C2587213|C0005767|C0033095|C0018017|C1442061|G0000000|C0025424|C0003364|C0450442|C1452534|C0243077|C0003018|G0000000|C0597357|C0233660|C0450442|C0006685|G0000000
Significantly more women randomized to the placebo (59%) underwent labor epidural analgesia than women randomized to misoprostol (39%) (P Ï­ .048).,women randomized placebo 59% underwent labor epidural analgesia women randomized misoprostol 39% 048,C0043210|C0034656|C0032042|C0450371|G0000000|C0022864|C0228134|C0002766|C0043210|C0034656|C0085174|C0450371|C1442061
Ruptured membranes were diagnosed when amnionic fluid was visualized coming through the cervical os on sterile speculum examination.,ruptured membranes diagnosed amnionic fluid visualized coming cervical os sterile speculum examination,C0443294|C0025255|C0011900|C0002630|C0005889|C0234621|G0000000|C0027530|C0229090|C0021359|C0037816|G0000000
"METHODS: Nulliparous women at 36 to 41 6 â7 weeks with a singleton, cephalic-presenting fetus and ruptured membranes without evidence of labor were randomized to receive oral misoprostol (100 â®g) or a placebo every 4 hours for a maximum of two doses.",methods nulliparous women 36 41 6 7 weeks singleton cephalic-presenting fetus ruptured membranes evidence labor randomized receive oral misoprostol 100 placebo 4 hours maximum doses,C0025663|C0425979|C0043210|C0450371|C0450371|G0000000|G0000000|C0439230|C0481462|C0205096|C0015965|C0443294|C0025255|C3887511|C0022864|C0034656|C1514756|C0442027|C0085174|C1442061|C0032042|G0000000|C0439227|C0806909|C0178602
"Six or more uterine contractions occurring in 10 minutes without fetal heart rate decelerations (uterine tachysystole) occurred in 25% of women receiving misoprostol, compared with 2% of women receiving placebos.",uterine contractions occurring 10 minutes fetal heart rate decelerations uterine tachysystole occurred 25% women receiving misoprostol compared 2% women receiving placebos,C0042149|C1140999|C1709305|C0450371|C0439232|C0015965|C0018787|C0871208|C0011100|C0042149|C2985339|C1709305|C0450371|C0043210|C1514756|C0085174|C1707455|G0000000|C0043210|C1514756|C0032042
"Maternal demographic characteristics for women with ruptured membranes less than 3 hours versus more than 3 hours were compared, as well as the combined misoprostol versus placebo study groups, which are shown in Table 1.",maternal demographic characteristics women ruptured membranes 3 hours versus 3 hours compared combined misoprostol versus placebo study table 1,C2347083|C0011298|C1521970|C0043210|C0443294|C0025255|G0000000|C0439227|G0000000|G0000000|C0439227|C1707455|C0205195|C0085174|G0000000|C0032042|C0557651|C0039224|G0000000
"After the instruction phase, patients received an exercise prescription similar to that of the Hosp-CR group, a wristwatch digital pulse monitor, a cycle ergometer, and a log book to record the heart rate attained during each exercise session and reasons for not finishing or missing a session.",instruction phase patients received exercise prescription hosp-cr wristwatch digital pulse monitor cycle ergometer log book record heart rate attained exercise session reasons finishing missing session,C0039401|C0205390|C0030705|C1514756|C0015259|C0033080|C0201975|G0000000|C0442015|C0232117|C0030695|C1511572|C0180748|C1708728|C0006002|C0034869|C0018787|C0871208|G0000000|C0015259|C1883016|C0392360|C1706059|C1551393|C1883016
Patients received cardiovascular risk factor management counseling at each in-hospital session and were invited to join a monthly familyoriented support group.,patients received cardiovascular risk factor management counseling in-hospital session invited join monthly familyoriented support,C0030705|C1514756|C0007226|C0035647|C1521761|C0001554|C0010210|C0019994|C1883016|G0000000|G0000000|C0332177|G0000000|C0183683
Patients received cardiovascular risk factor management counseling twice per week and were invited to join a monthly support group together with family members.,patients received cardiovascular risk factor management counseling week invited join monthly support family,C0030705|C1514756|C0007226|C0035647|C1521761|C0001554|C0010210|C0332174|G0000000|G0000000|C0332177|C0183683|C0015576
"A physical therapist made home visits every other week to adjust if necessary the exercise prescription, to enhance adherence with intervention, and to record the number of completed sessions and distance cycled.",physical therapist visits week adjust exercise prescription enhance adherence intervention record completed sessions distance cycled,C0031809|C0871525|C0545082|C0332174|G0000000|C0015259|C0033080|C2349975|C1510802|C0886296|C0034869|C0205197|C1883016|C0012751|C1511572
"After full informed consent, the women were randomly allocated to receive the misoprostol orally or vaginally (May-October 2001).",informed consent women randomly allocated receive misoprostol orally vaginally may-october 2001,C1522154|C1511481|C0043210|G0000000|G0000000|C1514756|C0085174|C0442027|G0000000|C3828732|G0000000
"In a double-blind randomized controlled trial with a single dose of 200 m g misoprostol versus placebo for cervical priming at term with premature ruptune of membranes, Ngai et al .",double-blind randomized controlled trial single dose 200 misoprostol versus placebo cervical priming term premature ruptune membranes ngai al,C0013072|C0034656|C2587213|C0008976|C0037179|C0178602|C1442061|C0085174|G0000000|C0032042|C0027530|C0871133|C0233324|C0151526|G0000000|C0025255|G0000000|C0202311
"The women were then given a choice of being delivered by cesarean section, or having PGE 2 vaginal gel after a rest period.",women choice delivered cesarean pge 2 vaginal gel rest period,C0043210|C0008300|C1705822|C3841297|C0033559|G0000000|C0042232|C0017243|C0035253|C0439531
"Induction to regular contraction time was 15.6 min faster in women who received misoprostol vaginally, but not significantly different.",induction regular contraction time 15 6 min faster women received misoprostol vaginally,C0205263|C0205272|C1140999|C0040223|C0450371|G0000000|C0702093|C0015663|C0043210|C1514756|C0085174|G0000000
Methods: One hundred and six pregnant women at term with unfavorable cervix (Bishop score Â£ 4) and no contraindication to prostaglandin therapy were randomized to receive either intravaginal misoprostol 50 m g every 4 h or oral misoprostol 50 m g every 4 h for prospective randomized controlled trial study.,methods pregnant women term unfavorable cervix bishop score 4 contraindication prostaglandin therapy randomized receive intravaginal misoprostol 50 4 oral misoprostol 50 4 prospective randomized controlled trial study,C0025663|C0549206|C0043210|C0233324|C3640815|C0007874|C1551458|C0449820|G0000000|C0522473|C0033554|C0039798|C0034656|C1514756|C0442122|C0085174|C0450371|G0000000|C0442027|C0085174|C0450371|G0000000|C0023981|C0034656|C2587213|C0008976|C0557651
Patients received 50 m g of misoprostol orally or vaginally every 4 h until one of the following outcomes had occurred: cervix favorable for amniotomy; increased Bishop score â¥ 3; spontaneous rupture of membranes; or active labor.,patients received 50 misoprostol orally vaginally 4 outcomes occurred cervix favorable amniotomy increased bishop score 3 spontaneous rupture membranes active labor,C0030705|C1514756|C0450371|C0085174|C0442027|G0000000|G0000000|C1274040|C1709305|C0007874|C3640814|G0000000|C0205217|C1551458|C0449820|G0000000|C0205359|C1881712|C0025255|C0205177|C0022864
"Of the 396 patients in the study, 5 had an intrauterine death, leaving 391 women with a live fetus at term who underwent induction of labour.",396 patients study 5 intrauterine death leaving 391 women live fetus term underwent induction labour,C1442061|C0030705|C0557651|G0000000|C0694756|C0011065|G0000000|C1442061|C0043210|C1548795|C0015965|C0233324|G0000000|C0205263|C0022864
"In the misoprostol group, 118 women (58%) had vaginal deliveries and 81 (40%) had CSs.",misoprostol 118 women 58% vaginal deliveries 81 40% css,C0085174|C1442061|C0043210|C0450371|C0042232|C0011209|C0450371|C0450371|C0265338
"Three hundred and ninety-six women with term pregnancies were randomised to receive either oral or vaginal misoprostol, or dinoprostone.",ninety-six women term pregnancies randomised receive oral vaginal misoprostol dinoprostone,C3816959|C0043210|C0233324|C0032961|G0000000|C1514756|C0442027|C0042232|C0085174|C0012472
The average induction to delivery time was 17 hours in the dinoprostone group and 16 hours in the misoprostol group (p = 0.493).,average induction delivery time 17 hours dinoprostone 16 hours misoprostol = 0 493,C1510992|C0205263|C0011209|C0040223|C0450371|C0439227|C0012472|C0450371|C0439227|C0085174|G0000000|G0000000|C1442061
"The difference was not Overall, vaginal delivery was achieved in 60.8% of women (N = 226) and CS in 142 (38%).",difference vaginal delivery achieved 60 8% women = 226 cs 142 38%,C1705241|C0042232|C0011209|G0000000|C0450371|G0000000|C0043210|G0000000|C1442061|C0010182|C1442061|C0450371
"There were slightly more primiparous women in the Foley catheter/misoprostol group (44%), compared with the misoprostol group (37%) and the dinoprostone group (36%).",primiparous women foley catheter/misoprostol 44% compared misoprostol 37% dinoprostone 36%,C0033150|C0043210|G0000000|C0085590|C0450371|C1707455|C0085174|C0450371|C0012472|C0450371
"In the Foley catheter group, misoprostol was required in all but 1 case.",foley catheter misoprostol required 1,G0000000|C0085590|C0085174|C1514873|G0000000
"Routine artificial rupture of membranes to augment labour was discouraged in all three groups because of a high prevalence of hepatitis, HIV and other perinatal infections.",routine artificial rupture membranes augment labour discouraged prevalence hepatitis hiv perinatal infections,C0205547|C2004457|C1881712|C0025255|C0205217|C0022864|G0000000|C0033105|C0019158|C0019682|C0178795|C3714514
"Continuous fetal heart rate monitoring was not possible in all low-risk women, because of the shortage of cardiotocograph machines and personnel.",continuous fetal heart rate monitoring low-risk women shortage cardiotocograph machines personnel,C0549178|C0015965|C0018787|C0871208|C0150369|C3272281|C0043210|C1282927|C0179625|C0336779|C0024752
"Those women with intact membranes enrolled at the South African sites were randomly allocated to Foley catheter/oral misoprostol, oral misoprostol alone or vaginal dinoprostone.",women intact membranes enrolled south african sites randomly allocated foley catheter/oral misoprostol oral misoprostol vaginal dinoprostone,C0043210|C0205266|C0025255|G0000000|C1710133|C0027567|C0205145|G0000000|G0000000|G0000000|C0085590|C0085174|C0442027|C0085174|C0042232|C0012472
"The next in a series of opaque, sealed and numbered treatment envelopes in computergenerated random sequence was taken out of one of four dispensers for: intact membranes/unfavourable cervix, intact m e m b r a n e s / f a v o u r a b l e cervix, ruptured membranes/unfavourable cervix and ruptured membranes/favourable cervix.",series opaque sealed numbered treatment envelopes computergenerated random sequence dispensers intact membranes/unfavourable cervix intact / cervix ruptured membranes/unfavourable cervix ruptured membranes/favourable cervix,C0205549|C0029053|C0036492|C0449788|C0039798|C1622204|G0000000|C0034656|C0004793|C0180463|C0205266|C0025255|C0007874|C0205266|G0000000|C0007874|C0443294|C0025255|C0007874|C0443294|C0025255|C0007874
Group B-control group-no preoperative IABC Note: N.S-nonstatistical significant difference; LVEF-left ventricular ejection fraction.,b-control group-no preoperative iabc note s-nonstatistical difference lvef-left ventricular ejection fraction,C0243148|C0441833|C0445204|G0000000|C1316572|G0000000|C1705241|C0428772|C0018827|C0302131|C1264633
Material: Group A-IABC started prior to induction of anesthesia (n = 15); group B-no preoperative IABC (n = 15).,material a-iabc started prior induction anesthesia = 15 b-no preoperative iabc = 15,C0520510|G0000000|C1272689|C0332152|C0205263|C0002903|G0000000|C0450371|G0000000|C0445204|G0000000|G0000000|C0450371
"Patients fulfilling the inclusion criteria were randomly allocated to either of two treatment paths: Group A-therapy group-preoperative IABC therapy, started prior to induction of anesthesia, followed by continuous IABC during the entire procedure as well as postoperatively.",patients fulfilling inclusion criteria randomly allocated treatment paths a-therapy group-preoperative iabc therapy started prior induction anesthesia continuous iabc entire procedure postoperatively,C0030705|C1550543|C0007637|C0243161|G0000000|G0000000|C0039798|C0919386|C0039798|C0441833|G0000000|C0039798|C1272689|C0332152|C0205263|C0002903|C0549178|G0000000|C0439751|C0184661|G0000000
"More women in the oxytocin group were delivered vaginally in 12 hours, but there was no significant difference in the number delivered vaginally within 24 hours.",women oxytocin delivered vaginally 12 hours difference delivered vaginally 24 hours,C0043210|C0030095|C1705822|G0000000|C0450371|C0439227|C1705241|C1705822|G0000000|C0450371|C0439227
"One group received oral misoprostol 75 lg (a half and a fourth of a 100-lg tablet) at 4-hour intervals until progressive labor (defined as regular uterine contractions with cervical change), contraction frequency of at least three in 10 minutes, nonreassuring fetal heart rate tracing, or delivery occurred.",received oral misoprostol 75 lg half fourth 100-lg tablet 4-hour intervals progressive labor defined regular uterine contractions cervical change contraction frequency 10 minutes nonreassuring fetal heart rate tracing delivery occurred,C1514756|C0442027|C0085174|C0450371|C0023128|C2825407|C0205438|C1442061|C0039225|C0439227|C1272706|C0205329|C0022864|C1704788|C0205272|C0042149|C1140999|C0027530|C0392747|C1140999|C0376249|C0450371|C0439232|G0000000|C0015965|C0018787|C0871208|G0000000|C0011209|C1709305
"There was a higher rate of tachysystole in the oxytocin group (29.2% vs 14.0%); however, this difference did not reach statistical significance.",rate tachysystole oxytocin 29 2% 14 0% difference reach statistical significance,C0871208|C2985339|C0030095|C0450371|G0000000|C0450371|G0000000|C1705241|C2584321|C0038215|C0237881
STUDY DESIGN: One hundred five women were stratified by parity and randomly assigned to oral misoprostol 75 lg every 4 hours as needed to establish labor or to intravenous oxytocin.,study design women stratified parity randomly assigned oral misoprostol 75 lg 4 hours establish labor intravenous oxytocin,C0557651|C1707689|C0043210|C0205363|C0030563|G0000000|C1516050|C0442027|C0085174|C0450371|C0023128|G0000000|C0439227|C0443211|C0022864|C0348016|C0030095
Women were assigned to receive oral misoprostol or intravenous oxytocin by opening the next sequentially numbered opaque sealed envelope.,women assigned receive oral misoprostol intravenous oxytocin sequentially numbered opaque sealed envelope,C0043210|C1516050|C1514756|C0442027|C0085174|C0348016|C0030095|G0000000|C0449788|C0029053|C0036492|C1622204
Continuous electronic fetal heart rate and uterine activity monitoring were performed until uterine activity resolved or for a minimum of 1 hour after any misoprostol administration.,continuous electronic fetal heart rate uterine activity monitoring performed uterine activity resolved minimum 1 hour misoprostol administration,C0549178|C0013850|C0015965|C0018787|C0871208|C0042149|C0205177|C0150369|C0884358|C0042149|C0205177|C1514893|C1524031|G0000000|C0439227|C0085174|C0001554
"The significant difference in neonatal antibiotic administration between the two groups persisted when logistic regression analysis was performed controlling for maternal age, meconium at entry, group B streptococci colonization, interval between rupture of membranes and randomization, interval between randomization and induction, maternal fever, and epidural use.",difference neonatal antibiotic administration persisted logistic regression analysis performed controlling maternal age meconium entry streptococci colonization interval rupture membranes randomization interval randomization induction maternal fever epidural,C1705241|C1552240|C0003232|C0001554|G0000000|C0242415|C0684320|C0002778|C0884358|C2239193|C2347083|C0001779|C0025047|C1705654|C0038402|G0000000|C1272706|C1881712|C0025255|C0034656|C1272706|C0034656|C0205263|C2347083|C0015967|C0228134
"There was a trend toward more cesarean deliveries for nonreassuring fetal heart rate tracings among women allocated to receive misoprostol, but this difference was not statistically significant.",trend cesarean deliveries nonreassuring fetal heart rate tracings women allocated receive misoprostol difference statistically,C1521798|C3841297|C0011209|G0000000|C0015965|C0018787|C0871208|G0000000|C0043210|G0000000|C1514756|C0085174|C1705241|C0038215
Baseline characteristics were similar in women allocated to the two groups.,baseline characteristics women allocated,C0168634|C1521970|C0043210|G0000000
"There was no difference in the proportion of women who underwent cesarean delivery (20.1% in the misoprostol group, 19.9% in the oxytocin group).",difference proportion women underwent cesarean delivery 20 1% misoprostol 19 9% oxytocin,C1705241|C1709707|C0043210|G0000000|C3841297|C0011209|C0450371|G0000000|C0085174|C0450371|G0000000|C0030095
Seventy-six women (47.5%) who were randomly assigned to misoprostol required oxytocin augmentation of labor.,seventy-six women 47 5% randomly assigned misoprostol required oxytocin augmentation labor,C3816957|C0043210|C0450371|G0000000|G0000000|C1516050|C0085174|C1514873|C0030095|C1293122|C0022864
"STUDY DESIGN: Three hundred five women at 10 centers were randomly assigned to receive oral misoprostol, 100 lg every 6 hours to a maximum of two doses or intravenous oxytocin.",study design women 10 centers randomly assigned receive oral misoprostol 100 lg 6 hours maximum doses intravenous oxytocin,C0557651|C1707689|C0043210|C0450371|C0205099|G0000000|C1516050|C1514756|C0442027|C0085174|C1442061|C0023128|G0000000|C0439227|C0806909|C0178602|C0348016|C0030095
"Women receiving misoprostol were less likely to have postpartum hemorrhage than those receiving oxytocin (1.9% vs 6.2%, P = .05).",women receiving misoprostol postpartum hemorrhage receiving oxytocin 1 9% 6 2% = 05,C0043210|C1514756|C0085174|C0086839|C0019080|C1514756|C0030095|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371
Similar numbers of women in both groups received epidural anesthesia.,women received epidural anesthesia,C0043210|C1514756|C0228134|C0002903
"More infants born to women in the misoprostol group received intravenous antibiotics in the neonatal period (16.4% vs 6.9%, P = .01), although there were no differences in chorioamnionitis or in proven neonatal infections.",infants born women misoprostol received intravenous antibiotics neonatal period 16 4% 6 9% = 01 differences chorioamnionitis proven neonatal infections,C0021270|C0005615|C0043210|C0085174|C1514756|C0348016|C0003232|C1552240|C0439531|C0450371|G0000000|G0000000|G0000000|G0000000|C0450371|C1705241|C0008495|C0456369|C1552240|C3714514
"We designed this prospective, randomized, double-blinded study to test the hypothesis that the technique used for maintaining hemodynamic stability during general anesthesia can influence recovery after ambulatory surgery.",designed prospective randomized double-blinded study test hypothesis technique maintaining hemodynamic stability anesthesia influence recovery ambulatory surgery,C1707689|C0023981|C0034656|C0205173|C0557651|C0022885|C1512571|C0449851|C0024501|C0019010|C0205360|C0002903|C4054723|C0237820|C0439841|C0038894
"Forty-five healthy consenting women undergoing gynecologic laparoscopy procedures were randomly assigned to 1 of 3 treatment groups: Group 1 (control, n Ï­ 15) received normal saline 5 mL and 1 mL, followed by a saline infusion at a rate of 0.005 mL Â· kg Ïª1 Â· min Ïª1 ; Group 2 (n Ï­ 15) received esmolol 50 mg and saline 1 mL, followed by an esmolol infusion 5 â®g Â· kg Ïª1 Â· min Ïª1 ; and Group 3 (n Ï­ 15) received esmolol 50 mg and nicardipine 1 mg, followed by an esmolol infusion 5 â®g Â· kg Ïª1 Â· min Ïª1.",forty-five healthy consenting women undergoing gynecologic laparoscopy procedures randomly assigned 1 3 treatment 1 control 15 received normal saline 5 1 saline infusion rate 0 005 1 min 1 2 15 received esmolol 50 saline 1 esmolol infusion 5 1 min 1 3 15 received esmolol 50 nicardipine 1 esmolol infusion 5 1 min 1,C3816449|C3898900|C1511481|C0043210|G0000000|C0205480|C0031150|C0025664|G0000000|C1516050|G0000000|G0000000|C0039798|G0000000|C0243148|C0450371|C1514756|C0205307|C0036082|G0000000|G0000000|C0036082|C0574032|C0871208|G0000000|C1442061|G0000000|C0702093|G0000000|G0000000|C0450371|C1514756|C0116569|C0450371|C0036082|G0000000|C0116569|C0574032|G0000000|G0000000|C0702093|G0000000|G0000000|C0450371|C1514756|C0116569|C0450371|C0028005|G0000000|C0116569|C0574032|G0000000|G0000000|C0702093|G0000000
"In Group 2, patients received esmolol 50 mg and saline 1 mL IV, and Group 3 received esmolol 50 mg and nicardipine 1 mg IV.",2 patients received esmolol 50 saline 1 iv 3 received esmolol 50 nicardipine 1 iv,G0000000|C0030705|C1514756|C0116569|C0450371|C0036082|G0000000|C0022326|G0000000|C1514756|C0116569|C0450371|C0028005|G0000000|C0022326
"In Group 1 (control), the patients received normal saline 5 mL and 1 mL.",1 control patients received normal saline 5 1,G0000000|C0243148|C0030705|C1514756|C0205307|C0036082|G0000000|G0000000
The study drug doses were doubled after 6 weeks if DBP was greater than or equal to 90 mm Hg.,study drug doses doubled 6 weeks dbp equal 90 mm hg,C0557651|C0013227|C0178602|C0205173|G0000000|C0439230|C0536221|C0205163|C0450371|G0000000|C0025424
"Neurohormone measurements and echocardiography were performed at weeks 0, 12, 24, and 48.",neurohormone measurements echocardiography performed weeks 0 12 24 48,C0597049|C0242485|C0013516|C0884358|C0439230|G0000000|C0450371|C0450371|C0450371
"Thus, 115 hypertensive patients with left ventricular hypertrophy were randomized to receive double-blind irbesartan or atenolol, with additional therapy if needed.",115 hypertensive patients left ventricular hypertrophy randomized receive double-blind irbesartan atenolol additional therapy,C1442061|C0857121|C0030705|C0205091|C0018827|C0020564|C0034656|C1514756|C0013072|C0288171|C0004147|C1524062|C0039798
"If DBP remained greater than or equal to 90 mm Hg at week 12, open label hydrochlorothiazide 12.5 mg once daily (titrated to 25 mg if necessary) was added.",dbp remained equal 90 mm hg week 12 label hydrochlorothiazide 12 5 daily titrated 25,C0536221|G0000000|C0205163|C0450371|G0000000|C0025424|C0332174|C0450371|C0181496|C0020261|C0450371|G0000000|C0332173|C1883350|C0450371
Ten patients in the misoprostol group and 22 patients in the placebo group were delivered by cesarean section.,ten patients misoprostol 22 patients placebo delivered cesarean,C0014518|C0030705|C0085174|C0450371|C0030705|C0032042|C1705822|C3841297
"Methods: In this double-blind randomized trial, 156 pregnant women requiring induction of labor with gestational age of 37-42 weeks and Bishop score F5, were randomized to receive either 200 mg of misoprostol or a placebo, orally.",methods double-blind randomized trial 156 pregnant women requiring induction labor gestational age 37-42 weeks bishop score f5 randomized receive 200 misoprostol placebo orally,C0025663|C0013072|C0034656|C0008976|C1442061|C0549206|C0043210|G0000000|C0205263|C0022864|C0439671|C0001779|C0450371|C0439230|C1551458|C0449820|G0000000|C0034656|C1514756|C1442061|C0085174|C0032042|C0442027
"There was no difference between the groups as regards incidence of maternal side effects, although two patients in the misoprostol group had nausea, three patients in the misoprostol group and two patients in the placebo group vomited after oral medication.",difference incidence maternal effects patients misoprostol nausea patients misoprostol patients placebo vomited oral medication,C1705241|C0021149|C2347083|C1280500|C0030705|C0085174|C0027497|C0030705|C0085174|C0030705|C0032042|C0042963|C0442027|C0013227
"Clinically stable CAD patients with hypertension were randomly assigned to either verapamil SR or atenolol for blood pressure treatment according to the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) (target: systolic blood pressure [SBP] Ï½140 and diastolic blood pressure [DBP] Ï½90 mm Hg or SBP Ï½130 mm Hg and DBP Ï½85 mm Hg when diabetes or renal impairment is present).",clinically stable cad patients hypertension randomly assigned verapamil sr atenolol blood pressure treatment sixth report joint national committee prevention detection evaluation treatment blood pressure jnc vi target systolic blood pressure sbp 140 diastolic blood pressure dbp 90 mm hg sbp 130 mm hg dbp 85 mm hg diabetes renal impairment,G0000000|C0205360|C3813548|C0030705|C0020538|G0000000|C1516050|C0042523|C3813610|C0004147|C0005767|C0033095|C0039798|C0205440|C0684224|C0022417|C3245503|C2699414|C0199176|C1511790|C0220825|C0039798|C0005767|C0033095|G0000000|C0205999|C1521840|C0039155|C0005767|C0033095|G0000000|C1442061|C0012000|C0005767|C0033095|C0536221|C0450371|G0000000|C0025424|G0000000|C1442061|G0000000|C0025424|C0536221|C0450371|G0000000|C0025424|C0011847|C0022646|C0221099
"Results At 24 months, in the CAS group, 6391 patients (81.5%) were taking verapamil sustained release; 4934 (62.9%) were taking trandolapril; and 3430 (43.7%) were taking hydrochlorothiazide.",24 months cas 6391 patients 81 5% verapamil sustained release 4934 62 9% trandolapril 3430 43 7% hydrochlorothiazide,C0450371|C0439231|G0000000|G0000000|C0030705|C0450371|G0000000|C0042523|C0443318|C0030685|G0000000|C0450371|G0000000|C0076891|G0000000|C0450371|G0000000|C0020261
"In the NCAS group, 6083 patients (77.5%) were taking aten-olol; 4733 (60.3%) were taking hydrochlorothiazide; and 4113 (52.4%) were taking trandolapril.",ncas 6083 patients 77 5% aten-olol 4733 60 3% hydrochlorothiazide 4113 52 4% trandolapril,C1413309|G0000000|C0030705|C0450371|G0000000|G0000000|G0000000|C0450371|G0000000|C0020261|G0000000|C0450371|G0000000|C0076891
The first six-week period of 'heart school' in the hospital was followed by nine weeks of organised physical exercise twice weekly at a gymnasium outside the hospital under the supervision of a physiotherapist.,six-week period heart school hospital weeks organised physical exercise weekly gymnasium hospital supervision physiotherapist,C0205452|C0439531|C0018787|C0036375|C0019994|C0439230|C1300196|C0031809|C0015259|C0332174|C0442572|C0019994|C0038842|C2362565
The first phase lasted for six weeks with physical exercise supervised by a specially educated physiotherapist (KP) in addition to regular group meeting twice a week.,phase lasted weeks physical exercise supervised specially educated physiotherapist kp addition regular meeting week,C0205390|C1517741|C0439230|C0031809|C0015259|G0000000|G0000000|C0039401|C2362565|C0022772|C0332287|C0205272|C0556656|C0332174
"Each training session started with 15 minutes of warm-up followed by 20 minutes of dynamic endurance training, 10 minutes of active cool-down activities and, finally, 10 minutes with stretching and relaxation.",training session started 15 minutes warm-up 20 minutes dynamic endurance training 10 minutes active cool-down activities finally 10 minutes stretching relaxation,C0040607|C1883016|C1272689|C0450371|C0439232|C2350169|C0450371|C0439232|C0729333|C0518031|C0040607|C0450371|C0439232|C0205177|C1548792|C0441655|G0000000|C0450371|C0439232|C0600080|C0035028
Two women in the misoprostol group and one in the PGE 2 group had abdominal delivery for failure of cervical ripening with the inducing agents.,women misoprostol pge 2 abdominal delivery failure cervical ripening inducing agents,C0043210|C0085174|C0033559|G0000000|C0000726|C0011209|C0231174|C0027530|C1160534|C0205263|C0450442
"While there were no cases of uterine hyperstimulation in the PGE 2 group, two primiparous women needed salbutamol in the misoprostol group.",uterine hyperstimulation pge 2 primiparous women salbutamol misoprostol,C0042149|G0000000|C0033559|G0000000|C0033150|C0043210|C0001927|C0085174
"Assuming that 40% of women receiving vaginal PGE 2 would deliver within 24 hours of the induction, 6 our sample size was calculated to detect a 25% increase in this number (to 65%) in the misoprostol group (power 90%, a Â¼ 0.10, h Â¼ 0.10, Instat Version 3.01, GraphPad Software, San Deigo, California, USA).",assuming 40% women receiving vaginal pge 2 deliver 24 hours induction 6 sample size calculated detect 25% increase 65% misoprostol power 90% 0 10 0 10 instat version 3 01 graphpad software san deigo california usa,G0000000|C0450371|C0043210|C1514756|C0042232|C0033559|G0000000|C0308779|C0450371|C0439227|C0205263|G0000000|C0370003|C0456389|C0444686|C0442726|C0450371|C0442805|C0450371|C0085174|C0032863|C0450371|G0000000|C0450371|G0000000|C0450371|G0000000|C0333052|G0000000|C0450371|G0000000|C0037585|C1826357|G0000000|C0006754|C0041703
Three other women had evidence of tachysystole while on oxytocin augmentation following priming with misoprostol.,women evidence tachysystole oxytocin augmentation priming misoprostol,C0043210|C3887511|C2985339|C0030095|C1293122|C0871133|C0085174
"After full informed consent, women were randomly assigned to receive oral misoprostol or vaginal PGE 2 tablet by means of a computer generated random table, with the allocation concealed in cards in sequentially numbered, opaque envelopes.",informed consent women randomly assigned receive oral misoprostol vaginal pge 2 tablet computer generated random table allocation concealed cards sequentially numbered opaque envelopes,C1522154|C1511481|C0043210|G0000000|C1516050|C1514756|C0442027|C0085174|C0042232|C0033559|G0000000|C0039225|C0009622|C3146294|C0034656|C0039224|C1706778|C0443189|C3275277|G0000000|C0449788|C0029053|C1622204
The main measure of efficacy was taken to be the number of women delivering vaginally within 24 hours of the first dose of prostaglandin in the two groups.,main measure efficacy women delivering vaginally 24 hours dose prostaglandin,C0205225|C0079809|C1280519|C0043210|C0308779|G0000000|C0450371|C0439227|C0178602|C0033554
"Of the 75 women in the misoprostol group and the 73 women in the PGE 2 group who delivered vaginally, 50.7% and 54.8%, respectively, did so within 24 hours of the administration of the first dose of the inducing agent (RR 0.92, 95% CI 0.7 to 1.3, Table 2).",75 women misoprostol 73 women pge 2 delivered vaginally 50 7% 54 8% 24 hours administration dose inducing agent rr 0 92 95% ci 0 7 1 3 table 2,C0450371|C0043210|C0085174|C0450371|C0043210|C0033559|G0000000|C1705822|G0000000|C0450371|G0000000|C0450371|G0000000|C0450371|C0439227|C0001554|C0178602|C0205263|C0450442|G0000000|G0000000|C0450371|C0450371|C0008107|G0000000|G0000000|G0000000|G0000000|C0039224|G0000000
"Methods The women were randomly allocated to receive either 100 Ag of misoprostol orally (which could be repeated 4 hourly to a maximum of five doses if indicated), or a 3 mg tablet of prostaglandin E 2 vaginally (which could be repeated in 6 hours, according to routine departmental protocol).",methods women randomly allocated receive 100 ag misoprostol orally repeated 4 hourly maximum doses 3 tablet prostaglandin 2 vaginally repeated 6 hours routine departmental protocol,C0025663|C0043210|G0000000|G0000000|C1514756|C1442061|C0002037|C0085174|C0442027|C0205341|G0000000|C0558292|C0806909|C0178602|G0000000|C0039225|C0033554|G0000000|G0000000|C0205341|G0000000|C0439227|C0205547|C1704729|C0442711
"If a diagnosis of labour was made or the cervical Bishop's score was 8 or more, the woman was transferred to the labour ward for artificial rupture of membranes.",diagnosis labour cervical bishops score 8 woman transferred labour ward artificial rupture membranes,C0011900|C0022864|C0027530|C0649610|C0449820|G0000000|C0043210|C0348011|C0022864|C1305702|C2004457|C1881712|C0025255
"Women assigned to the oral misoprostol received a 100 Ag misoprostol tablet (Cytotec, Searle Pharmaceuticals, Ontario, Canada) orally and the dose could be repeated every 4 hours to a maximum of five doses.",women assigned oral misoprostol received 100 ag misoprostol tablet cytotec searle pharmaceuticals ontario canada orally dose repeated 4 hours maximum doses,C0043210|C1516050|C0442027|C0085174|C1514756|C1442061|C0002037|C0085174|C0039225|C0591321|C0331897|C1135440|C0029040|C0006823|C0442027|C0178602|C0205341|G0000000|C0439227|C0806909|C0178602
After 4 weeks doses were doubled if blood pressure exceeded 150 mm Hg systolic or 90 mm Hg diastolic.,4 weeks doses doubled blood pressure exceeded 150 mm hg systolic 90 mm hg diastolic,G0000000|C0439230|C0178602|C0205173|C0005767|C0033095|G0000000|C1442061|G0000000|C0025424|C0039155|C0450371|G0000000|C0025424|C0012000
"This randomized, double-blind trial was conducted at 14 universityaffiliated centers in Germany.",randomized double-blind trial conducted 14 universityaffiliated centers germany,C0034656|C0013072|C0008976|C0004927|C0450371|G0000000|C0205099|C0017480
"After withdrawal of previous antihypertensive therapy, subjects were randomized 1:1 to receive either 150-mg irbesartan or 50-mg atenolol once daily.",withdrawal previous antihypertensive therapy subjects randomized 1 1 receive 150-mg irbesartan 50-mg atenolol daily,C2349954|C0205156|C0003364|C0039798|C0681850|C0034656|G0000000|G0000000|C1514756|C1442061|C0288171|C0450371|C0004147|C0332173
Intervention Patients were allocated randomly to groups to receive amlodipine 5-10 mg or lisinopril 10-20 mg for 2 years.,intervention patients allocated randomly receive amlodipine 5-10 lisinopril 10-20 2,C0886296|C0030705|G0000000|G0000000|C1514756|C0051696|C0450371|C0065374|C0450371|G0000000
After 6 weeks of active treatment the dosage was increased to 10 mg amlodipine and 20 mg lisinopril.,6 weeks active treatment dosage increased 10 amlodipine 20 lisinopril,G0000000|C0439230|C0205177|C0039798|C0178602|C0205217|C0450371|C0051696|C0450371|C0065374
"If blood pressure remained stable during this run-in period, the patients were randomly assigned to the double-blind treatment phase, to receive 5 mg amlodipine or 10 mg lisinopril.",blood pressure remained stable run-in period patients randomly assigned double-blind treatment phase receive 5 amlodipine 10 lisinopril,C0005767|C0033095|G0000000|C0205360|C3274438|C0439531|C0030705|G0000000|C1516050|C0013072|C0039798|C0205390|C1514756|G0000000|C0051696|C0450371|C0065374
"Patients already receiving antihypertensive treatment discontinued taking previous drugs and were directly rolled over to one of the two VALUE arms starting with either valsartan 80 mg or amlodipine 5 mg, without a placebo run-in period (figure 1).",patients receiving antihypertensive treatment discontinued previous drugs directly rolled arms starting valsartan 80 amlodipine 5 placebo run-in period figure 1,C0030705|C1514756|C0003364|C0039798|C1444662|C0205156|C0013227|C1947931|C3841382|C0206655|C0439659|C0216784|C0450371|C0051696|G0000000|C0032042|C3274438|C0439531|G0000000|G0000000
"When study drug interruptions were included, the median doses were 149Â·3 mg (80Â·2-158Â·5) and 8Â·2 mg (5Â·0-9Â·9), respectively.",study drug interruptions included median doses 1493 802-1585 82 50-99,C0557651|C0013227|C0332453|C0332257|C0549183|C0178602|G0000000|C1442061|C0450371|C0450371
The median daily doses were 151Â·7 mg (IQR 83Â·2-158Â·5) for valsartan and 8Â·5 mg (IQR 5Â·0-9Â·9) for amlodipine.,median daily doses 1517 iqr 832-1585 valsartan 85 iqr 50-99 amlodipine,C0549183|C0332173|C0178602|G0000000|G0000000|C1442061|C0216784|C0450371|G0000000|C0450371|C0051696
"Sixty-nine of 78 patients were candidates for the BMSC procedure and were randomized to receive BMSCs (n Ï­ 34) or saline (PCI-only group, n Ï­ 35) as the control arm.",sixty-nine 78 patients candidates bmsc procedure randomized receive bmscs 34 saline pci-only 35 control arm,C0450388|C0450371|C0030705|G0000000|G0000000|C0184661|C0034656|C1514756|G0000000|C0450371|C0036082|C4049621|C0450371|C0243148|C0446516
Sixty-nine patients who underwent primary percuta-neous coronary intervention within 12 hours after onset of acute myocardial infarction were random-ized to receive intracoronary injection of autologous bone marrow mesenchymal stem cell or standard saline.,sixty-nine patients underwent primary percuta-neous coronary intervention 12 hours onset acute myocardial infarction random-ized receive intracoronary injection autologous bone marrow mesenchymal stem cell standard saline,C0450388|C0030705|G0000000|C0205225|G0000000|C0018787|C0886296|C0450371|C0439227|C0206132|C0205178|C0027061|C0021308|C0034656|C1514756|C0595454|C0021485|C0439859|C0262950|C0086590|C1513143|C0242767|C0007634|C1442989|C0036082
One hundred ten (55.6%) women who were randomly assigned to misoprostol received 100 mcg tablets every 4 hours to a maximum of 6 doses (maximum total dose of 600 mcg) or 24 hours of cervical ripening regardless of the number of doses received.,ten 55 6% women randomly assigned misoprostol received 100 mcg tablets 4 hours maximum 6 doses maximum total dose 600 mcg 24 hours cervical ripening doses received,C0014518|C0450371|G0000000|C0043210|G0000000|C1516050|C0085174|C1514756|C1442061|C0439211|C0039225|G0000000|C0439227|C0806909|G0000000|C0178602|C0806909|C0439175|C0178602|C1442061|C0439211|C0450371|C0439227|C0027530|C1160534|C0178602|C1514756
"Misoprostol, 100 mg, was administered every 4 hours up to 6 doses, or intravenous oxytocin was administered by standardized protocol.",misoprostol 100 administered 4 hours 6 doses intravenous oxytocin administered standardized protocol,C0085174|C1442061|C1521801|G0000000|C0439227|G0000000|C0178602|C0348016|C0030095|C1521801|G0000000|C0442711
Results: One hundred ten (55.6%) women received misoprostol; 88 (44.4%) received intravenous oxytocin.,ten 55 6% women received misoprostol 88 44 4% received intravenous oxytocin,C0014518|C0450371|G0000000|C0043210|C1514756|C0085174|C0450371|C0450371|G0000000|C1514756|C0348016|C0030095
"Period of gestation did not correlate with cumulative misoprostol (rsy0.24, PsNS) or cumulative oxytocin dose (rsy0.11, PsNS); suggesting that same dose is effective for all term pregnancies, whether 37 weeks or 41 weeks.",period gestation correlate cumulative misoprostol rsy0 24 psns cumulative oxytocin dose rsy0 11 psns suggesting dose effective term pregnancies 37 weeks 41 weeks,C0439531|C0032961|G0000000|C1511559|C0085174|G0000000|C0450371|C3826968|C1511559|C0030095|C0178602|G0000000|C0450371|C3826968|C1705535|C0178602|C1280519|C0233324|C0032961|C0450371|C0439230|C0450371|C0439230
"Seventy term-pregnant women (37-42 weeks gestation) were randomized to Group A or B, after informed written consent and excluding the following-cervix favorable for amniotomy (Bishop score)6), non-vertex presentation, intrauterine demise, previous uterine scar, oligohydramnios, intrauterine growth retardation, multifetal pregnancy, clinical evidence of cardiopulmonaryyhepaticyrenal disease, electrolyte abnormalities, pre-eclampsiayeclampsia.",seventy term-pregnant women 37-42 weeks gestation randomized informed written consent excluding following-cervix favorable amniotomy bishop score 6 non-vertex presentation intrauterine demise previous uterine scar oligohydramnios intrauterine growth retardation multifetal pregnancy clinical evidence cardiopulmonaryyhepaticyrenal disease electrolyte abnormalities pre-eclampsiayeclampsia,C3816957|C0233324|C0043210|C0450371|C0439230|C0032961|C0034656|C1522154|C0043266|C1511481|C0332196|C0231290|C3640814|G0000000|C1551458|C0449820|G0000000|C1518422|C0449450|C0694756|G0000000|C0205156|C0042149|C0241158|C0079924|C0694756|C0018270|C0521111|G0000000|C0032961|C0205210|C3887511|G0000000|C0012634|C0013832|C0000768|C0332152
"Induction-delivery interval was shorter with misoprostol (7.7""2.8 h against 14.3""4.8 h with oxytocin) but the rates of vaginal delivery, cesarean, neonatal outcome variables were similar.",induction-delivery interval shorter misoprostol 7 72 8 14 34 8 oxytocin rates vaginal delivery cesarean neonatal outcome variables,C0205263|C1272706|C1282927|C0085174|G0000000|C0450371|G0000000|C0450371|C0450371|G0000000|C0030095|C0871208|C0042232|C0011209|C3841297|C1552240|C1274040|C0439828
"Group B (ns34) received controlled oxytocin intravenous infusion, initiated at 2 mUy min; stepped up by 2 mUymin every 15 min until optimal response, then continued at the same rate until delivery.",ns34 received controlled oxytocin intravenous infusion initiated 2 muy min stepped 2 muymin 15 min optimal response continued rate delivery,G0000000|C1514756|C2587213|C0030095|C0348016|C0574032|C1548602|G0000000|G0000000|C0702093|C1261552|G0000000|G0000000|C0450371|C0702093|C2698651|C0871261|C0549178|C0871208|C0011209
"Induction-delivery interval for vaginal deliveries, mode of delivery, Apgar score at 1 and 5 min, need for neonatal resuscitation and presence of neonatal asphyxia were recorded.",induction-delivery interval vaginal deliveries mode delivery apgar score 1 5 min neonatal resuscitation presence neonatal asphyxia recorded,C0205263|C1272706|C0042232|C0011209|C1513371|C0011209|C0741195|C0449820|G0000000|G0000000|C0702093|C1552240|C0035273|C0150312|C1552240|C0004044|C0034869
"Seventy patients were randomized to Group A (ns36, oral misoprostol 50 mg four hourly to maximum of 5 doses) and B (ns34, continuous oxytocin infusion).",seventy patients randomized ns36 oral misoprostol 50 hourly maximum 5 doses ns34 continuous oxytocin infusion,C3816957|C0030705|C0034656|G0000000|C0442027|C0085174|C0450371|C0558292|C0806909|G0000000|C0178602|G0000000|C0549178|C0030095|C0574032
"In Group A, 22.2% needed 50 mg oral misoprostol while 44.4% and 27.8%, respectively, required 2 and 3 doses.",22 2% 50 oral misoprostol 44 4% 27 8% required 2 3 doses,C0450371|G0000000|C0450371|C0442027|C0085174|C0450371|G0000000|C0450371|G0000000|C1514873|G0000000|G0000000|C0178602
"Oral misoprostol is associated with shorter duration of labor and shorter induction-delivery interval, with no difference in neonatal or maternal outcomes w1x.",oral misoprostol shorter duration labor shorter induction-delivery interval difference neonatal maternal outcomes w1x,C0442027|C0085174|C1282927|C0449238|C0022864|C1282927|C0205263|C1272706|C1705241|C1552240|C2347083|C1274040|G0000000
"In Group B, 38.2% each required a maximum oxytocin infusion rate of 6 mUymin and 8 mUymin, while 23.6% needed higher rates.",38 2% required maximum oxytocin infusion rate 6 muymin 8 muymin 23 6% rates,C0450371|G0000000|C1514873|C0806909|C0030095|C0574032|C0871208|G0000000|G0000000|G0000000|G0000000|C0450371|G0000000|C0871208
"After PCI, all patients received aspirin 100 mg once daily and ticlopidine 100 mg twice daily for Ï¾3 weeks and cilostazol 100 mg twice daily for 4 days.",pci patients received aspirin 100 daily ticlopidine 100 daily 3 weeks cilostazol 100 daily 4 days,C4049621|C0030705|C1514756|C0004057|C1442061|C0332173|C0040207|C1442061|C0332173|G0000000|C0439230|C0055729|C1442061|C0332173|G0000000|C0439228
All patients underwent emergency coronary angiography and percutaneous coronary intervention (PCI).,patients underwent emergency coronary angiography percutaneous coronary intervention pci,C0030705|G0000000|C0013956|C0018787|C0002978|C0522523|C0018787|C0886296|C4049621
"Patients were randomized to receive intensive lipid-lowering therapy (atorvastatin 20 mg PO once daily) or usual care [lipid-lowering diet, and if LDL cholesterol (LDL-C) level was",patients randomized receive intensive lipid-lowering therapy atorvastatin 20 po daily usual care lipid-lowering diet ldl cholesterol ldl-c level,C0030705|C0034656|C1514756|C0162425|C0023779|C0039798|C0286651|C0450371|C0032729|C0332173|C3538928|C1947933|C0023779|C0012155|G0000000|C0008377|G0000000|C0441889
The measurements were performed after 30 minutes of rest and BP was measured at the same time.,measurements performed 30 minutes rest bp measured time,C0242485|C0884358|C0450371|C0439232|C0035253|C0037623|C0444706|C0040223
"After 1 year of treatment, and still on active medication, PET scan, echocardiography, and subcutaneous biopsy were repeated.",1 treatment active medication pet scan echocardiography subcutaneous biopsy repeated,G0000000|C0039798|C0205177|C0013227|C0031268|C0034606|C0013516|C0443315|C0005558|C0205341
"Thirty previously untreated hypertensive patients were randomized in a double-blind design to treatment for 1 year with either perindopril (4 to 8 mg per day, nÏ­15) or atenolol (50 to 100 mg per day, nÏ­15) and furthermore compared with normotensive controls.",thirty untreated hypertensive patients randomized double-blind design treatment 1 perindopril 4 8 day n15 atenolol 50 100 day n15 compared normotensive controls,C3816446|C0332155|C0857121|C0030705|C0034656|C0013072|C1707689|C0039798|G0000000|C0136123|G0000000|G0000000|C0332173|G0000000|C0004147|C0450371|C1442061|C0332173|G0000000|C1707455|C2712122|C0243148
"After selection, the patients entered a placebo period of 3 to 4 weeks, during which positron emission tomography (PET) scan, echocardiography, and subcutaneous biopsy were performed.",selection patients entered placebo period 3 4 weeks positron emission tomography pet scan echocardiography subcutaneous biopsy performed,C0036576|C0030705|C1521975|C0032042|C0439531|G0000000|G0000000|C0439230|C0032744|C0233929|C0040395|C0031268|C0034606|C0013516|C0443315|C0005558|C0884358
A sample size of 94 women (47 in each group) was calculated using a two-tailed alpha of 0.05 and a power of 90%.,sample size 94 women 47 calculated two-tailed alpha 0 05 power 90%,C0370003|C0456389|C0450371|C0043210|C0450371|C0444686|C0205448|C0439095|G0000000|C0450371|C0032863|C0450371
Women received 100 mg of misoprostol orally or 50 mg of misoprostol vaginally every 6 h until one of the following outcomes occurred: Bishop score â¥8; spontaneous ruptured membranes; or completion of eight doses.,women received 100 misoprostol orally 50 misoprostol vaginally 6 outcomes occurred bishop score 8 spontaneous ruptured membranes completion doses,C0043210|C1514756|C1442061|C0085174|C0442027|C0450371|C0085174|G0000000|G0000000|C1274040|C1709305|C1551458|C0449820|G0000000|C0205359|C0443294|C0025255|C0205197|C0178602
Methods: One hundred and fifty-three pregnant women at term with indications for induction of labor and Bishop score Â£6 were randomly assigned to receive misoprostol either 100 mg orally or 50 mg vaginally every 6 h for 48 h. Repeated doses were given until Bishop score â¥8 was achieved or spontaneous rupture of membranes occurred.,methods fifty-three pregnant women term indications induction labor bishop score 6 randomly assigned receive misoprostol 100 orally 50 vaginally 6 48 repeated doses bishop score 8 achieved spontaneous rupture membranes occurred,C0025663|C3816723|C0549206|C0043210|C0233324|C0392360|C0205263|C0022864|C1551458|C0449820|G0000000|G0000000|C1516050|C1514756|C0085174|C1442061|C0442027|C0450371|G0000000|G0000000|C0450371|C0205341|C0178602|C1551458|C0449820|G0000000|G0000000|C0205359|C1881712|C0025255|C1709305
"From October 2001 to May 2003, a total of 153 women gave signed written informed consent to participate in the trial and were randomized into two groups; one group to receive 100 mg of oral misoprostol and the other group to receive 50 mg of vaginal misoprostol.",october 2001 2003 total 153 women signed written informed consent participate trial randomized receive 100 oral misoprostol receive 50 vaginal misoprostol,C3828732|G0000000|G0000000|C0439175|C1442061|C0043210|C1519316|C0043266|C1522154|C1511481|G0000000|C0008976|C0034656|C1514756|C1442061|C0442027|C0085174|C1514756|C0450371|C0042232|C0085174
All women had electronic fetal heart rate (FHR) monitoring for 20 min prior to and following administration of misoprostol.,women electronic fetal heart rate fhr monitoring 20 min prior administration misoprostol,C0043210|C0013850|C0015965|C0018787|C0871208|G0000000|C0150369|C0450371|C0702093|C0332152|C0001554|C0085174
The median total misoprostol doses required and the number of women received oxytocin augmentation were not significantly different between the two groups.,median total misoprostol doses required women received oxytocin augmentation,C0549183|C0439175|C0085174|C0178602|C1514873|C0043210|C1514756|C0030095|C1293122
"Women randomized to vaginal route had Bishop score assessed prior to each dose, and the same procedure applied to the oral route.",women randomized vaginal route bishop score assessed prior dose procedure applied oral route,C0043210|C0034656|C0042232|C0013153|C1551458|C0449820|C1516048|C0332152|C0178602|C0184661|C4048755|C0442027|C0013153
"Tachysystole was identified in four women in the oral group compared with 13 women in the vaginal group, and the difference was statistically significant.",tachysystole identified women oral compared 13 women vaginal difference statistically,C2985339|C0205396|C0043210|C0442027|C1707455|C0450371|C0043210|C0042232|C1705241|C0038215
They were randomized to either an early intensive statin treatment strategy (40 mg/d of simvastatin for 30 days and then 80 mg/d of simvastatin thereafter) or a less aggressive strategy (placebo for 4 months and then 20 mg/d of simvastatin thereafter).,randomized intensive statin treatment strategy 40 mg/d simvastatin 30 days 80 mg/d simvastatin aggressive strategy placebo 4 months 20 mg/d simvastatin,C0034656|C0162425|C0360714|C0039798|C0679199|C0450371|C0439422|C0074554|C0450371|C0439228|C0450371|C0439422|C0074554|C0001807|C0679199|C0032042|G0000000|C0439231|C0450371|C0439422|C0074554
"Patients who had LDL cholesterol levels that were higher than 130 mg/dL (3.37 mmol/L) at month 8 or any subsequent visitwereprovidedadditionaldietary,lifestyle, and compliance counseling.",patients ldl cholesterol levels 130 mg/dl 3 37 mmol/l month 8 subsequent visitwereprovidedadditionaldietary lifestyle compliance counseling,C0030705|G0000000|C0008377|C0441889|C1442061|C0439269|G0000000|C0450371|C1532563|C0332177|G0000000|C0332282|G0000000|C0023676|C0009563|C0010210
creased by 11% during the 4-month placebo period from 111 mg/dL (2.87 mmol/L) to 124 mg/dL (3.21 mmol/L) and then decreased to 77 mg/dL (1.99 mmol/L) at month 8 after the initiation of 20 mg of simvastatin (31% change from baseline).,creased 11% 4-month placebo period 111 mg/dl 2 87 mmol/l 124 mg/dl 3 21 mmol/l decreased 77 mg/dl 1 99 mmol/l month 8 initiation 20 simvastatin 31% change baseline,G0000000|C0450371|C0332177|C0032042|C0439531|C1442061|C0439269|G0000000|C0450371|C1532563|C1442061|C0439269|G0000000|C0450371|C1532563|C0205216|C0450371|C0439269|G0000000|C0450371|C1532563|C0332177|G0000000|C0589507|C0450371|C0074554|C0450371|C0392747|C0168634
"The patients randomly assigned to Echocardiography Two-dimensional echocardiography was performed with an Acuson 128 imaging system on day 1 after thrombolysis or immediately after thrombolysis plus HBO treatment, on day 2, and after 3 weeks in all patients.",patients randomly assigned echocardiography two-dimensional echocardiography performed acuson 128 imaging system day 1 thrombolysis thrombolysis hbo treatment day 2 3 weeks patients,C0030705|G0000000|C1516050|C0013516|C1705052|C0013516|C0884358|G0000000|C1442061|C0011923|C0449913|C0332173|G0000000|C0520997|C0520997|G0000000|C0039798|C0332173|G0000000|G0000000|C0439230|C0030705
"Streptokinase was administered at the dose of 1.5 mU/L over 30 to 60 minutes, followed by intravenous heparin infusion.",streptokinase administered dose 1 5 mu/l 30 60 minutes intravenous heparin infusion,C0038418|C1521801|C0178602|G0000000|G0000000|C0439342|C0450371|C0450371|C0439232|C0348016|C0019134|C0574032
They remained at this pressure during 60 minutes in the monoplace hyperbaric chamber.,remained pressure 60 minutes monoplace hyperbaric chamber,G0000000|C0033095|C0450371|C0439232|G0000000|G0000000|C0179874
"After an initial 4-week placebo washout period of previous antihypertensive therapy, patients were randomized to receive telmisartan 40 mg or nifedipine GITS 20 mg once daily for 12 months.",initial 4-week placebo washout period previous antihypertensive therapy patients randomized receive telmisartan 40 nifedipine gits 20 daily 12 months,C0205265|C0332174|C0032042|C1710661|C0439531|C0205156|C0003364|C0039798|C0030705|C0034656|C1514756|C0248719|C0450371|C0028066|C1418224|C0450371|C0332173|C0450371|C0439231
"Methods: In this double-blind trial, patients taking oral hypoglycemic agents were randomized to receive telmisartan 40 mg or nifedipine GITS 20 mg once daily for 12 months.",methods double-blind trial patients oral hypoglycemic agents randomized receive telmisartan 40 nifedipine gits 20 daily 12 months,C0025663|C0013072|C0008976|C0030705|C0442027|C0020616|C0450442|C0034656|C1514756|C0248719|C0450371|C0028066|C1418224|C0450371|C0332173|C0450371|C0439231
"Patients were instructed to take their medication in the morning after breakfast, except on the days of clinic visits.",patients instructed medication morning breakfast days clinic visits,C0030705|G0000000|C0013227|C0332170|C2698559|C0439228|C0002424|C0545082
"The control group also attended a 2-hour talk that explained the disease, the importance of risk-factor modification, and the potential benefits of physical activity.",control attended 2-hour talk explained disease risk-factor modification potential benefits physical activity,C0243148|C1456498|C0439227|C0037817|G0000000|C0012634|C0035648|C0392747|C3245505|C0814225|C0031809|C0205177
"Once they were received in the rehabilitation center, consecutive patients within 6 weeks of an AMI or PCI performed for angina pectoris were randomized into the cardiac rehabilitation group (CRPP group) or the control group, at a ratio of 2 to 1.",received rehabilitation center consecutive patients 6 weeks ami pci performed angina pectoris randomized cardiac rehabilitation crpp control ratio 2 1,C1514756|C0034991|C0205099|C1707491|C0030705|G0000000|C0439230|G0000000|C4049621|C0884358|C0002962|G0000000|C0034656|C0018787|C0034991|G0000000|C0243148|C0456603|G0000000|G0000000
Intervention: Patients received either CRPP (an 8-wk exercise and education class in phase 2) or conventional therapy without exercise program (control group).,intervention patients received crpp 8-wk exercise education class phase 2 conventional therapy exercise program control,C0886296|C0030705|C1514756|G0000000|C0332174|C0015259|C0013621|C0456387|C0205390|G0000000|C0439858|C0039798|C0015259|C1709697|C0243148
"After the phase 1 ambulatory phase, the control group received conventional therapy without undergoing the outpatient exercise training program.",phase 1 ambulatory phase control received conventional therapy undergoing outpatient exercise training program,C0205390|G0000000|C0439841|C0205390|C0243148|C1514756|C0439858|C0039798|G0000000|C0029921|C0015259|C0040607|C1709697
"We did echocardiography, assessments of vascular function, laboratory assessments, blood pressure and pulse rate measurements at baseline, and after 6 and 12 months of treatment.",echocardiography assessments vascular function laboratory assessments blood pressure pulse rate measurements baseline 6 12 months treatment,C0013516|C1261322|C0005847|C0031843|C0022877|C1261322|C0005767|C0033095|C0232117|C0871208|C0242485|C0168634|G0000000|C0450371|C0439231|C0039798
When target pressure was not reached the following steps were added consecutively: 12.5 mg hydrochlorothiazide; doubling of study medication; 5 mg felodipine; 50 mg metoprolol; 2 mg doxazosin; 5 mg felodipine; 50 mg metoprolol; 2 mg doxazosin; 5 mg felodipine; 100 mg metoprolol; and 4 mg doxazosin (when contraindications were present or,target pressure reached steps consecutively 12 5 hydrochlorothiazide doubling study medication 5 felodipine 50 metoprolol 2 doxazosin 5 felodipine 50 metoprolol 2 doxazosin 5 felodipine 100 metoprolol 4 doxazosin contraindications,C1521840|C0033095|C2584321|C1261552|G0000000|C0450371|G0000000|C0020261|C0205173|C0557651|C0013227|G0000000|C0015772|C0450371|C0025859|G0000000|C0114873|G0000000|C0015772|C0450371|C0025859|G0000000|C0114873|G0000000|C0015772|C1442061|C0025859|G0000000|C0114873|C0079164
"A total of 70 hypertensive type II diabetic individuals were treated with three antihyper-tensive strategies in a randomized, double-blind, double dummy design.",total 70 hypertensive type ii diabetic individuals treated antihyper-tensive strategies randomized double-blind double dummy design,C0439175|C0450371|C0857121|C0332307|G0000000|C0241863|C0027361|C1522326|C0233494|C0679199|C0034656|C0013072|C0205173|G0000000|C1707689
"Subjects were assigned to receive either 25 or 50 Ag of misoprostol by means of a commercially available computer program (Rancode-Plus 3.1.1 [idv-Datenanalyse und Versuchsplanung, Munich, Germany]).",subjects assigned receive 25 50 ag misoprostol commercially computer program rancode-plus 3 1 1 idv-datenanalyse und versuchsplanung munich germany,C0681850|C1516050|C1514756|C0450371|C0450371|C0002037|C0085174|G0000000|C0009622|C1709697|C0332287|G0000000|G0000000|G0000000|C0376637|C1413574|G0000000|G0000000|C0017480
Study subjects received oral doses of the study medication every 3 days for a maximum of three courses over 9 days.,study subjects received oral doses study medication 3 days maximum courses 9 days,C0557651|C0681850|C1514756|C0442027|C0178602|C0557651|C0013227|G0000000|C0439228|C0806909|C0750729|G0000000|C0439228
"Method: Forty-nine subjects followed in an outpatient obstetrical clinic with pregnancies of at least 40 weeks' gestation, and an unfavorable Bishop score were assigned randomly to receive oral misoprostol 50 or 25 Ag every 3 days for a maximum of three doses.",method forty-nine subjects outpatient obstetrical clinic pregnancies 40 weeks gestation unfavorable bishop score assigned randomly receive oral misoprostol 50 25 ag 3 days maximum doses,C0025663|C3816450|C0681850|C0029921|C0028773|C0002424|C0032961|C0450371|C0439230|C0032961|C3640815|C1551458|C0449820|C1516050|G0000000|C1514756|C0442027|C0085174|C0450371|C0450371|C0002037|G0000000|C0439228|C0806909|C0178602
"Continuous electronic FHR monitoring was performed in all subjects for at least 2 h. At that point, the subjects were discharged with instructions to return in 3 days if spontaneous labor failed to occur or if they experienced diminished fetal kick counts or contractions occurring one every 5 min.",continuous electronic fhr monitoring performed subjects 2 subjects discharged instructions return 3 days spontaneous labor failed occur experienced diminished fetal kick counts contractions occurring 5 min,C0549178|C0013850|G0000000|C0150369|C0884358|C0681850|G0000000|C0681850|C0030685|C0302828|C0332156|G0000000|C0439228|C0205359|C0022864|C0231175|C1709305|C0237607|C0205216|C0015965|G0000000|C0439157|C1140999|C1709305|G0000000|C0702093
"Patients received either dinoprostone (Prepidil GelR, Pharmacia, South Africa) 0.5 mg intracervically (6-h inerval) or misoprostol 50 Ag per os (4-h interval), until the cervix was favourable (Bishop scoreN7) allowing amniotomy, or causing spontaneous rupture of membranes, or inducing progressive painful contractions.",patients received dinoprostone prepidil gelr pharmacia south africa 0 5 intracervically 6-h inerval misoprostol 50 ag os 4-h interval cervix favourable bishop scoren7 allowing amniotomy causing spontaneous rupture membranes inducing progressive painful contractions,C0030705|C1514756|C0012472|C0592000|G0000000|C0331955|C1710133|C0001737|G0000000|G0000000|G0000000|C0033727|G0000000|C0085174|C0450371|C0002037|C0229090|C0033727|C1272706|C0007874|C3640814|C1551458|G0000000|C0683607|G0000000|C0678227|C0205359|C1881712|C0025255|C0205263|C0205329|C0030193|C1140999
"Methods: In a randomized controlled trial, 200 patients received either misoprostol 50 Ag orally for every 4 h, or dinoprostone 0.5 mg intracervically for every 6 h. Cardiotocographic recordings, in 10-min windows 30, 60, and 80 min after prostaglandin administration during induction and continuously during labor, were compared between the two groups.",methods randomized controlled trial 200 patients received misoprostol 50 ag orally 4 dinoprostone 0 5 intracervically 6 cardiotocographic recordings 10-min windows 30 60 80 min prostaglandin administration induction continuously labor compared,C0025663|C0034656|C2587213|C0008976|C1442061|C0030705|C1514756|C0085174|C0450371|C0002037|C0442027|G0000000|C0012472|G0000000|G0000000|G0000000|G0000000|C0007208|G0000000|C0450371|C0557702|C0450371|C0450371|C0450371|C0702093|C0033554|C0001554|C0205263|G0000000|C0022864|C1707455
"Blood glucose, serum potassium, sodium, urea, and creatinine levels were measured at baseline and every three months thereafter.",blood glucose serum potassium sodium urea creatinine levels measured baseline months,C0005767|C0017725|C0229671|C0032821|C0037473|C0041942|C0010294|C0441889|C0444706|C0168634|C0439231
"After a six-week washout period during which any previous therapy with agents that inhibit the renin-angiotensin system was discontinued, and a three-week washout period during which any previous therapy with non-dihydropyridine calciumchannel blockers was discontinued, eligible subjects were randomly assigned to receive one of the study treatments: the non-dihydropyridine calciumchannel blocker verapamil (in a sustained-release formulation, at a dose of 240 mg per day), the ACE inhibitor trandolapril (2 mg per day), the combination of verapamil (in a sustained-release formulation, 180 mg per day) plus trandolapril (2 mg per day), or placebo.",six-week washout period previous therapy agents inhibit renin-angiotensin system discontinued three-week washout period previous therapy non-dihydropyridine calciumchannel blockers discontinued eligible subjects randomly assigned receive study treatments non-dihydropyridine calciumchannel blocker verapamil sustained-release formulation dose 240 day ace inhibitor trandolapril 2 day combination verapamil sustained-release formulation 180 day trandolapril 2 day placebo,C0205452|C1710661|C0439531|C0205156|C0039798|C0450442|C0018790|C0035094|C0449913|C1444662|C0205449|C1710661|C0439531|C0205156|C0039798|C1518422|G0000000|G0000000|C1444662|C1548635|C0681850|G0000000|C1516050|C1514756|C0557651|C0087111|C1518422|G0000000|G0000000|C0042523|C1710261|C0524527|C0178602|C1442061|C0332173|C1452534|C1999216|C0076891|G0000000|C0332173|C0205195|C0042523|C1710261|C0524527|C1442061|C0332173|C0076891|G0000000|C0332173|C0032042
"Blood pressure and randomly collected morning urine samples were evaluated at the time of randomization, at one week, one month, and three months after randomization, and every three months thereafter.",blood pressure randomly collected morning urine samples evaluated time randomization week month months randomization months,C0005767|C0033095|G0000000|C1516695|C0332170|C0042036|C0370003|C0220825|C0040223|C0034656|C0332174|C0332177|C0439231|C0034656|C0439231
"The use of potassium-sparing diuretics, inhibitors of the renin-angiotensin system, and non-dihydropyridine calcium-channel blockers different from the study drugs was not allowed.",potassium-sparing diuretics inhibitors renin-angiotensin system non-dihydropyridine calcium-channel blockers study drugs allowed,C0032821|C0012798|C0243077|C0035094|C0449913|C1518422|C0006685|G0000000|C0557651|C0013227|C0683607
Additional evaluations were performed within one week after any change in antihypertensive therapy and whenever deemed clinically appropriate.,additional evaluations performed week change antihypertensive therapy deemed clinically,C1524062|C0220825|C0884358|C0332174|C0392747|C0003364|C0039798|G0000000|G0000000
"A total of 1209 subjects were randomly assigned to one of four treatments, and of those, 1204 were followed for a median of 3.6 years (interquartile range, 1.3 to 4.3) (see the Supplementary Appendix, available with the full text of this article at www.nejm.org).",total 1209 subjects randomly assigned treatments 1204 median 3 6 interquartile range 1 3 4 3 supplementary appendix text article nejm org,C0439175|G0000000|C0681850|G0000000|C1516050|C0087111|G0000000|C0549183|G0000000|G0000000|G0000000|C1514721|G0000000|G0000000|G0000000|G0000000|G0000000|C0003617|C1527021|C1706852|G0000000|C1522486
"Women assigned to the stepwise oral misoprostol arm received 50 mg initially, followed by 100 mg every 4 hours up to 4 doses; those assigned to the vaginal misoprostol arm received 25 mg every 4 hours up to 4 doses.",women assigned stepwise oral misoprostol arm received 50 initially 100 4 hours 4 doses assigned vaginal misoprostol arm received 25 4 hours 4 doses,C0043210|C1516050|G0000000|C0442027|C0085174|C0446516|C1514756|C0450371|C0205265|C1442061|G0000000|C0439227|G0000000|C0178602|C1516050|C0042232|C0085174|C0446516|C1514756|C0450371|G0000000|C0439227|G0000000|C0178602
All women had continuous electronic FHR and uterine contraction monitoring.,women continuous electronic fhr uterine contraction monitoring,C0043210|C0549178|C0013850|G0000000|C0042149|C1140999|C0150369
"We hypothesized that stepwise dosing of oral misoprostol (50 mg followed by 100 mg) would be as effective for cervical ripening as vaginal misoprostol in the ACOG approved dose of 25 mg every 4 hours, without increasing the rates of hyperstimulation, and with the potential for greater patient satisfaction.",hypothesized stepwise dosing oral misoprostol 50 100 effective cervical ripening vaginal misoprostol acog approved dose 25 4 hours increasing rates hyperstimulation potential patient satisfaction,G0000000|G0000000|G0000000|C0442027|C0085174|C0450371|C1442061|C1280519|C0027530|C1160534|C0042232|C0085174|C1515938|C0205540|C0178602|C0450371|G0000000|C0439227|C0442808|C0871208|G0000000|C3245505|C0030705|C0242428
"From these, 90 consecutive patients with unstable angina or acute MI who fulfilled the inclusion criteria were prospectively included in the randomized protocol, and 44 patients received atorvastatin 40 mg daily and 46 patients placebo.",90 consecutive patients unstable angina acute mi fulfilled inclusion criteria prospectively included randomized protocol 44 patients received atorvastatin 40 daily 46 patients placebo,C0450371|C1707491|C0030705|C0443343|C0002962|C0205178|C3810814|C1550543|C0007637|C0243161|G0000000|C0332257|C0034656|C0442711|C0450371|C0030705|C1514756|C0286651|C0450371|C0332173|C0450371|C0030705|C0032042
"After an initial 4-week placebo run-in/washout period, patients were randomized to receive doxazosin, 4 mg once daily, or irbesartan, 300 mg once daily, for 12 months.",initial 4-week placebo run-in/washout period patients randomized receive doxazosin 4 daily irbesartan 300 daily 12 months,C0205265|C0332174|C0032042|C3274438|C0439531|C0030705|C0034656|C1514756|C0114873|G0000000|C0332173|C0288171|C1442061|C0332173|C0450371|C0439231
All patients received placebo and antidiabetic medication and did not receive any other treatment during the washout period.,patients received placebo antidiabetic medication receive treatment washout period,C0030705|C1514756|C0032042|C0935929|C0013227|C1514756|C0039798|C1710661|C0439531
"Patients and Methods Patients were randomly assigned to six cycles of docetaxel 100 mg/m 2 every 3 weeks, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg weekly until disease progression.",patients methods patients randomly assigned cycles docetaxel 100 mg/m 2 3 weeks trastuzumab 4 mg/kg loading dose 2 mg/kg weekly disease progression,C0030705|C0025663|C0030705|G0000000|C1516050|C1511572|C0246415|C1442061|C0026410|G0000000|G0000000|C0439230|C0728747|G0000000|C0439272|C1708715|C0178602|G0000000|C0439272|C0332174|C0012634|C0242656
"Fifty-three patients (57%) in the docetaxel-alone arm were reported to have crossed over to receive trastuzumab, usually at disease progression (30 patients) but in some cases after discontinuation of docetaxel because of toxicity (10 patients) or other reasons (13 patients).",fifty-three patients 57% docetaxel-alone arm reported crossed receive trastuzumab disease progression 30 patients discontinuation docetaxel toxicity 10 patients reasons 13 patients,C3816723|C0030705|C0450371|C0246415|C0446516|C0684224|C0205203|C1514756|C0728747|C0012634|C0242656|C0450371|C0030705|C0457454|C0246415|C0040539|C0450371|C0030705|C0392360|C0450371|C0030705
Trastuzumab was to be administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly until disease progression.,trastuzumab administered 4 mg/kg intravenous loading dose 2 mg/kg weekly disease progression,C0728747|C1521801|G0000000|C0439272|C0348016|C1708715|C0178602|G0000000|C0439272|C0332174|C0012634|C0242656
"In the BCIRG 006 trial, docetaxel is administered either on its own or concurrently with trastuzumab, after AC chemotherapy; a third arm of this trial is examining the combination of docetaxel, trastuzumab, and carboplatin (analogous to BCIRG 007).",bcirg 006 trial docetaxel administered concurrently trastuzumab ac chemotherapy arm trial examining combination docetaxel trastuzumab carboplatin analogous bcirg 007,G0000000|C1442061|C0008976|C0246415|C1521801|G0000000|C0728747|C0003354|C0013216|C0446516|C0008976|C0332128|C0205195|C0246415|C0728747|C0079083|G0000000|G0000000|C1442061
We randomized the patients into two groups: those receiving 100 mg oral misoprostol every 4 h and those receiving 50 mg vaginal misoprostol placed in the posterior fornix every 4 h. Randomization was done by pulling sealed numbers from a box; odd numbers were assigned to oral misoprostol and even numbers to vaginal misoprostol.,randomized patients receiving 100 oral misoprostol 4 receiving 50 vaginal misoprostol posterior fornix 4 randomization pulling sealed box odd assigned oral misoprostol vaginal misoprostol,C0034656|C0030705|C1514756|C1442061|C0442027|C0085174|G0000000|C1514756|C0450371|C0042232|C0085174|C0205095|C0152334|G0000000|C0034656|C0580846|C0036492|C0179400|C1415068|C1516050|C0442027|C0085174|C0042232|C0085174
"In this study, 50 mg vaginal misoprostol every 4 h, which has been the commonly preferred method, is compared with 100 mg oral misoprostol every 4 h.",study 50 vaginal misoprostol 4 commonly preferred method compared 100 oral misoprostol 4,C0557651|C0450371|C0042232|C0085174|G0000000|G0000000|C0558295|C0025663|C1707455|C1442061|C0442027|C0085174|G0000000
"Study design: Ninety-nine patients with indications for labor induction randomly received 100 mg oral misoprostol every 4 h or 50 mg vaginal misoprostol every 4 h, using maximum six doses.",study design ninety-nine patients indications labor induction randomly received 100 oral misoprostol 4 50 vaginal misoprostol 4 maximum doses,C0557651|C1707689|C3828813|C0030705|C0392360|C0022864|C0205263|G0000000|C1514756|C1442061|C0442027|C0085174|G0000000|C0450371|C0042232|C0085174|G0000000|C0806909|C0178602
Patients were assigned either amlodipine 5-10 mg adding perindopril 4-8 mg as required (amlodipine-based regimen; n=9639) or atenolol 50-100 mg adding bendroflumethiazide 1Â·25-2Â·5 mg and potassium as required (atenolol-based regimen; n=9618).,patients assigned amlodipine 5-10 adding perindopril 4-8 required amlodipine-based regimen n=9639 atenolol 50-100 adding bendroflumethiazide 125-25 potassium required atenolol-based regimen n=9618,C0030705|C1516050|C0051696|C0450371|C1883712|C0136123|G0000000|C1514873|C0051696|C0040808|C0369718|C0004147|C0450371|C1883712|C0004975|C1442061|C0032821|C1514873|C0004147|C0040808|C0369718
Step 1 Amlodipine 5 mg Atenolol 50 mg Step 2 Amlodipine 10 mg Atenolol 100 mg Step 3 Amlodipine 10 mgÏ©perindopril 4 mg Atenolol 100 mgÏ©bendroflumethiazide 1Â·25 mg Ï©potassium Step 4 Amlodipine 10 mgÏ©perindopril 8 mg (2Ï«4 mg) Atenolol 100 mgÏ©bendroflumethiazide 2Â·5 mg Ï©potassium Step 5 Amlodipine 10 mgÏ©perindopril 8 mg (2Ï«4 mg) Atenolol 100 mgÏ©bendroflumethiazide 2Â·5 mg Ï©doxazosin gastrointestinal transport system 4 mg Ï©potassiumÏ©doxazosin gastrointestinal transport system 4 mg Step 6 Amlodipine 10 mgÏ©perindopril 8 mg (2Ï«4 mg) Atenolol 100 mgÏ©bendroflumethiazide 2Â·5 mg Ï©doxazosin gastrointestinal transport system 8 mg Ï©potassiumÏ©doxazosin gastrointestinal transport system 8 mg,step 1 amlodipine 5 atenolol 50 step 2 amlodipine 10 atenolol 100 step 3 amlodipine 10 mgperindopril 4 atenolol 100 mgbendroflumethiazide 125 potassium step 4 amlodipine 10 mgperindopril 8 24 atenolol 100 mgbendroflumethiazide 25 potassium step 5 amlodipine 10 mgperindopril 8 24 atenolol 100 mgbendroflumethiazide 25 doxazosin gastrointestinal transport system 4 potassiumdoxazosin gastrointestinal transport system 4 step 6 amlodipine 10 mgperindopril 8 24 atenolol 100 mgbendroflumethiazide 25 doxazosin gastrointestinal transport system 8 potassiumdoxazosin gastrointestinal transport system 8,C1261552|G0000000|C0051696|G0000000|C0004147|C0450371|C1261552|G0000000|C0051696|C0450371|C0004147|C1442061|C1261552|G0000000|C0051696|C0450371|G0000000|G0000000|C0004147|C1442061|G0000000|C1442061|C0032821|C1261552|G0000000|C0051696|C0450371|G0000000|G0000000|C0450371|C0004147|C1442061|G0000000|C0450371|C0032821|C1261552|G0000000|C0051696|C0450371|G0000000|G0000000|C0450371|C0004147|C1442061|G0000000|C0450371|C0114873|C0521362|C0005528|C0449913|G0000000|G0000000|C0521362|C0005528|C0449913|G0000000|C1261552|G0000000|C0051696|C0450371|G0000000|G0000000|C0450371|C0004147|C1442061|G0000000|C0450371|C0114873|C0521362|C0005528|C0449913|G0000000|G0000000|C0521362|C0005528|C0449913|G0000000
"Methods We did a multicentre, prospective, randomised controlled trial in 19 257 patients with hypertension who were aged 40-79 years and had at least three other cardiovascular risk factors.",methods multicentre prospective randomised controlled trial 19 257 patients hypertension aged 40-79 cardiovascular risk factors,C0025663|C0439743|C0023981|G0000000|C2587213|C0008976|C0450371|C1442061|C0030705|C0020538|C0001779|C0450371|C0007226|C0035647|C1521761
"Consequently, along with their favourable metabolic profiles, we chose to compare the effect on non-fatal myocardial infarction and fatal CHD of a combination of a dihydropyridine calcium-channel blocker (amlodipine) and an ACE inhibitor (perindopril) with that of a â¤ blocker and a thiazide diuretic.",favourable metabolic profiles chose compare non-fatal myocardial infarction fatal chd combination dihydropyridine calcium-channel blocker amlodipine ace inhibitor perindopril blocker thiazide diuretic,C3640814|C0311400|C1979963|C1707391|C1707455|C1518422|C0027061|C0021308|C1302234|C0280604|C0205195|C0012315|C0006685|G0000000|C0051696|C1452534|C1999216|C0136123|G0000000|C0541746|C0012798
Participants were allocated at random to hospital-based cardiac rehabilitation or conventional care and followed up for 12 months.,participants allocated random hospital-based cardiac rehabilitation conventional care 12 months,C0679646|G0000000|C0034656|C0019994|C0018787|C0034991|C0439858|C1947933|C0450371|C0439231
"Patients from both groups received individualised medical treatment including non-invasive and invasive cardiological procedures, surgical revascularisation, pharmacotherapy, and lifestyle counselling as determined by their usual doctors.",patients received individualised medical treatment including non-invasive invasive cardiological procedures surgical revascularisation pharmacotherapy lifestyle counselling determined usual doctors,C0030705|C1514756|G0000000|C0199168|C0039798|C0332257|C0205303|C0205281|C0007189|C0025664|C0543467|C0581603|C0013216|C0023676|C0010210|G0000000|C3538928|C0031831
"Patients allocated to rehabilitation were to start within 2 weeks of leaving hospital, and were offered a 6-week package of thrice-weekly sessions, each comprising 60-90 minutes of supervised exercise, combined with 45 minutes of education (12 occasions) and 45 minutes of psychosocial counselling (6 occasions).",patients allocated rehabilitation start 2 weeks leaving hospital offered 6-week package thrice-weekly sessions comprising 60-90 minutes supervised exercise combined 45 minutes education 12 occasions 45 minutes psychosocial counselling 6 occasions,C0030705|G0000000|C0034991|C0439659|G0000000|C0439230|G0000000|C0019994|C1444648|C0332174|C0013194|C0556987|C1883016|C2700400|C0450371|C0439232|G0000000|C0015259|C0205195|C0450371|C0439232|C0013621|C0450371|C0521114|C0450371|C0439232|C0542298|C0010210|G0000000|C0521114
"With respect to cell transfer, centrifugation and resuspension reduced cell volume from the bone marrow harvest (mean 130 mL, SD 22) to a final volume of 10 mL, which we injected into the infarct-related coronary artery and which contained 304Ï«10 6 (SD 128Ï«10 lesion during cell or placebo injection did not impair TIMI frame count or trigger an increase in concentrations of troponin.",respect cell transfer centrifugation resuspension reduced cell volume bone marrow harvest 130 sd 22 final volume 10 injected infarct-related coronary artery contained 30410 6 sd 12810 lesion cell placebo injection impair timi frame count trigger increase concentrations troponin,C0679133|C0007634|C0040671|C0007703|G0000000|C0392756|C0007634|C0449468|C0262950|C0086590|C1512335|C1442061|C2699239|C0450371|C0205088|C0449468|C0450371|C1720154|C0021308|C0018787|C0003842|C0332256|G0000000|G0000000|C2699239|G0000000|C0221198|C0007634|C0032042|C0021485|G0000000|G0000000|C0080089|C0750480|C0032930|C0442805|C0086045|C0041199
We harvested bone marrow from every patient under local anaesthesia (posterior iliac crest punctures by a staff haematologist) and isolated BMSC by Ficoll density gradient centrifugation.,harvested bone marrow patient local anaesthesia posterior iliac crest punctures staff haematologist isolated bmsc ficoll density gradient centrifugation,C1512335|C0262950|C0086590|C0030705|C0205276|C0002903|C0205095|C0020889|C0332243|C0033119|C0851286|C0278598|C0205409|G0000000|C0016071|C0178587|C0439182|C0007703
"Of these, 741 (78.8%) were admitted for induction of labour and randomised, 365 women to oral misoprostol, and 376 to vaginal dinoprostone.",741 78 8% admitted induction labour randomised 365 women oral misoprostol 376 vaginal dinoprostone,C1442061|C0450371|G0000000|C0184666|C0205263|C0022864|G0000000|C1442061|C0043210|C0442027|C0085174|C1442061|C0042232|C0012472
Interventions 20 g oral misoprostol solution at two hourly intervals and placebo vaginal gel or vaginal dinoprostone gel at six hourly intervals and placebo oral solution.,interventions 20 oral misoprostol solution hourly intervals placebo vaginal gel vaginal dinoprostone gel hourly intervals placebo oral solution,C0886296|C0450371|C0442027|C0085174|C0037633|C0558292|C1272706|C0032042|C0042232|C0017243|C0042232|C0012472|C0017243|C0558292|C1272706|C0032042|C0442027|C0037633
"The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial was a prospective, multicenter, randomized, double-blind, placebocontrolled study of the efficacy and safety of clopidogrel plus aspirin as compared with aspirin alone in patients at high risk for a cardiovascular event.",clopidogrel atherothrombotic risk ischemic stabilization management avoidance charisma trial prospective multicenter randomized double-blind placebocontrolled study efficacy safety clopidogrel aspirin compared aspirin patients risk cardiovascular event,C0070166|G0000000|C0035647|C0475224|C1293130|C0001554|C0870186|C0248593|C0008976|C0023981|C0439743|C0034656|C0013072|C1706408|C0557651|C1280519|C0036043|C0070166|C0004057|C1707455|C0004057|C0030705|C0035647|C0007226|C0441471
"With a median of 28 months of follow-up, the rate of the primary event was 6.8 percent in the clopidogrel group and 7.3 percent in the placebo group (relative risk, 0.93; 95 percent confidence interval, 0.83 to 1.05; P = 0.22) (Fig.",median 28 months follow-up rate primary event 6 8 percent clopidogrel 7 3 percent placebo relative risk 0 93 95 percent confidence interval 0 83 1 05 = 0 22 fig,C0549183|C0450371|C0439231|C0589120|C0871208|C0205225|C0441471|G0000000|G0000000|C0439165|C0070166|G0000000|G0000000|C0439165|C0032042|C0080103|C0035647|G0000000|C0450371|C0450371|C0439165|C0237529|C1272706|G0000000|C0450371|G0000000|C0450371|G0000000|G0000000|C0450371|C0349966
Intermittent fetal blood sampling (FBS) for pH determination during periods of nonreassuring CTG has been used as a complementary method to improve specificity.,intermittent fetal blood sampling fbs ph determination periods nonreassuring ctg complementary method improve specificity,C0205267|C0015965|C0005767|C0441621|C3812213|C0450407|C1148554|C0439531|G0000000|G0000000|G0000000|C0025663|G0000000|C0037791
Methods Women were randomly assigned to be monitored either by STAN or by CTG.,methods women randomly assigned monitored stan ctg,C0025663|C0043210|G0000000|C1516050|C0030695|C2985331|G0000000
"Power analysis calculated using Stata 7.0 software (Stata Corp LP, Bryan/College Station, TX, USA) to show a 50% reduction in the incidence of neonatal acidemia indicated a sample size of 761 per arm (a = 0.05, b = 0.20).",power analysis calculated stata 7 0 software stata corp lp bryan/college station tx usa 50% reduction incidence neonatal acidemia sample size 761 arm = 0 05 = 0 20,C0032863|C0002778|C0444686|G0000000|G0000000|G0000000|C0037585|G0000000|C0683758|C0037943|C0557806|C1883167|C0041403|C0041703|C0450371|C0301630|C0021149|C1552240|C0001122|C0370003|C0456389|C1442061|C0446516|G0000000|G0000000|C0450371|G0000000|G0000000|C0450371
"Seventy-two patients were randomized to return to full normal activities, including work at 2 weeks, after AMI without a formal rehabilitation program (early return to normal activities [ERNA] group).",seventy-two patients randomized return normal activities including 2 weeks ami formal rehabilitation program return normal activities erna,C3816957|C0030705|C0034656|C0332156|C0205307|C0441655|C0332257|G0000000|C0439230|G0000000|C0348078|C0034991|C1709697|C0332156|C0205307|C0441655|G0000000
This group of patients was contacted over the telephone by the nurse coordinator once per week for 5 weeks.,patients contacted telephone nurse coordinator week 5 weeks,C0030705|C0332158|C0039457|C0028661|C1711307|C0332174|G0000000|C0439230
"Seventy patients were randomized to undergo the standard cardiac rehabilitation program and return to full normal activities, including work at 6 weeks after AMI (conventional treatment group).",seventy patients randomized undergo standard cardiac rehabilitation program return normal activities including 6 weeks ami conventional treatment,C3816957|C0030705|C0034656|G0000000|C1442989|C0018787|C0034991|C1709697|C0332156|C0205307|C0441655|C0332257|G0000000|C0439230|G0000000|C0439858|C0039798
The 2 groups of patients were encouraged to exercise at home on a regular basis.,2 patients encouraged exercise regular basis,G0000000|C0030705|G0000000|C0015259|C0205272|C1527178
"Fatigue in patients receiving high-dose (400 mg) ER metoprolol succinate in combination with medium-to high-dose (10 and 20 mg) ER felodipine was relatively common (20% for 10/400 mg and 18% for 20/400 mg, and 2% to 9% for the other treatment groups).",fatigue patients receiving high-dose 400 er metoprolol succinate combination medium-to high-dose 10 20 er felodipine common 20% 10/400 18% 20/400 2% 9% treatment,C0015672|C0030705|C1514756|C0444956|C1442061|C3810541|C0025859|C0038617|C0205195|C0009458|C0444956|C0450371|C0450371|C3810541|C0015772|C0205214|C0450371|C0450371|C0450371|C0450371|G0000000|G0000000|C0039798
"After the placebo run-in, patients meeting BP criteria were randomized to one of the 16 treatment groups.",placebo run-in patients meeting bp criteria randomized 16 treatment,C0032042|C3274438|C0030705|C0556656|C0037623|C0243161|C0034656|C0450371|C0039798
Patients assigned to ER felodipine 20 mg and/or ER metoprolol succinate 400 mg received half doses for 1 week before escalation to the full dose.,patients assigned er felodipine 20 and/or er metoprolol succinate 400 received half doses 1 week escalation dose,C0030705|C1516050|C3810541|C0015772|C0450371|G0000000|C3810541|C0025859|C0038617|C1442061|C1514756|C2825407|C0178602|G0000000|C0332174|G0000000|C0178602
"To maintain blinding, patients received 6 active or placebo tablets or both each morning, packaged according to a double-dummy dosing scheme.",maintain blinding patients received 6 active placebo tablets morning packaged double-dummy dosing scheme,C0024501|C0150108|C0030705|C1514756|G0000000|C0205177|C0032042|C0039225|C0332170|C0030176|C0205173|G0000000|C1519193
All patients received instruction and counseling to promote compliance with the Japan Atherosclerosis Society Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases Step I diet.,patients received instruction counseling promote compliance japan atherosclerosis society guidelines diagnosis treatment atherosclerotic cardiovascular diseases step diet,C0030705|C1514756|C0039401|C0010210|C0033414|C0009563|C0022341|C0003850|C0037455|C0162791|C0011900|C0039798|C0333482|C0007226|C0012634|C1261552|C0012155
All patients were observed for 6 months.,patients observed 6 months,C0030705|C1441672|G0000000|C0439231
"Apart from endovascular intervention, the patients of both groups received heparin, aspirin, plavix, statins, angiotensin-converting enzyme inhibitors, and Î²-adrenoceptor blockers in individual doses.",endovascular intervention patients received heparin aspirin plavix statins angiotensin-converting enzyme inhibitors -adrenoceptor blockers individual doses,C0524425|C0886296|C0030705|C1514756|C0019134|C0004057|C0633084|C0360714|C0003018|C0014442|C0243077|C0034783|G0000000|C0027361|C0178602
"MATERIALS AND METHODS Open randomized parallel controlled study included 44 patients (22 patients in the main and control groups, groups 1 and 2, respectively, Fig, 1).",materials methods randomized parallel controlled study included 44 patients 22 patients main control 1 2 fig 1,C0520510|C0025663|C0034656|C2348042|C2587213|C0557651|C0332257|C0450371|C0030705|C0450371|C0030705|C0205225|C0243148|G0000000|G0000000|C0349966|G0000000
"The incidence and severity of chronic heart failure, heart rhythm disturbances, exercise tolerance, and quality of life were similar in both groups (Table 1).",incidence severity chronic heart failure heart rhythm disturbances exercise tolerance quality life table 1,C0021149|C0439793|C0205191|C0018787|C0231174|C0018787|C0871269|C2699787|C0015259|C0013220|C0332306|C0376558|C0039224|G0000000
BMMC were isolated by gradient centrifugation (HISTOPAQUE-1077 density gradient) [9].,bmmc isolated gradient centrifugation histopaque-1077 density gradient 9,G0000000|C0205409|C0439182|C0007703|C0164836|C0178587|C0439182|G0000000
Bone marrow was harvested one day after successful PCI for ST elevation myocardial infarction.,bone marrow harvested day successful pci st elevation myocardial infarction,C0262950|C0086590|C1512335|C0332173|C0597535|C4049621|C0036056|C0439775|C0027061|C0021308
"Methods: 20 patients admitted within 24 h after the onset of a first AMI were randomly allocated to receive intracoronary autologous BMT (n = 10) or bone marrow supernatant (controls, n = 10) immediately after primary percutaneous coronary intervention.",methods 20 patients admitted 24 onset ami randomly allocated receive intracoronary autologous bmt = 10 bone marrow supernatant controls = 10 primary percutaneous coronary intervention,C0025663|C0450371|C0030705|C0184666|C0450371|C0206132|G0000000|G0000000|G0000000|C1514756|C0595454|C0439859|C0005961|G0000000|C0450371|C0262950|C0086590|C1550101|C0243148|G0000000|C0450371|C0205225|C0522523|C0018787|C0886296
Methods: Ninety nor-motensive patients (ASA I) undergoing elective surgery were divided into three groups of 30 patients each.,methods nor-motensive patients asa undergoing elective surgery divided 30 patients,C0025663|G0000000|C0030705|C0004057|G0000000|C0206058|C0038894|C0332849|C0450371|C0030705
"Ephedrine (3 mg increments) was administered for hypotension (systolic arterial pressure (SAP) Ï½ 100 mmHg, or a decrease of Ï¾30% from baseline values for Ï¾60 s) and atropine, in 300 Âµg increments, for bradycardia (HR Ï½ 45 beats min",ephedrine 3 increments administered hypotension systolic arterial pressure sap 100 mmhg decrease 30% baseline values 60 atropine 300 increments bradycardia hr 45 beats min,C0014479|G0000000|C1705117|C1521801|C0020649|C0039155|C0003842|C0033095|C1420017|C1442061|C0439475|C0392756|C0450371|C0168634|C0042295|C0450371|C0004259|C1442061|C1705117|C0428977|G0000000|C0450371|G0000000|C0702093
"Patients received oral placebo (Group I), 400 mg of gabapentin (Group II) or 800 mg of gabapentin (Group III) 1 h prior to surgery in the operating theatre.",patients received oral placebo 400 gabapentin ii 800 gabapentin iii 1 prior surgery operating theatre,C0030705|C1514756|C0442027|C0032042|C1442061|C0060926|G0000000|C1442061|C0060926|C0439070|G0000000|C0332152|C0038894|C3242339|C0475307
One patient in Group I and one patient in Group II received an increased inspired concentration of sevoflurane to treat hypertension.,patient patient ii received increased inspired concentration sevoflurane treat hypertension,C0030705|C0030705|G0000000|C1514756|C0205217|C0004048|C0004268|C0074414|C0087111|C0020538
"Patients received weekly paclitaxel single agent (80 mg/m 2) or combined with trastuzumab (4 mg/kg loading dose, then weekly 2 mg/kg).",patients received weekly paclitaxel single agent 80 mg/m 2 combined trastuzumab 4 mg/kg loading dose weekly 2 mg/kg,C0030705|C1514756|C0332174|C0144576|C0037179|C0450442|C0450371|C0026410|G0000000|C0205195|C0728747|G0000000|C0439272|C1708715|C0178602|C0332174|G0000000|C0439272
"Eligible patients were women with untreated metastatic BC over-expressing HER-2/neu by the HercepTrastuzumab was administered at the loading dose of 4 mg/kg on day 1, as 90-min infusion followed by weekly doses of 2 mg/kg given over 30 min.",eligible patients women untreated metastatic bc over-expressing her-2/neu herceptrastuzumab administered loading dose 4 mg/kg day 1 90-min infusion weekly doses 2 mg/kg 30 min,C1548635|C0030705|C0043210|C0332155|C0036525|C0006041|C0205136|C1702024|G0000000|C1521801|C1708715|C0178602|G0000000|C0439272|C0332173|G0000000|C0450371|C0574032|C0332174|C0178602|G0000000|C0439272|C0450371|C0702093
The ECOG performance status was 0-1 in 95 A) and 36 cases (57.1%) (arm B) treated with anthracyclines-based regimens (Table 1).,ecog performance status 0-1 95 36 57 1% arm treated anthracyclines-based regimens table 1,C0430797|C0597198|C0449438|G0000000|C0450371|C0450371|C0450371|G0000000|C0446516|C1522326|C0003234|C2945654|C0039224|G0000000
"The patients were allocated by the independent monitoring agency to treatment group by randomization code envelopes, with a 1:1 randomization (paclitaxel, arm A vs. paclitaxel plus trastuzumab, arm B), stratified according to visceral involvement (yes vs. not), HER-2/neu over-expression (2+ vs. 3+) and center.",patients allocated independent monitoring agency treatment randomization code envelopes 1 1 randomization paclitaxel arm paclitaxel trastuzumab arm stratified visceral involvement her-2/neu over-expression 2+ 3+ center,C0030705|G0000000|C0085862|C0150369|C0237463|C0039798|C0034656|C0009219|C1622204|G0000000|G0000000|C0034656|C0144576|C0446516|C0144576|C0728747|C0446516|C0205363|C0442045|C1314939|C1702024|C0205136|G0000000|G0000000|C0205099
The rate of vaginal delivery within 24 h of induction was similar in both groups: 75% with oral misoprostol 25 Âµg every 3 h and 72% with misoprostol (two doses) plus routine oxytocin.,rate vaginal delivery 24 induction 75% oral misoprostol 25 3 72% misoprostol doses routine oxytocin,C0871208|C0042232|C0011209|C0450371|C0205263|C0450371|C0442027|C0085174|C0450371|G0000000|C0450371|C0085174|C0178602|C0205547|C0030095
"Methods: A prospective randomised trial in which 200 women with an unfavourable cervix received either oral misoprostol 25 Âµg every 3 h (group 1, n = 100) or two such doses routinely followed by oxytocin (group 2, n = 100).",methods prospective randomised trial 200 women unfavourable cervix received oral misoprostol 25 3 1 = 100 doses routinely oxytocin 2 = 100,C0025663|C0023981|G0000000|C0008976|C1442061|C0043210|C3640815|C0007874|C1514756|C0442027|C0085174|C0450371|G0000000|G0000000|G0000000|C1442061|C0178602|G0000000|C0030095|G0000000|G0000000|C1442061
Group 1 (n = 100) received 25 Âµg misoprostol (1/4 of a double-scored 100 Âµg tablet) every 3 h (without concomitant food) to a maximum of six doses.,1 = 100 received 25 misoprostol 1/4 double-scored 100 tablet 3 concomitant food maximum doses,G0000000|G0000000|C1442061|C1514756|C0450371|C0085174|G0000000|C0205173|C1442061|C0039225|G0000000|C0521115|C0016452|C0806909|C0178602
"After a 4-week drug-free period, patients were randomized with minimization for ethnic origin, sex, age, and left ventricular hypertrophy to receive either candesartan (8 to 16 mg once daily) or atenolol (50 to 100 mg once daily).",4-week drug-free period patients randomized minimization ethnic origin sex age left ventricular hypertrophy receive candesartan 8 16 daily atenolol 50 100 daily,C0332174|C0678752|C0439531|C0030705|C0034656|G0000000|C0015031|C0079946|C0009253|C0001779|C0205091|C0018827|C0020564|C1514756|C0717550|G0000000|C0450371|C0332173|C0004147|C0450371|C1442061|C0332173
"Methods-We compared the treatment effects of an ARB (candesartan cilexetil)-based regimen and a â¤-blocker (atenolol)-based regimen for 52 weeks on common carotid artery (CCA) and left ventricular structure in hypertensive patients in a randomized, double-blind study.",methods-we compared treatment effects arb candesartan cilexetil -based regimen -blocker atenolol -based regimen 52 weeks common carotid artery cca left ventricular structure hypertensive patients randomized double-blind study,C0025663|C1707455|C0039798|C1280500|C3888198|C0717550|G0000000|C1527178|C0040808|G0000000|C0004147|C1527178|C0040808|C0450371|C0439230|C0205214|C0741968|C0003842|C0220668|C0205091|C0018827|C0678594|C0857121|C0030705|C0034656|C0013072|C0557651
"Eighty-eight patients with uncontrolled essential hypertension (Ï¾160/Ï¾100 mm Hg untreated; Ï¾140/Ï¾90 mm Hg on treatment  tonometry in the right common carotid artery (CCA) with an SPT-301 high-fidelity strain-gauge tonometer (Millar instruments Inc, Houston, Tex).",eighty-eight patients uncontrolled essential hypertension 160/100 mm hg untreated 140/90 mm hg treatment tonometry common carotid artery cca spt-301 high-fidelity strain-gauge tonometer millar instruments houston tex,C3816958|C0030705|C0205318|C0205224|C0020538|C1442061|G0000000|C0025424|C0332155|C1442061|G0000000|C0025424|C0039798|C0040420|C0205214|C0741968|C0003842|C0220668|C1442061|C0205250|C0080194|C0183969|G0000000|C0348000|G0000000|G0000000
"Hydrochlorothiazide (12.5 to 25 mg once daily), felodipine (5 to 10 mg once daily), and doxazosin (4 to 16 mg once daily) were added as required.",hydrochlorothiazide 12 5 25 daily felodipine 5 10 daily doxazosin 4 16 daily required,C0020261|C0450371|G0000000|C0450371|C0332173|C0015772|G0000000|C0450371|C0332173|C0114873|G0000000|C0450371|C0332173|C1514873
"Thus, while 100 mg oral misoprostol appeared more active than 25 mg by the intravaginal route (17), 50 mg oral doses were less effective than the 25 mg vaginal doses (6).",100 oral misoprostol appeared active 25 intravaginal route 17 50 oral doses effective 25 vaginal doses 6,C1442061|C0442027|C0085174|C0700364|C0205177|C0450371|C0442122|C0013153|C0450371|C0450371|C0442027|C0178602|C1280519|C0450371|C0042232|C0178602|G0000000
"Nursing staff helped to supervise and ensure that the patient took the medication every 4 h. At onset of labor, the patient was kept nil by mouth and given an intravenous infusion with two bottles of 500 ml dextrose 5% solution alternating with one bottle of 500 ml 0.9% normal saline solution every 6 h. Continuous fetal heart rate monitoring with CTG was started.",nursing staff helped supervise ensure patient medication 4 onset labor patient nil mouth intravenous infusion bottles 500 dextrose 5% solution alternating bottle 500 0 9% normal saline solution 6 continuous fetal heart rate monitoring ctg started,C0006147|C0851286|C1269765|G0000000|C0218063|C0030705|C0013227|G0000000|C0206132|C0022864|C0030705|C0442734|C0226896|C0348016|C0574032|C0179376|C1442061|C0017725|G0000000|C0037633|C0332270|C0179376|C1442061|G0000000|G0000000|C0205307|C0036082|C0037633|G0000000|C0549178|C0015965|C0018787|C0871208|C0150369|G0000000|C1272689
"The envelope contained the study drug (placebo, 50 mg or 100 mg misoprostol) for the subject.",envelope contained study drug placebo 50 100 misoprostol subject,C1622204|C0332256|C0557651|C0013227|C0032042|C0450371|C1442061|C0085174|C0681850
"Intracoronary cell injection was performed a median of 6 days (interquartile range, 5 to 6) after the acute PCI.",intracoronary cell injection performed median 6 days interquartile range 5 6 acute pci,C0595454|C0007634|C0021485|C0884358|C0549183|G0000000|C0439228|G0000000|C1514721|G0000000|G0000000|C0205178|C4049621
"The aspirate was centrifuged on a Ficoll density gradient to isolate the mononuclear cells, which were washed and resuspended in heparin-treated plasma.",aspirate centrifuged ficoll density gradient isolate mononuclear cells washed resuspended heparin-treated plasma,C0370199|C0179834|C0016071|C0178587|C0439182|C1875400|C1513475|C0007634|C1548982|G0000000|C0019134|C0032105
"After SPECT, echocardiography, and MRI were performed at 6 months, coronary angiography was carried out according to the standard protocol, resulting in PCI being performed for culpritlesion restenosis in eight patients in each group and coronary-artery bypass grafting being performed in two patients in the mononuclear BMC group and one in the control group.",spect echocardiography mri performed 6 months coronary angiography carried standard protocol pci performed culpritlesion restenosis patients coronary-artery bypass grafting performed patients mononuclear bmc control,C0040399|C0013516|C0024485|C0884358|G0000000|C0439231|C0018787|C0002978|C0206243|C1442989|C0442711|C4049621|C0884358|G0000000|C0333186|C0030705|C0205042|C0741847|C0332835|C0884358|C0030705|C1513475|C0065839|C0243148
Progenitor cells were isolated and enriched with the use of Ficoll-Hypaque centrifugation procedures.,progenitor cells isolated enriched ficoll-hypaque centrifugation procedures,C0870134|C0007634|C0205409|C0359583|C0016071|C0007703|C0025664
"At 4 months, paired left ventricular angiograms with adequate contrast opacification for quantitative analysis were available for 95 patients in the BMC group and 92 patients in the placebo group.",4 months paired left ventricular angiograms adequate contrast opacification quantitative analysis 95 patients bmc 92 patients placebo,G0000000|C0439231|C1709450|C0205091|C0018827|C0002978|C0205410|C0009924|C0449584|C0392762|C0002778|C0450371|C0030705|C0065839|C0450371|C0030705|C0032042
All patients underwent bone marrow aspiration 3 to 6 days after receiving reperfusion therapy for acute myocardial infarction.,patients underwent bone marrow aspiration 3 6 days receiving reperfusion therapy acute myocardial infarction,C0030705|G0000000|C0262950|C0086590|C0220787|G0000000|G0000000|C0439228|C1514756|C0035124|C0039798|C0205178|C0027061|C0021308
"In a multicenter trial, we randomly assigned 204 patients with acute myocardial infarction to receive an intracoronary infusion of progenitor cells derived from bone marrow (BMC) or placebo medium into the infarct artery 3 to 7 days after successful reperfusion therapy.",multicenter trial randomly assigned 204 patients acute myocardial infarction receive intracoronary infusion progenitor cells derived bone marrow bmc placebo medium infarct artery 3 7 days successful reperfusion therapy,C0439743|C0008976|G0000000|C1516050|C1442061|C0030705|C0205178|C0027061|C0021308|C1514756|C0595454|C0574032|C0870134|C0007634|C1441547|C0262950|C0086590|C0065839|C0032042|C0009458|C0021308|C0003842|G0000000|G0000000|C0439228|C0597535|C0035124|C0039798
Some patients took lipid-lowering drugs.,patients lipid-lowering drugs,C0030705|C0023779|C0013227
Patients of the main group received moderate-intensity PT.,patients main received moderate-intensity pt,C0030705|C0205225|C1514756|C0205081|C0699718
Patients were randomized into 2 groups in order of admittance (next but one): the main group (n=197) and the control group (n=195).,patients randomized 2 admittance main n=197 control n=195,C0030705|C0034656|G0000000|G0000000|C0205225|C0369718|C0243148|C0369718
Patients of the main group received moderate-intensity PT (50-60% of the performed capacity by bicycle ergometry (BE) test) 3 times per week with duration of exercises from 45 minutes to 1 hour during 1 year.,patients main received moderate-intensity pt 50-60% performed capacity bicycle ergometry test 3 times week duration exercises 45 minutes 1 hour 1,C0030705|C0205225|C1514756|C0205081|C0699718|C0450371|C0884358|C1516240|C0005375|C0085143|C0022885|G0000000|C0040223|C0332174|C0449238|C0015259|C0450371|C0439232|G0000000|C0439227|G0000000
"Patients received standard medical therapy which included beta-blocker, acetylsalicylic acid or other antithrombotic drug, as well as nitrate, and ACE inhibitor.",patients received standard medical therapy included beta-blocker acetylsalicylic acid antithrombotic drug nitrate ace inhibitor,C0030705|C1514756|C1442989|C0199168|C0039798|C0332257|C0001645|G0000000|C0001128|G0000000|C0013227|C0028125|C1452534|C1999216
"All patients received beta-blocker, nitrate, ACE inhibitors and acetylsalicylic acid.",patients received beta-blocker nitrate ace inhibitors acetylsalicylic acid,C0030705|C1514756|C0001645|C0028125|C1452534|C0243077|G0000000|C0001128
"These low-dose combinations include (ER-metoprolol/HCT): 25/12.5, 50/6.25, and 50/12.5 mg (Table 4).",low-dose combinations er-metoprolol/hct 25/12 5 50/6 25 50/12 5 table 4,C0445550|C0453882|C3810541|C0450371|G0000000|C0450371|C0450371|C0450371|G0000000|C0039224|G0000000
All 10 patients underwent a second cardiac catheterization 5 to 12 days after AMI (7 [2] days) where intracoronary infusion of MNBMCs into the infarcted area was performed.,10 patients underwent cardiac catheterization 5 12 days ami 7 2 days intracoronary infusion mnbmcs infarcted performed,C0450371|C0030705|G0000000|C0018787|C0007430|G0000000|C0450371|C0439228|G0000000|G0000000|G0000000|C0439228|C0595454|C0574032|G0000000|C0333541|C0884358
"In Group I, intracoronary infusion was carried out 7(2) days after AMI.",intracoronary infusion carried 7 2 days ami,C0595454|C0574032|C0206243|G0000000|G0000000|C0439228|G0000000
"Patients were randomly assigned to receive either an intracoronary infusion of autologous mononuclear bone marrow cells (Group I; n=10) or systemic administration of granulocyte colony-stimulating factor (G-CSF) (Group II; n=10), or to a control group (Group III; n=10).",patients randomly assigned receive intracoronary infusion autologous mononuclear bone marrow cells n=10 systemic administration granulocyte colony-stimulating factor g-csf ii n=10 control iii n=10,C0030705|G0000000|C1516050|C1514756|C0595454|C0574032|C0439859|C1513475|C0262950|C0086590|C0007634|C0369718|C0205373|C0001554|C0018183|C0439158|C1521761|C0079459|G0000000|C0369718|C0243148|C0439070|C0369718
Eligible patients were randomly assigned in a 2:1 ratio either to intracoronary BMNCs injection (n Ï­ 17) or standard medical therapy (n Ï­ 10).,eligible patients randomly assigned 2 1 ratio intracoronary bmncs injection 17 standard medical therapy 10,C1548635|C0030705|G0000000|C1516050|G0000000|G0000000|C0456603|C0595454|G0000000|C0021485|C0450371|C1442989|C0199168|C0039798|C0450371
He had a complicated PCI followed by coronary artery bypass grafting and died 2 weeks later from sepsis and acute respiratory distress syndrome.,complicated pci coronary artery bypass grafting died 2 weeks sepsis acute respiratory distress syndrome,C0231242|C4049621|C0018787|C0003842|C0741847|C0332835|C0011065|G0000000|C0439230|C0036690|C0205178|C0521346|C0231303|C0039082
"Patients were then randomly assigned to treatment with either Changes in right brachial artery diameter in response to reactive hyperemia were measured using highresolution ultrasound (Acuson 128XP/10 with a 7.0-MHz linear-array transducer, Mountain View, California) as previously described (12)(13)(14).",patients randomly assigned treatment brachial artery diameter response reactive hyperemia measured highresolution ultrasound acuson 128xp/10 7 0-mhz linear-array transducer mountain view california 12 13 14,C0030705|G0000000|C1516050|C0039798|C0445456|C0003842|C1301886|C0871261|C0205332|C0020452|C0444706|G0000000|C0041618|G0000000|C0450371|G0000000|C0556962|C0205132|C0040661|C0442533|C0449911|C0006754|C0450371|C0450371|C0450371
"After inclusion, the patients entered a period of 3-4 weeks with placebo treatment, during which the brachial artery measurements and subcutaneous biopsy were performed (see below).",inclusion patients entered period 3-4 weeks placebo treatment brachial artery measurements subcutaneous biopsy performed,C0007637|C0030705|C1521975|C0439531|G0000000|C0439230|C0032042|C0039798|C0445456|C0003842|C0242485|C0443315|C0005558|C0884358
Only three women in vaginal group developed abnormal uterine contractile patterns while no such event occurred in the oral group.,women vaginal developed abnormal uterine contractile patterns event occurred oral,C0043210|C0042232|G0000000|C0205161|C0042149|C0026820|C0449774|C0441471|C1709305|C0442027
"Inclusion criteria were (1) singleton gestation in a cephalic presentation, (2) reassuring fetal heart rate (FHR) pattern, (3) unfavorable cervix (was defined as Bishop score of < 6) next early morning (6 AM, day 1) for uterine contraction and reassuring fetal heart rate (FHR) pattern with external fetal monitoring and external tocodynamometry used for a 20-minute period.",inclusion criteria 1 singleton gestation cephalic presentation 2 reassuring fetal heart rate fhr pattern 3 unfavorable cervix defined bishop score < 6 morning 6 day 1 uterine contraction reassuring fetal heart rate fhr pattern external fetal monitoring external tocodynamometry 20-minute period,C0007637|C0243161|G0000000|C0481462|C0032961|C0205096|C0449450|G0000000|C0557055|C0015965|C0018787|C0871208|G0000000|C0449774|G0000000|C3640815|C0007874|C1704788|C1551458|C0449820|G0000000|G0000000|C0332170|G0000000|C0332173|G0000000|C0042149|C1140999|C0557055|C0015965|C0018787|C0871208|G0000000|C0449774|C0205101|C0015965|C0150369|C0205101|C0040345|C0450371|C0439531
Of those women who obtained Bishop score < 6 were randomized to receive either oral or vaginal misoprostol.,women bishop score < 6 randomized receive oral vaginal misoprostol,C0043210|C1551458|C0449820|G0000000|G0000000|C0034656|C1514756|C0442027|C0042232|C0085174
The median time interval from initiation of labor induction to vaginal delivery of the women in the vaginal group was approximately 5 hour sooner than the median time of the oral group (p=0.01).,median time interval initiation labor induction vaginal delivery women vaginal 5 hour sooner median time oral p=0 01,C0549183|C0040223|C1272706|C0589507|C0022864|C0205263|C0042232|C0011209|C0043210|C0042232|G0000000|C0439227|G0000000|C0549183|C0040223|C0442027|C0369773|C0450371
"The median 5 and 10 minutes Apgar scores were comparable in both groups, and the number of neonatal resuscitation were similar.",median 5 10 minutes apgar scores comparable neonatal resuscitation,C0549183|G0000000|C0450371|C0439232|C0741195|C0449820|G0000000|C1552240|C0035273
The indications for cesarean section were either fetal distress or induction failure (was defined as failure to achieve a cervical dilatation of > 4 cm after oxytocin augmentation on day 2) and arrest disorder of labor.,indications cesarean fetal distress induction failure defined failure achieve cervical dilatation 4 cm oxytocin augmentation day 2 arrest disorder labor,C0392360|C3841297|C0015965|C0231303|C0205263|C0231174|C1704788|C0231174|G0000000|C0027530|C0012359|G0000000|G0000000|C0030095|C1293122|C0332173|G0000000|C0237477|C0012634|C0022864
The fetus from these women developed some degree of fetal distress but all were recovered to maternal resuscitation with intravenous fluid and oxygen administration.,fetus women developed degree fetal distress recovered maternal resuscitation intravenous fluid oxygen administration,C0015965|C0043210|G0000000|C0441889|C0015965|C0231303|C0521108|C2347083|C0035273|C0348016|C0005889|C0030054|C0001554
"At 6 hours after misoprostol administration the median cervical changes of women who received oral or vaginal misoprostol were statistically significant different, 3 and 4, respectively.",6 hours misoprostol administration median cervical women received oral vaginal misoprostol statistically 3 4,G0000000|C0439227|C0085174|C0001554|C0549183|C0027530|C0043210|C1514756|C0442027|C0042232|C0085174|C0038215|G0000000|G0000000
Continuous external fetal monitoring and external tocodynamometry [Ohaus-model AP210S] were used in all women.,continuous external fetal monitoring external tocodynamometry ohaus-model ap210s women,C0549178|C0205101|C0015965|C0150369|C0205101|C0040345|C1224051|G0000000|C0043210
Emergency cesarean section delivery were performed in seven women; three in the oral group and four in the vaginal group.,emergency cesarean delivery performed women oral vaginal,C0013956|C3841297|C0011209|C0884358|C0043210|C0442027|C0042232
"A total of 909 patients were randomized to receive placebo or nebivolol 1.25, 2.5, 5, 10, 20, or 40 mg once daily for up to 84 days.",total 909 patients randomized receive placebo nebivolol 1 25 2 5 5 10 20 40 daily 84 days,C0439175|C1442061|C0030705|C0034656|C1514756|C0032042|C0068475|G0000000|C0450371|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371|C0332173|C0450371|C0439228
"Of the 166 patients randomized to nebivolol 40 mg, 147 patients (88.6%) had their dosage increased from the initial 30-mg once-daily to a 40-mg once daily dose, and 19 patients remained at a 30-mg dose.",166 patients randomized nebivolol 40 147 patients 88 6% dosage increased initial 30-mg once-daily 40-mg daily dose 19 patients remained 30-mg dose,C1442061|C0030705|C0034656|C0068475|C0450371|C1442061|C0030705|C0450371|G0000000|C0178602|C0205217|C0205265|C0450371|C0332173|C0450371|C0332173|C0178602|C0450371|C0030705|G0000000|C0450371|C0178602
"Secondary outcome criteria were total rate of operative delivery (irrespective of cause), percentage of cases with at least 1 scalp pH test during labor, and abnormal neonate outcome (pH Ï½7.05 or BD ecf Ï¾12 mmol/L or 5-minute Apgar score Ï½7 or neonatal intensive care unit admission or convulsions or neonatal death).",secondary outcome criteria total rate operative delivery irrespective percentage 1 scalp ph test labor abnormal neonate outcome ph 7 05 bd ecf 12 mmol/l 5-minute apgar score 7 neonatal intensive care unit admission convulsions neonatal death,C0027627|C1274040|C0243161|C0439175|C0871208|C1882154|C0011209|G0000000|C0439165|G0000000|C0036270|C0450407|C0022885|C0022864|C0205161|C0021289|C1274040|C0450407|G0000000|C0450371|C0005126|G0000000|C0450371|C1532563|C0439232|C0741195|C0449820|G0000000|C1552240|C0162425|C1947933|C0439148|C0184666|C0036572|C1552240|C0011065
The principal outcome measure was rate of operative delivery (assisted vaginal birth or cesarean delivery) for NRFS.,principal outcome measure rate operative delivery assisted vaginal birth cesarean delivery nrfs,C0205225|C1274040|C0079809|C0871208|C1882154|C0011209|C1269765|C0042232|C0005615|C3841297|C0011209|G0000000
"STUDY DESIGN: Seven hundred ninety-nine women at term with abnormal cardiotocography or meconium-stained amniotic fluid (7%) were assigned randomly to the intervention group (cardiotocography Ï© STAN) or the control group (cardiotocography) in 2 university hospitals in Strasbourg, France.",study design ninety-nine women term abnormal cardiotocography meconium-stained amniotic fluid 7% assigned randomly intervention cardiotocography stan control cardiotocography 2 university hospitals strasbourg france,C0557651|C1707689|C3828813|C0043210|C0233324|C0205161|C0007208|C1112318|C0002630|C0005889|G0000000|C1516050|G0000000|C0886296|C0007208|C2985331|C0243148|C0007208|G0000000|C0041740|C0019994|G0000000|C0016674
"Finally, the study included 799 women, 399 women in the cardiotocography Ï© STAN group and 400 women in the cardiotocography-only group.",finally study included 799 women 399 women cardiotocography stan 400 women cardiotocography-only,G0000000|C0557651|C0332257|C1442061|C0043210|C1442061|C0043210|C0007208|C2985331|C1442061|C0043210|C0007208
"The control group (n Ï­ 20) received oral placebo Ï© IV 2 mL saline (group C), group G (n Ï­ 20) received oral 800 mg of gabapentin (Neurontin, 400-mg capsule, Pfizer, Goedecke GmbH, Germany) Ï© IV 2 mL saline, group D (n Ï­ 20) received oral placebo Ï© IV 8 mg dexamethasone (Dekort amp 4 mg/mL, Deva, Istanbul), and group GD (n Ï­ 20) received 800 mg of gabapentin Ï© 8 mg of dexamethasone 1 h before surgery in the operating room.",control 20 received oral placebo iv 2 saline 20 received oral 800 gabapentin neurontin 400-mg capsule pfizer goedecke gmbh germany iv 2 saline 20 received oral placebo iv 8 dexamethasone dekort amp 4 mg/ml deva istanbul gd 20 received 800 gabapentin 8 dexamethasone 1 surgery operating,C0243148|C0450371|C1514756|C0442027|C0032042|C0022326|G0000000|C0036082|C0450371|C1514756|C0442027|C1442061|C0060926|C0678176|C1442061|C0006935|C0331888|G0000000|G0000000|C0017480|C0022326|G0000000|C0036082|C0450371|C1514756|C0442027|C0032042|C0022326|G0000000|C0011777|G0000000|G0000000|G0000000|C0439294|G0000000|G0000000|G0000000|C0450371|C1514756|C1442061|C0060926|G0000000|C0011777|G0000000|C0038894|C3242339
"After the patients had been taken to the operating room, crystalloid infusion was started through a 20-gauge IV cannula inserted in an appropriate antecubital vein, and the mean arterial blood pressure (MAP), heart rate (HR), and peripheral oxygen saturation (Spo 2 ) were monitored.",patients operating crystalloid infusion started 20-gauge iv cannula inserted antecubital vein arterial blood pressure map heart rate hr peripheral oxygen saturation spo 2 monitored,C0030705|C3242339|C0056562|C0574032|C1272689|C0450371|C0022326|C0520453|C0441587|C1549091|C0042449|C0003842|C0005767|C0033095|C0024779|C0018787|C0871208|G0000000|C0205100|C0030054|C0522534|C1416903|G0000000|C0030695
"After 3 min of administration of oxygen, induction of anesthesia was achieved in all patients with a continuous infusion of remifentanil 0.5 â®g â kg Ïª1 â min Ïª1 followed by propofol 2 mg/kg.",3 min administration oxygen induction anesthesia achieved patients continuous infusion remifentanil 0 5 1 min 1 propofol 2 mg/kg,G0000000|C0702093|C0001554|C0030054|C0205263|C0002903|G0000000|C0030705|C0549178|C0574032|C0246631|G0000000|G0000000|G0000000|C0702093|G0000000|C0033487|G0000000|C0439272
"Then, 0.5 mg/kg atracurium was given to facilitate tracheal intubation and to maintain neuromuscular blockade, monitored by train-of-four stimulation with a peripheral nerve stimulator.",0 5 mg/kg atracurium facilitate tracheal intubation maintain neuromuscular blockade monitored train-of-four stimulation peripheral nerve stimulator,G0000000|G0000000|C0439272|C0004234|G0000000|C0040578|C0021925|C0024501|C1979768|C0332206|C0030695|C0336809|C1292856|C0205100|C0027740|C0175727
"A PowerPoint presentation was introduced to educate the patients about the issues related to sexual activity in general and after MI and CABG in particular, including a review of the current effective interventions.",powerpoint presentation introduced educate patients issues sexual activity mi cabg including review current effective interventions,G0000000|C0449450|C1292748|C0039401|C0030705|C0033213|C0036864|C0205177|C3810814|C0010055|C0332257|C0282443|C0521116|C1280519|C0886296
"The therapists used cognitive-behavioral techniques, provided more assignments and instructions and directed the patients to additional medical checks, and when appropriate, prescribed Sildenafil (which were the only relevant available drugs in Israel at the time of the study).",therapists cognitive-behavioral techniques provided assignments instructions directed patients additional medical checks prescribed sildenafil relevant drugs israel time study,C0871525|C1516691|C0025664|C1999230|C1516050|C0302828|C0439851|C0030705|C1524062|C0199168|C1283174|C0278329|C0529793|C2347946|C0013227|C0022271|C0040223|C0557651
"In addition, patients were randomly assigned in a 2Ã2 factorial design to either placebo or 300 mg clopidogrel loading dose immediately followed by 75 mg clopidogrel daily, and to placebo or 40 mg simvastatin immediately followed by 40 mg daily in the evening.",addition patients randomly assigned 22 factorial design placebo 300 clopidogrel loading dose 75 clopidogrel daily placebo 40 simvastatin 40 daily evening,C0332287|C0030705|G0000000|C1516050|C0450371|C2826344|C1707689|C0032042|C1442061|C0070166|C1708715|C0178602|C0450371|C0070166|C0332173|C0032042|C0450371|C0074554|C0450371|C0332173|C0587117
"In addition, weakness or speech disturbance, dysarthria or All patients were given 81 mg aspirin daily for the study duration, with a loading dose of 162 mg if they were naive to aspirin before study enrolment.",addition weakness speech disturbance dysarthria patients 81 aspirin daily study duration loading dose 162 naive aspirin study enrolment,C0332287|C3714552|C0037817|C2699787|C0013362|C0030705|C0450371|C0004057|C0332173|C0557651|C0449238|C1708715|C0178602|C1442061|G0000000|C0004057|C0557651|C1516879
"Systems of care have been forced to become more responsive with the evidence that selected patients who receive thrombolysis with alteplase (recombinant tissue plasminogen activator, rt-PA) within 3 h of the onset of ischaemic stroke have an increased chance of excellent functional outcome.",systems care forced responsive evidence selected patients receive thrombolysis alteplase recombinant tissue plasminogen activator rt-pa 3 onset ischaemic stroke increased chance excellent functional outcome,C0449913|C1947933|C0441722|C0205342|C3887511|C1707391|C0030705|C1514756|C0520997|C0032143|C1514798|C0040300|C0032140|G0000000|C0032143|G0000000|C0206132|C0475224|C0038454|C0205217|C0237506|C1548784|C0205245|C1274040
MATCH-Management of Atherothrombosis with clopidogrel in high-risk patients with recent Transient ischaemic attack or isCHaemic stroke [4][5][6][7],match-management atherothrombosis clopidogrel high-risk patients transient ischaemic attack ischaemic stroke 4567,C0150103|G0000000|C0070166|C0332167|C0030705|C0040704|C0475224|C0277793|C0475224|C0038454|G0000000
The maximum doses were 5 mg/day for ramipril and 100 mg/day for metoprolol.,maximum doses 5 mg/day ramipril 100 mg/day metoprolol,C0806909|C0178602|G0000000|C0439422|C0072973|C1442061|C0439422|C0025859
"After the washout period, patients received either 2.5 mg ramipril or 50 mg metoprolol per day.",washout period patients received 2 5 ramipril 50 metoprolol day,C1710661|C0439531|C0030705|C1514756|G0000000|G0000000|C0072973|C0450371|C0025859|C0332173
"The patients were randomly assigned to either receive pravastatin (10 mg/daily, n=176) or not (n=177).",patients randomly assigned receive pravastatin 10 mg/daily n=176 n=177,C0030705|G0000000|C1516050|C1514756|C0085542|C0450371|C0026410|C0369718|C0369718
The titrated oral misoprostol group received a basal unit of 20 mL misoprostol solution (1 mcg/mL) every 1 hour for four doses and then were titrated against individual uterine response.,titrated oral misoprostol received basal unit 20 misoprostol solution 1 mcg/ml 1 hour doses titrated individual uterine response,C1883350|C0442027|C0085174|C1514756|C0205112|C0439148|C0450371|C0085174|C0037633|G0000000|C0439268|G0000000|C0439227|C0178602|C1883350|C0027361|C0042149|C0871261
"By contrast, uterine hyperstimulation occurred in 12 (11.3%) women in the vaginal group.",contrast uterine hyperstimulation occurred 12 11 3% women vaginal,C0009924|C0042149|G0000000|C1709305|C0450371|C0450371|G0000000|C0043210|C0042232
METHODS: Women between 34 and 42 weeks of gestation with an unfavorable cervix (Bishop score less than or equal to 6) and an indication for labor induction were randomLy assigned to receive titrated oral or vaginal misoprostol.,methods women 34 42 weeks gestation unfavorable cervix bishop score equal 6 indication labor induction randomly assigned receive titrated oral vaginal misoprostol,C0025663|C0043210|C0450371|C0450371|C0439230|C0032961|C3640815|C0007874|C1551458|C0449820|C0205163|G0000000|C0392360|C0022864|C0205263|G0000000|C1516050|C1514756|C1883350|C0442027|C0042232|C0085174
Women assigned to the titrated oral route were induced with a basal unit of 20 mL misoprostol solution (1 mcg/mL) prepared as described above.,women assigned titrated oral route induced basal unit 20 misoprostol solution 1 mcg/ml prepared,C0043210|C1516050|C1883350|C0442027|C0013153|C0205263|C0205112|C0439148|C0450371|C0085174|C0037633|G0000000|C0439268|C4082130
"The secondary measures used to evaluate efficacy or safety included total dosage of misoprostol, rate of women given oxytocin, cesarean delivery and induction failure, neonatal outcomes including lower Apgar score (less than 7 at 5 minutes), and admittance to the neonatal unit.",secondary measures evaluate efficacy safety included total dosage misoprostol rate women oxytocin cesarean delivery induction failure neonatal outcomes including lower apgar score 7 5 minutes admittance neonatal unit,C0027627|C0079809|C0220825|C1280519|C0036043|C0332257|C0439175|C0178602|C0085174|C0871208|C0043210|C0030095|C3841297|C0011209|C0205263|C0231174|C1552240|C1274040|C0332257|C0441994|C0741195|C0449820|G0000000|G0000000|C0439232|G0000000|C1552240|C0439148
Ten of these    women received tocolysis and four of them underwent urgent delivery by cesarean method.,ten women received tocolysis underwent urgent delivery cesarean method,C0014518|C0043210|C1514756|C0040348|G0000000|C0439609|C0011209|C3841297|C0025663
All patients underwent an incremental cardiopulmonary exercise on a bicycle ergometer with a ramp protocol of 15 W/min continued until exhaustion.,patients underwent incremental cardiopulmonary exercise bicycle ergometer ramp protocol 15 w/min continued exhaustion,C0030705|G0000000|C1705117|C0553534|C0015259|C0005375|C0180748|C0034646|C0442711|C0450371|C0702093|C0549178|C0392674
"At entry and at 6 month follow-up, all patients underwent Doppler-echocardiography and cardiopulmonary exercise test, and completed a questionnaire for evaluation of leisure time physical activity [18].",entry 6 month follow-up patients underwent doppler-echocardiography cardiopulmonary exercise test completed questionnaire evaluation leisure time physical activity 18,C1705654|G0000000|C0332177|C0589120|C0030705|G0000000|C0013520|C0553534|C0015259|C0022885|C0205197|C0034394|C0220825|C0086542|C0040223|C0031809|C0205177|C0450371
"Group T patients were enroled in a 6 month exercise-based Cardiac Rehabilitation programme, whereas group C patients were discharged with generic instructions to maintaining physical activity and a correct lifestyle, and were seen only at 6 months.",patients enroled 6 month exercise-based cardiac rehabilitation programme patients discharged generic instructions maintaining physical activity correct lifestyle 6 months,C0030705|G0000000|G0000000|C0332177|C0015259|C0018787|C0034991|C1709697|C0030705|C0030685|C0085155|C0302828|C0024501|C0031809|C0205177|C2349182|C0023676|G0000000|C0439231
"NT-proBNP assay, Doppler-echocardiography and cardiopulmonary exercise test were performed upon enrolment and at sixth months.",nt-probnp assay doppler-echocardiography cardiopulmonary exercise test performed enrolment sixth months,C0669479|C0005507|C0013520|C0553534|C0015259|C0022885|C0884358|C1516879|C0205440|C0439231
"The patients in the training group performed three endurance resistance exercises and trained on a cycle ergometer 30 min, 5 times a week for 8 months at 70% of VO 2max.",patients training performed endurance resistance exercises trained cycle ergometer 30 min 5 times week 8 months 70% vo 2max,C0030705|C0040607|C0884358|C0518031|C0237834|C0015259|C0336809|C1511572|C0180748|C0450371|C0702093|G0000000|C0040223|C0332174|G0000000|C0439231|C0450371|G0000000|G0000000
"The patients in the training group were asked to exercise at home on a bicycle ergometer (Monark 915E, Monark exercise AB, Varberg, Sweden) for 30 min (including a 10 min warm up and a 5 min cool down), 5 days a week for 8 months.",patients training exercise bicycle ergometer monark 915e monark exercise ab varberg sweden 30 min including 10 min warm 5 min cool 5 days week 8 months,C0030705|C0040607|C0015259|C0005375|C0180748|G0000000|G0000000|G0000000|C0015259|G0000000|G0000000|C0038995|C0450371|C0702093|C0332257|C0450371|C0702093|C0184348|G0000000|C0702093|C1548792|G0000000|C0439228|C0332174|G0000000|C0439231
Twice a week the training patients were allowed exchanging cycling for an equivalent exercise such as jogging or swimming.,week training patients allowed exchanging cycling equivalent exercise jogging swimming,C0332174|C0040607|C0030705|C0683607|C0678640|C1511572|C0205163|C0015259|C0022400|C0039003
It consisted of group based lifestyle education and aerobic as well as resistance exercise twice a week during 4-6 months.,consisted based lifestyle education aerobic resistance exercise week 4-6 months,C0332529|C1527178|C0023676|C0013621|C1510824|C0237834|C0015259|C0332174|G0000000|C0439231
"The patients performed the resistance exercise 3 times a week, each exercise with 3 sets of 10 repetitions with intensity level of 75% of 1 repetition maximum.",patients performed resistance exercise 3 times week exercise 3 sets 10 repetitions intensity level 75% 1 repetition maximum,C0030705|C0884358|C0237834|C0015259|G0000000|C0040223|C0332174|C0015259|G0000000|C0036849|C0450371|C0205341|C0522510|C0441889|C0450371|G0000000|C0205341|C0806909
Methods: Patients (aged 18-80 years) entered a 4-week placebo run-in washout period and previous antihypertensive drugs were tapered off over 2 weeks.,methods patients aged 18-80 entered 4-week placebo run-in washout period previous antihypertensive drugs tapered 2 weeks,C0025663|C0030705|C0001779|C0450371|C1521975|C0332174|C0032042|C3274438|C1710661|C0439531|C0205156|C0003364|C0013227|C0441640|G0000000|C0439230
"Add-on treatments were atenolol (50-100 mg/d), loop diuretics (furosemide, 20-500 mg/d or torsemide, 5-200 mg/d), Î±-blockers (prazosin, 2.5-5 mg/d or doxa-zosin, 1-16 mg/d), and centrally acting drugs (rilmeni-dine, 1-2 mg/d or methyldopa, 250-500 mg/d).",add-on treatments atenolol 50-100 mg/d loop diuretics furosemide 20-500 mg/d torsemide 5-200 mg/d -blockers prazosin 2 5-5 mg/d doxa-zosin 1-16 mg/d centrally acting drugs rilmeni-dine 1-2 mg/d methyldopa 250-500 mg/d,C1883712|C0087111|C0004147|C0450371|C0439422|C0445022|C0012798|C0016860|C0450371|C0439422|C0076840|C1442061|C0439422|G0000000|C0032912|G0000000|G0000000|C0439422|C2248745|C0450371|C0439422|G0000000|G0000000|C0013227|C0337879|G0000000|C0439422|C0025741|C1442061|C0439422
Patients entered a 4-week placebo run-in washout period and previous antihypertensive drugs were tapered off over 2 weeks.,patients entered 4-week placebo run-in washout period previous antihypertensive drugs tapered 2 weeks,C0030705|C1521975|C0332174|C0032042|C3274438|C1710661|C0439531|C0205156|C0003364|C0013227|C0441640|G0000000|C0439230
"Results: Three hundred eighteen patients entered the run-in period and 263 patients (156 men/107 women ; mean age, 58 years) were randomized to receive either amlodipine (5 mg/d, n = 132) or enalapril (5 mg/d, n = 131).",eighteen patients entered run-in period 263 patients 156 men/107 women age 58 randomized receive amlodipine 5 mg/d = 132 enalapril 5 mg/d = 131,C3715206|C0030705|C1521975|C3274438|C0439531|C1442061|C0030705|C1442061|C0025266|C0043210|C0001779|C0450371|C0034656|C1514756|C0051696|G0000000|C0439422|G0000000|C1442061|C0014025|G0000000|C0439422|G0000000|C1442061
"We undertook a randomized clinical superiority trialthe DANREHAB Trial-to evaluate the effect of hospitalbased CCR on mortality, reinfarction, and acute first-time readmission due to heart disease compared with usual care (UC) among a broad group of patients.",undertook randomized clinical superiority trialthe danrehab trial-to evaluate hospitalbased ccr mortality reinfarction acute first-time readmission heart disease compared usual care uc broad patients,G0000000|C0034656|C0205210|C0680218|G0000000|G0000000|C0008976|C0220825|G0000000|C1955905|C0026565|G0000000|C0205178|C0205435|C1548168|C0018787|C0012634|C1707455|C3538928|C1947933|G0000000|C0332464|C0030705
"A 6-week intensive CCR program was planned, including patient education, 12 exercise training sessions, dietary counseling, smoking cessation, psychosocial support, risk factor management, and clinical assessment.",6-week intensive ccr program planned including patient education 12 exercise training sessions dietary counseling smoking cessation psychosocial support risk factor management clinical assessment,C0332174|C0162425|C1955905|C1709697|C1301732|C0332257|C0030705|C0013621|C0450371|C0015259|C0040607|C1883016|C0012155|C0010210|C0037369|C1880019|C0542298|C0183683|C0035647|C1521761|C0001554|C0205210|C1261322
"The patients randomized to CCR were offered a standardized cardiac rehabilitation program designed in accordance with the national guidelines, 6 the program was individually tailored and carried out by a multidisciplinary team.",patients randomized ccr offered standardized cardiac rehabilitation program designed national guidelines 6 program individually tailored carried multidisciplinary team,C0030705|C0034656|C1955905|C1444648|G0000000|C0018787|C0034991|C1709697|C1707689|C3245503|C0162791|G0000000|C1709697|G0000000|C0402883|C0206243|C0242479|C0871489
"Methods Twenty-five patients (17 men, age range 24-71 years) with untreated hypertension were randomized to treatment with an amlodipine-based (n U 12) or lisinopril-based (n U 13) regimen in a double-blind, prospective parallel limb trial for 52 weeks.",methods twenty-five patients 17 age range 24-71 untreated hypertension randomized treatment amlodipine-based 12 lisinopril-based 13 regimen double-blind prospective parallel limb trial 52 weeks,C0025663|C3715062|C0030705|C0450371|C0001779|C1514721|C0450371|C0332155|C0020538|C0034656|C0039798|C0051696|C0450371|C0065374|C0450371|C0040808|C0013072|C0023981|C2348042|C0015385|C0008976|C0450371|C0439230
Follow-up visits were at 2-week intervals until BP was controlled and every 3 months subsequently.,follow-up visits 2-week intervals bp controlled 3 months subsequently,C0589120|C0545082|C0332174|C1272706|C0037623|C2587213|G0000000|C0439231|G0000000
"After a 4-week run-in period (2 weeks on single-blinded placebo tablets), eligible patients were randomly allocated to a double-blind, prospective two parallel limb trial with minimization for age and sex.",4-week run-in period 2 weeks single-blinded placebo tablets eligible patients randomly allocated double-blind prospective parallel limb trial minimization age sex,C0332174|C3274438|C0439531|G0000000|C0439230|C0037179|C0032042|C0039225|C1548635|C0030705|G0000000|G0000000|C0013072|C0023981|C2348042|C0015385|C0008976|G0000000|C0001779|C0009253
Participants received either amlodipine (5 mg daily) or lisinopril (5 mg daily).,participants received amlodipine 5 daily lisinopril 5 daily,C0679646|C1514756|C0051696|G0000000|C0332173|C0065374|G0000000|C0332173
"In the intervention group, subjects participated in a weekly outpatient phase III cardiac rehabilitation program that included an exercise session, exercise prescription, dietary instruction and an educational program for 6 months as described previously.",intervention subjects participated weekly outpatient phase iii cardiac rehabilitation program included exercise session exercise prescription dietary instruction educational program 6 months,C0886296|C0681850|G0000000|C0332174|C0029921|C0205390|C0439070|C0018787|C0034991|C1709697|C0332257|C0015259|C1883016|C0015259|C0033080|C0012155|C0039401|C0587721|C1709697|G0000000|C0439231
"In addition to the weekly supervised exercise sessions, subjects were encouraged to perform aerobic exercise twice weekly (â¥30 min) at home at an intensity of heat rate of AT or a rating of 12-13 on the Borg scale.",addition weekly supervised exercise sessions subjects encouraged perform aerobic exercise weekly 30 min intensity heat rate rating 12-13 borg scale,C0332287|C0332174|G0000000|C0015259|C1883016|C0681850|G0000000|C0884358|C1510824|C0015259|C0332174|C0450371|C0702093|C0522510|C0018837|C0871208|C0871208|C0450371|G0000000|C0175659
"In the intervention group, patients were instructed about the phase II diet of the American Heart Association at the beginning and every 2 months of the study.",intervention patients instructed phase ii diet american heart association 2 months study,C0886296|C0030705|G0000000|C0205390|G0000000|C0012155|C0596070|C0018787|C0004083|G0000000|C0439231|C0557651
"In the intervention group, subjects participated in an outpatient phase III cardiac rehabilitation program, while the control group received usual outpatient care, including monthly medical examination by the physician in charge.",intervention subjects participated outpatient phase iii cardiac rehabilitation program control received usual outpatient care including monthly medical examination physician charge,C0886296|C0681850|G0000000|C0029921|C0205390|C0439070|C0018787|C0034991|C1709697|C0243148|C1514756|C3538928|C0029921|C1947933|C0332257|C0332177|C0199168|G0000000|C0031831|C0007961
Differences between two groups were compared with Student's t-test for normally distributed data and the Mann-Whitney U test for non-normally distributed data.,differences compared students t-test distributed data mann-whitney test non-normally distributed data,C1705241|C1707455|C0038492|C0871472|C1704711|C1511726|G0000000|C0022885|C1518422|C1704711|C1511726
"All patients received premedication with midazolam, (0.03 mg/ kg i.v.)",patients received premedication midazolam 0 03 mg/,C0030705|C1514756|C0033045|C0026056|G0000000|C0450371|C0026410
"Following the exclusions, 60 normotensive patients (ASA I-II) undergoing elective surgery were randomly divided into two groups of 30 patients each.",exclusions 60 normotensive patients asa i-ii undergoing elective surgery randomly divided 30 patients,C0680251|C0450371|C2712122|C0030705|C0004057|C0021966|G0000000|C0206058|C0038894|G0000000|C0332849|C0450371|C0030705
"Patients received oral gabapentin 800 mg (Neurontin 400-mg capsule; Pfizer, Goedecke GmbH, Freiburg, Germany) or oral placebo capsules 2 h before surgery.",patients received oral gabapentin 800 neurontin 400-mg capsule pfizer goedecke gmbh freiburg germany oral placebo capsules 2 surgery,C0030705|C1514756|C0442027|C0060926|C1442061|C0678176|C1442061|C0006935|C0331888|G0000000|G0000000|G0000000|C0017480|C0442027|C0032042|C0006935|G0000000|C0038894
"After stenting, the medium containing the BMCs or placebo medium was injected intracoronarily through over the wire balloon by using intermittent balloon inflation in the stent at the time of injection.",stenting medium bmcs placebo medium injected intracoronarily wire balloon intermittent balloon inflation stent time injection,C0038257|C0009458|C0065839|C0032042|C0009458|C1720154|G0000000|C0005978|C0336867|C0205267|C0336867|C0021398|C0038257|C0040223|C0021485
"Therefore, we designed a randomized, placebo-controlled, double blind, twocentre FINnish stem CELL study (FINCELL) aimed at assessing the efficacy and safety of BMC therapy in patients with acute STEMI treated with thrombolytic therapy followed by PCI 2 -6 days later.",designed randomized placebo-controlled double blind twocentre finnish stem cell study fincell aimed assessing efficacy safety bmc therapy patients acute stemi treated thrombolytic therapy pci 2 -6 days,C1707689|C0034656|C1706408|C0205173|C0150108|G0000000|C1711254|C0242767|C0007634|C0557651|G0000000|C1947946|C1516048|C1280519|C0036043|C0065839|C0039798|C0030705|C0205178|C3538872|C1522326|C0016018|C0039798|C4049621|G0000000|G0000000|C0439228
Global LVEF could be reliably analysed by 2-D echocardiography in all 39 patients randomized to the BMC group at baseline and at 6 months and in all except one patient who had died in the placebo group (n Â¼ 38).,global lvef reliably analysed 2-d echocardiography 39 patients randomized bmc baseline 6 months patient died placebo 38,C0205246|C0428772|G0000000|G0000000|C0073187|C0013516|C0450371|C0030705|C0034656|C0065839|C0168634|G0000000|C0439231|C0030705|C0011065|C0032042|C0450371
"Methods and Results-After a 2-to 4-week placebo run-in, 1124 patients (mean sitting diastolic blood pressure [BP] 95 to 109 mm Hg) were randomized to aliskiren 150 mg (nÏ­459), hydrochlorothiazide 12.5 mg (nÏ­444), or placebo (nÏ­221) once daily.",methods results-after 2-to 4-week placebo run-in 1124 patients sitting diastolic blood pressure bp 95 109 mm hg randomized aliskiren 150 n459 hydrochlorothiazide 12 5 n444 placebo n221 daily,C0025663|C1274040|C0040363|C0332174|C0032042|C3274438|G0000000|C0030705|C0277814|C0012000|C0005767|C0033095|C0037623|C0450371|C1442061|G0000000|C0025424|C0034656|C1120110|C1442061|G0000000|C0020261|C0450371|G0000000|G0000000|C0032042|G0000000|C0332173
"Patients not meeting the eligibility requirements for BP after 2 weeks could continue for an additional 2 weeks to establish eligibility, after which patients not meeting the criteria were discontinued from the study.",patients meeting eligibility requirements bp 2 weeks continue additional 2 weeks establish eligibility patients meeting criteria discontinued study,C0030705|C0556656|C0013893|C1514873|C0037623|G0000000|C0439230|C0549178|C1524062|G0000000|C0439230|C0443211|C0013893|C0030705|C0556656|C0243161|C1444662|C0557651
"Forced titration (to aliskiren 300 mg or hydrochlorothiazide 25 mg) occurred at week 3; at week 6, patients receiving placebo were reassigned (1:1 ratio) to aliskiren 300 mg or hydrochlorothiazide 25 mg. From week 12, amlodipine 5 mg was added and titrated to 10 mg from week 18 for patients whose BP remained uncontrolled.",forced titration aliskiren 300 hydrochlorothiazide 25 occurred week 3 week 6 patients receiving placebo reassigned 1 1 ratio aliskiren 300 hydrochlorothiazide 25 week 12 amlodipine 5 titrated 10 week 18 patients bp remained uncontrolled,C0441722|C0162621|C1120110|C1442061|C0020261|C0450371|C1709305|C0332174|G0000000|C0332174|G0000000|C0030705|C1514756|C0032042|G0000000|G0000000|G0000000|C0456603|C1120110|C1442061|C0020261|C0450371|C0332174|C0450371|C0051696|G0000000|C1883350|C0450371|C0332174|C0450371|C0030705|C0037623|G0000000|C0205318
"Clinic BP was measured at baseline and at weeks 3, 6, 9, 12, 15, 18, 21, 26, 35, 44, and 52.",clinic bp measured baseline weeks 3 6 9 12 15 18 21 26 35 44 52,C0002424|C0037623|C0444706|C0168634|C0439230|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371|C0450371|C0450371|C0450371|C0450371|C0450371
"More than one chemotherapy drug for metastatic disease was allowed in the lapatinib trial, whereas, in our trial, the vast majority of the patients started capecitabine as second-line chemotherapy for metastatic disease.",chemotherapy drug metastatic disease allowed lapatinib trial trial vast majority patients started capecitabine second-line chemotherapy metastatic disease,C0013216|C0013227|C0036525|C0012634|C0683607|C1506770|C0008976|C0008976|C0814230|C0680220|C0030705|C1272689|C0671970|C0205436|C0013216|C0036525|C0012634
Trastuzumab treatment could be continued at the investigator's discretion while capecitabine was being withheld.,trastuzumab treatment continued investigators discretion capecitabine withheld,C0728747|C0039798|C0549178|C0035173|G0000000|C0671970|G0000000
HER-2 status was considered positive if overexpression was detected in either the primary or metastatic tumor tissue by local immunohistochemistry (grade 3Ï© staining intensity) or by fluorescence in situ hybridization.,her-2 status considered positive overexpression detected primary metastatic tumor tissue local immunohistochemistry grade 3 staining intensity fluorescence situ hybridization,G0000000|C0449438|C0750591|C0439178|C1514559|C0442726|C0205225|C0036525|C0027651|C0040300|C0205276|C0021044|C0441800|G0000000|C0487602|C0522510|C0016315|G0000000|C0020202
Participants were assessed clinically for tumor symptoms and toxicity and for hematology (weekly) and blood biochemistry every 3 weeks during treatment and every 3 months thereafter.,participants assessed clinically tumor symptoms toxicity hematology weekly blood biochemistry 3 weeks treatment 3 months,C0679646|C1516048|G0000000|C0027651|C0683368|C0040539|C0018943|C0332174|C0005767|C0005477|G0000000|C0439230|C0039798|G0000000|C0439231
Patients: 56 ASA physical status I and II adult patients scheduled for elective surgery requiring orotracheal intubation and general anesthesia.,patients 56 asa physical status ii adult patients scheduled elective surgery requiring orotracheal intubation anesthesia,C0030705|C0450371|C0004057|C0031809|C0449438|G0000000|C0001675|C0030705|C0086960|C0206058|C0038894|G0000000|G0000000|C0021925|C0002903
"Interventions: Patients were randomized to receive oropharyngeal instillation with either 5 mL 2% lidocaine (n = 28, lidocaine group) or 5 mL normal saline (n = 28, control group) 45 seconds after anesthetic induction bolus.",interventions patients randomized receive oropharyngeal instillation 5 2% lidocaine = 28 lidocaine 5 normal saline = 28 control 45 anesthetic induction bolus,C0886296|C0030705|C0034656|C1514756|C0521367|C0184959|G0000000|G0000000|C0023660|G0000000|C0450371|C0023660|G0000000|C0205307|C0036082|G0000000|C0450371|C0243148|C0450371|C0002932|C0205263|C1511237
Patients were randomly allocated to receive oropharyngeal instillation of either 5 mL 2% lidocaine (lidocaine group) or 5 mL normal saline (control group) via a 5 mL plastic syringe (without needle) 45 seconds after induction bolus.,patients randomly allocated receive oropharyngeal instillation 5 2% lidocaine lidocaine 5 normal saline control 5 plastic syringe needle 45 induction bolus,C0030705|G0000000|G0000000|C1514756|C0521367|C0184959|G0000000|G0000000|C0023660|C0023660|G0000000|C0205307|C0036082|C0243148|G0000000|C0032167|C0039142|C0027551|C0450371|C0205263|C1511237
An aseptic speculum examination was performed to confirm that the membranes had ruptured by noting the presence of pooling of amniotic fluid in the vaginal vault.,aseptic speculum examination performed confirm membranes ruptured noting presence pooling amniotic fluid vaginal vault,C0232920|C0037816|G0000000|C0884358|C0521093|C0025255|C0443294|C1316572|C0150312|C2349200|C0002630|C0005889|C0042232|C1550319
The 2 groups were compared using Ï 2 and unpaired t test where applicable.,2 compared 2 unpaired test applicable,G0000000|C1707455|G0000000|C2700112|C0022885|C1272460
"A detailed history was taken for all patients followed by clinical examination, and details were recorded on a standardized pretested proforma.",detailed history patients clinical examination details recorded standardized pretested proforma,C1522508|C0019664|C0030705|C0205210|G0000000|C1522508|C0034869|G0000000|C0033101|G0000000
"A sterile digital examination was then carried out in all patients to note cervical effacement, dilation, consistency, and cervical length.",sterile digital examination carried patients note cervical effacement dilation consistency cervical length,C0021359|C0442015|G0000000|C0206243|C0030705|C1316572|C0027530|C0552443|C0012359|C0332529|C0027530|C1444754
"Two women in the PGE2 gel group had an operative vaginal delivery by vacuum extraction, and 1 woman in the misoprostol group required an outlet forceps delivery.",women pge2 gel operative vaginal delivery vacuum extraction 1 woman misoprostol required outlet forceps delivery,C0043210|G0000000|C0017243|C1882154|C0042232|C0011209|C0042221|C0185115|G0000000|C0043210|C0085174|C1514873|C1709362|C0016533|C0011209
"In the misoprostol group, 5 (16.1%) women required oxytocin augmentation compared with 27 (90%) in the PGE2 group (P b 0.001).",misoprostol 5 16 1% women required oxytocin augmentation compared 27 90% pge2 0 001,C0085174|G0000000|C0450371|G0000000|C0043210|C1514873|C0030095|C1293122|C1707455|C0450371|C0450371|G0000000|G0000000|C1442061
Twenty-seven of 31 women (87.1%) in the misoprostol group and 25 of 30 women (83.3%) in the PGE2 group had a normal vaginal delivery (Table 2).,twenty-seven 31 women 87 1% misoprostol 25 30 women 83 3% pge2 normal vaginal delivery table 2,C0724000|C0450371|C0043210|C0450371|G0000000|C0085174|C0450371|C0450371|C0043210|C0450371|G0000000|G0000000|C0205307|C0042232|C0011209|C0039224|G0000000
Methods: Women with pregnancies between 37 and 42 weeks presenting with PROM at term and a Bishop score of 5 or less were randomly assigned to receive either a 4-hourly oral dose of 50 Âµg of misoprostol up to a maximum of 3 doses or 2 applications of intracervical PGE2 gel at a 6-hour interval.,methods women pregnancies 37 42 weeks prom term bishop score 5 randomly assigned receive 4-hourly oral dose 50 misoprostol maximum 3 doses 2 applications intracervical pge2 gel 6-hour interval,C0025663|C0043210|C0032961|C0450371|C0450371|C0439230|C0015944|C0233324|C1551458|C0449820|G0000000|G0000000|C1516050|C1514756|C0558292|C0442027|C0178602|C0450371|C0085174|C0806909|G0000000|C0178602|G0000000|C0185125|C0444978|G0000000|C0017243|C0439227|C1272706
"After intracoronary transplantation of BMMNC, no statistically significant changes were found on CK, CK-MB, homocysteine, PT, TT, APTT, FIB, INR, UN, creatinine, routine blood tests, blood cholesterol, blood glucose, blood pressure or ECG tests (data not shown).",intracoronary transplantation bmmnc statistically ck ck-mb homocysteine pt tt aptt fib inr creatinine routine blood tests blood cholesterol blood glucose blood pressure ecg tests data,C0595454|C0040732|G0000000|C0038215|C0009212|C0010290|C0019878|C0699718|C1452561|C0030605|C1414538|C0525032|C0010294|C0205547|C0005767|C0022885|C0005767|C0008377|C0005767|C0017725|C0005767|C0033095|C1623258|C0022885|C1511726
The control group did not undergo bone marrow aspiration and was injected with the same volume of heparinized saline as the BMMNC groups.,control undergo bone marrow aspiration injected volume heparinized saline bmmnc,C0243148|G0000000|C0262950|C0086590|C0220787|C1720154|C0449468|G0000000|C0036082|G0000000
One patient (2.4%) had transient acute heart failure in the BMMNC group 7 days after cell transplantation and one death (2.2%) occurred in the control group at 1 year follow-up.,patient 2 4% transient acute heart failure bmmnc 7 days cell transplantation death 2 2% occurred control 1 follow-up,C0030705|G0000000|G0000000|C0040704|C0205178|C0018787|C0231174|G0000000|G0000000|C0439228|C0007634|C0040732|C0011065|G0000000|G0000000|C1709305|C0243148|G0000000|C0589120
"Study limitations cell delivery in small animals, 29 we find molecular imaging techby guest on June 12, 2015 niques to be the ideal tools to further assess cellular therapy systematically in vivo.",study limitations cell delivery animals 29 molecular imaging techby guest june 12 2015 niques ideal tools assess cellular therapy systematically vivo,C0557651|C0449295|C0007634|C0011209|C0003062|C0450371|C1521991|C0011923|G0000000|G0000000|C3829443|C0450371|G0000000|G0000000|C1512612|C0336791|C1516048|C0007634|C0039798|G0000000|C1515655
All of the patients received medication in accordance with current guidelines for the management of patients with STEMI.,patients received medication current guidelines management patients stemi,C0030705|C1514756|C0013227|C0521116|C0162791|C0001554|C0030705|C3538872
"In the present study, stem cell therapy improved LVEF by 3.5% when compared with controls over a 4 years follow-up period.",study stem cell therapy improved lvef 3 5% compared controls 4 follow-up period,C0557651|C0242767|C0007634|C0039798|C0184511|C0428772|G0000000|G0000000|C1707455|C0243148|G0000000|C0589120|C0439531
"In addition, BP was measured monthly; specifically, systolic (SBP) and diastolic (DBP) BP were measured in triplicate with a mercury sphygmomanometer after 5 minutes in a supine position.",addition bp measured monthly systolic sbp diastolic dbp bp measured triplicate mercury sphygmomanometer 5 minutes supine position,C0332287|C0037623|C0444706|C0332177|C0039155|G0000000|C0012000|C0536221|C0037623|C0444706|C0205174|C0025424|C0183427|G0000000|C0439232|C0038846|C0733755
"At recruitment and 12 months after treatment, cardiac output and renal haemodynamics and function were evaluated by echocardiography and radionuclide studies, respectively.",recruitment 12 months treatment cardiac output renal haemodynamics function evaluated echocardiography radionuclide studies,C2949735|C0450371|C0439231|C0039798|C0018787|C1709366|C0022646|C0019010|C0031843|C0220825|C0013516|C0034595|C0947630
"At the end of the run-in period and at the end of the treatment period (12 months), clinical characteristics were evaluated and renal haemodynamic, laboratory and biochemical tests were performed.",run-in period treatment period 12 months clinical characteristics evaluated renal haemodynamic laboratory biochemical tests performed,C3274438|C0439531|C0039798|C0439531|C0450371|C0439231|C0205210|C1521970|C0220825|C0022646|C0019010|C0022877|C0205474|C0022885|C0884358
"After a run-in period of 14 days on placebo, the patients were randomized in a double-blind, prospective study to receive either bisoprolol 5 mg or losartan 50 mg, administered once daily for 1 year.",run-in period 14 days placebo patients randomized double-blind prospective study receive bisoprolol 5 losartan 50 administered daily 1,C3274438|C0439531|C0450371|C0439228|C0032042|C0030705|C0034656|C0013072|C0023981|C0557651|C1514756|C0053799|G0000000|C0126174|C0450371|C1521801|C0332173|G0000000
"Randomly assigned patients received anastrozole 1 mg/d orally (control) or trastuzumab (4 mg/kg by intravenous infusion on day 1, followed by 2 mg/kg weekly) plus anastrozole (1 mg/d orally); no patients received chemotherapy.",randomly assigned patients received anastrozole 1 mg/d orally control trastuzumab 4 mg/kg intravenous infusion day 1 2 mg/kg weekly anastrozole 1 mg/d orally patients received chemotherapy,G0000000|C1516050|C0030705|C1514756|C0290883|G0000000|C0439422|C0442027|C0243148|C0728747|G0000000|C0439272|C0348016|C0574032|C0332173|G0000000|G0000000|C0439272|C0332174|C0290883|G0000000|C0439422|C0442027|C0030705|C1514756|C0013216
Prior chemotherapy for MBC or adjuvant chemotherapy within 6 months was not permitted.,prior chemotherapy mbc adjuvant chemotherapy 6 months permitted,C0332152|C0013216|C0065839|C0001551|C0013216|G0000000|C0439231|C0329040
"Patients and Methods Postmenopausal women with HER2/hormone receptor-copositive MBC were randomly assigned to anastrozole (1 mg/d orally) with or without trastuzumab (4 mg/kg intravenous infusion on day 1, then 2 mg/kg every week) until progression.",patients methods postmenopausal women her2/hormone receptor-copositive mbc randomly assigned anastrozole 1 mg/d orally trastuzumab 4 mg/kg intravenous infusion day 1 2 mg/kg week progression,C0030705|C0025663|C0232970|C0043210|C0019932|C0597357|C0065839|G0000000|C1516050|C0290883|G0000000|C0439422|C0442027|C0728747|G0000000|C0439272|C0348016|C0574032|C0332173|G0000000|G0000000|C0439272|C0332174|C0242656
"Afterwards, there was 5 minutes of cool-down, 10 minutes of abdominal and spine resistance exercises, and 5 minutes of stretching and relaxing.",5 minutes cool-down 10 minutes abdominal spine resistance exercises 5 minutes stretching relaxing,G0000000|C0439232|C1548792|C0450371|C0439232|C0000726|C0037949|C0237834|C0015259|G0000000|C0439232|C0600080|C0542193
"The training model included 10 minutes of warm-up at 60% to 70% of maximal heart rate, followed by 4-minute intervals at 80% to 90% of maximal heart rate, when patients were riding an ergometric bicycle or were running.",training model included 10 minutes warm-up 60% 70% maximal heart rate 4-minute intervals 80% 90% maximal heart rate patients riding ergometric bicycle running,C0040607|C3161035|C0332257|C0450371|C0439232|C2350169|C0450371|C0450371|C0205289|C0018787|C0871208|C0439232|C1272706|C0450371|C0450371|C0205289|C0018787|C0871208|C0030705|G0000000|C0085143|C0005375|C0035953
Patients were randomized to either a highintensity interval training program for 6 months or usual care.,patients randomized highintensity interval training program 6 months usual care,C0030705|C0034656|G0000000|C1272706|C0040607|C1709697|G0000000|C0439231|C3538928|C1947933
"Echocardiography was performed in all patients at baseline (day 3 after primary PCI) and after 6 months of follow-up with standard parasternal and apical views using a VIVID 7 Dimension system (GE Vingmed Ultrasound AS, Horten, Norway).",echocardiography performed patients baseline day 3 primary pci 6 months follow-up standard parasternal apical views vivid 7 dimension system ge vingmed ultrasound horten norway,C0013516|C0884358|C0030705|C0168634|C0332173|G0000000|C0205225|C4049621|G0000000|C0439231|C0589120|C1442989|C0442146|C0205111|C0449911|C1268943|G0000000|C0439534|C0449913|C1292300|G0000000|C0041618|G0000000|C0028423
"In our study, we assessed the LV function using the new echocardiographic method-2-dimensional speckle tracking myocardial velocity and strain analysis.",study assessed lv function echocardiographic method-2-dimensional speckle tracking myocardial velocity strain analysis,C0557651|C1516048|C0023128|C0031843|C0013516|C0025663|C0439691|C0546881|C0027061|C0439830|C0080194|C0002778
"A total of 60 patients with first anterior wall STEMI and LV ejection fraction of <40%, treated with successful primary percutaneous coronary intervention were randomly assigned to the treatment group (BMSC group) or the control group in a 2:1 ratio.",total 60 patients anterior wall stemi lv ejection fraction <40% treated successful primary percutaneous coronary intervention randomly assigned treatment bmsc control 2 1 ratio,C0439175|C0450371|C0030705|C0205094|C0677535|C3538872|C0023128|C0302131|C1264633|C0450371|C1522326|C0597535|C0205225|C0522523|C0018787|C0886296|G0000000|C1516050|C0039798|G0000000|C0243148|G0000000|G0000000|C0456603
All the patients were successfully treated with primary PCI within 12 hours after the onset of symptoms.,patients treated primary pci 12 hours onset symptoms,C0030705|C1522326|C0205225|C4049621|C0450371|C0439227|C0206132|C0683368
"Within the third and sixth day after successful reperfusion of the AMI-related artery, the eligible patients were randomized and assigned to three groups: intracoronary route (AG), retrograde intravenous coronary route (VG), and control group (CG), in a 2:2:1 ratio, respectively.",sixth day successful reperfusion ami-related artery eligible patients randomized assigned intracoronary route ag retrograde intravenous coronary route vg control cg 2 2 1 ratio,C0205440|C0332173|C0597535|C0035124|C0439849|C0003842|C1548635|C0030705|C0034656|C1516050|C0595454|C0013153|C0002037|C0439784|C0348016|C0018787|C0013153|C0205999|C0243148|C0043444|G0000000|G0000000|G0000000|C0456603
Autologous bone marrow was aspirated from the posterior iliac crest under sedation and analgesia of the patients randomly assigned for the treatment group.,autologous bone marrow aspirated posterior iliac crest sedation analgesia patients randomly assigned treatment,C0439859|C0262950|C0086590|C0700198|C0205095|C0020889|C0332243|C0235195|C0002766|C0030705|G0000000|C1516050|C0039798
"The profile of bone-marrow cells, as well as the amount of cells used in this and other studies aiming at myocardial regeneration is variable, although there is evidence suggesting that there is no preferable bone-marrow cell population in the setting of intracoronary injection Further analyses with a higher number of patients are necessary so that subanalyses comparing the performance of myocardial segments in the infarct area of patients treated with the infarct area of patients of the control group can be carried out.",profile bone-marrow cells amount cells studies aiming myocardial regeneration variable evidence suggesting preferable bone-marrow cell population setting intracoronary injection analyses patients subanalyses comparing performance myocardial segments infarct patients treated infarct patients control carried,C1979963|C0005953|C0007634|C1265611|C0007634|C0947630|C1947946|C0027061|C0034963|C0439828|C3887511|C1705535|G0000000|C0005953|C0007634|C0032659|C0542559|C0595454|C0021485|C0002778|C0030705|G0000000|C1707455|C0597198|C0027061|C0441635|C0021308|C0030705|C1522326|C0021308|C0030705|C0243148|C0206243
"Treatment of patients with heart failure increasingly involves social and economic issues and the requirements for this treatment grow increasingly more complex cardiomyocytes -and once cell death has startedthey cannot be regenerated 1  June 24, 2008;accepted July 16, 2008. used the intracoronary route to inject autologous mononuclear bone marrow cells in a population of 10 patients after AMI.",treatment patients heart failure increasingly involves social economic issues requirements treatment grow increasingly complex cardiomyocytes -and cell death startedthey regenerated 1 june 24 2008 accepted july 16 2008 intracoronary route inject autologous mononuclear bone marrow cells population 10 patients ami,C0039798|C0030705|C0018787|C0231174|G0000000|G0000000|C0728831|C0013556|C0033213|C1514873|C0039798|G0000000|G0000000|C0439855|C0225828|G0000000|C0007634|C0011065|G0000000|C0334213|G0000000|C3829443|C0450371|G0000000|C1272684|C3829447|C0450371|G0000000|C0595454|C0013153|C1720154|C0439859|C1513475|C0262950|C0086590|C0007634|C0032659|C0450371|C0030705|G0000000
Patients were assigned to BMSC or control group by means of restricted randomization (permuted blocks randomization).,patients assigned bmsc control restricted randomization permuted blocks randomization,C0030705|C1516050|G0000000|C0243148|C0443288|C0034656|G0000000|C0028778|C0034656
"At 3, 6, and 12 months, the 2-day protocol with rest and dipyridamole studies were carried out.",3 6 12 months 2-day protocol rest dipyridamole studies carried,G0000000|G0000000|C0450371|C0439231|C0332173|C0442711|C0035253|C0012582|C0947630|C0206243
"Semi-quantitative evaluation of the images was based on the assessment of Tc-99m-MIBI uptake in the left ventricle divided into 16 myocardial segments and scored in a five-point scale by two independent observers blinded to group assignment; 5, no uptake; 4, severe defect; 3, moderate defect; 2, slight impairment of uptake; and 1, normal isotope uptake in a segment.",semi-quantitative evaluation images based assessment tc-99m-mibi uptake left ventricle divided 16 myocardial segments scored five-point scale independent observers blinded assignment 5 uptake 4 severe defect 3 moderate defect 2 slight impairment uptake 1 normal isotope uptake segment,C0522525|C0220825|C1704254|C1527178|C1261322|C0162680|C0243144|C0205091|C0018827|C0332849|C0450371|C0027061|C0441635|C0449820|C0205451|C0175659|C0085862|C0870992|C0150108|C1516050|G0000000|C0243144|G0000000|C0205082|C1457869|G0000000|C0205081|C1457869|G0000000|C2937276|C0221099|C0243144|G0000000|C0205307|C0022262|C0243144|C0441635
"The bonemarrow (BM) group received optimized therapy plus intracoronary transfer of autologous BMC after PCI, the control group (C) received optimized therapy only.",bonemarrow bm received optimized therapy intracoronary transfer autologous bmc pci control received optimized therapy,C0005953|C0006416|C1514756|G0000000|C0039798|C0595454|C0040671|C0439859|C0065839|C4049621|C0243148|C1514756|G0000000|C0039798
"Participants underwent CPET according to a modified Bruce protocol to measure maximum treadmill exercise time, peak VO 2 , and ventilatory response to exercise (VE/VCO 2 ).",participants underwent cpet modified bruce protocol measure maximum treadmill exercise time peak vo 2 ventilatory response exercise ve/vco 2,C0679646|G0000000|C0055954|C0392747|C1332417|C0442711|C0079809|C0806909|C0184069|C0015259|C0040223|C0444505|G0000000|G0000000|G0000000|C0871261|C0015259|C0042469|G0000000
"Of these, 19 patients received BMC (BM group) and 19 patients received no intracoronary cell infusion (C group).",19 patients received bmc bm 19 patients received intracoronary cell infusion,C0450371|C0030705|C1514756|C0065839|C0006416|C0450371|C0030705|C1514756|C0595454|C0007634|C0574032
"In order to further investigate this issue and the potential mechanisms of benefit from BMC in MI, we conducted a randomized, controlled trial-the Cellular Cardiomyoplasty by Autologous Intracoronary Mononuclear Bone Marrow in MI (CARDIAC) study, which was designed to assess the effects of intracoronary injections of autologous mononuclear BMC on LV function, 4 to 8 days after ST elevation MI treated with acute percutaneous coronary intervention (PCI).",investigate issue potential mechanisms benefit bmc mi conducted randomized controlled trial-the cellular cardiomyoplasty autologous intracoronary mononuclear bone marrow mi cardiac study designed assess effects intracoronary injections autologous mononuclear bmc lv function 4 8 days st elevation mi treated acute percutaneous coronary intervention pci,C1292732|C0033213|C3245505|C0441712|C0814225|C0065839|C3810814|C0004927|C0034656|C2587213|C0008976|C0007634|C0242637|C0439859|C0595454|C1513475|C0262950|C0086590|C3810814|C0018787|C0557651|C1707689|C1516048|C1280500|C0595454|C0021485|C0439859|C1513475|C0065839|C0023128|C0031843|G0000000|G0000000|C0439228|C0036056|C0439775|C3810814|C1522326|C0205178|C0522523|C0018787|C0886296|C4049621
"In addition, full blood count and immune-phenotype analyses of the cell suspension were performed, including absolute CD34 and CD45 positive cell count and five colour MoAb panel for the identification of the cellular subpopulation CD66b/CD33/CD45/CD11b/CD34, CD31/CD133/CD45/CD117/CD34, and CD71/CD105/CD45/CD38/ CD41.",addition blood count immune-phenotype analyses cell suspension performed including absolute cd34 cd45 positive cell count colour moab panel identification cellular subpopulation cd66b/cd33/cd45/cd11b/cd34 cd31/cd133/cd45/cd117/cd34 cd71/cd105/cd45/cd38/ cd41,C0332287|C0005767|C0750480|C0439662|C0002778|C0007634|C0038960|C0884358|C0332257|C0205344|G0000000|G0000000|C0439178|C0007634|C0750480|C0009393|C0003250|C0441833|C0020792|C0007634|C1257890|G0000000|G0000000|G0000000|G0000000
"Clopidogrel and Inflammatory Markers in Metabolic Syndrome population were -151 pg/mL (95% CI, -251.1 to -34.92 pg/mL) for the clopidogrel plus aspirin group and -33.8 pg/mL (95% CI, 185 to 120.4 pg/mL) for the placebo plus aspirin group (Table II,  Fig.",clopidogrel inflammatory markers metabolic syndrome population -151 pg/ml 95% ci -251 1 -34 92 pg/ml clopidogrel aspirin -33 8 pg/ml 95% ci 185 120 4 pg/ml placebo aspirin table ii fig,C0070166|C0333348|C0005516|C0311400|C0039082|C0032659|C1442061|C0439297|C0450371|C0008107|C1442061|G0000000|C0450371|C0450371|C0439297|C0070166|C0004057|C0450371|G0000000|C0439297|C0450371|C0008107|C1442061|C1442061|G0000000|C0439297|C0032042|C0004057|C0039224|G0000000|C0349966
"The adverse events that were observed only in the placebo plus aspirin group included peripheral edema, cardiac palpitations, dyslipidemia, and spinal stenosis.",adverse events observed placebo aspirin included peripheral edema cardiac palpitations dyslipidemia spinal stenosis,G0000000|C0441471|C1441672|C0032042|C0004057|C0332257|C0205100|C0013604|C0018787|C0030252|C0242339|C0521329|C0678234
Patients who had metabolic syndrome were randomized to receive clopidogrel 75 mg/ day plus aspirin 81 mg/day (n=89) or placebo plus aspirin 81 mg/day (n=92) for 9 weeks to assess the efficacy of each treatment in suppression of inflammatory markers.,patients metabolic syndrome randomized receive clopidogrel 75 mg/ day aspirin 81 mg/day n=89 placebo aspirin 81 mg/day n=92 9 weeks assess efficacy treatment suppression inflammatory markers,C0030705|C0311400|C0039082|C0034656|C1514756|C0070166|C0450371|C0026410|C0332173|C0004057|C0450371|C0439422|C0369718|C0032042|C0004057|C0450371|C0439422|C0369718|G0000000|C0439230|C1516048|C1280519|C0039798|C0221103|C0333348|C0005516
"At Week 0, consenting, eligible patients were randomly assigned to receive blinded treatment with clopidogrel 75 mg/day plus aspirin 81 mg/day or placebo plus aspirin 81 mg/day.",week 0 consenting eligible patients randomly assigned receive blinded treatment clopidogrel 75 mg/day aspirin 81 mg/day placebo aspirin 81 mg/day,C0332174|G0000000|C1511481|C1548635|C0030705|G0000000|C1516050|C1514756|C0150108|C0039798|C0070166|C0450371|C0439422|C0004057|C0450371|C0439422|C0032042|C0004057|C0450371|C0439422
"Minor adverse events that were observed only in the clopidogrel plus aspirin group included immune hypersensitivity, seasonal allergy, hematuria, and renal failure.",minor adverse events observed clopidogrel aspirin included immune hypersensitivity seasonal allergy hematuria renal failure,C0026193|G0000000|C0441471|C1441672|C0070166|C0004057|C0332257|C0439662|C0020517|C0439601|C0002111|C0018965|C0022646|C0231174
"Patients were stratified by hormone receptor and visceral disease status and randomly assigned in a 1:1 ratio to receive either oral lapatinib 1,500 mg daily or oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 2 mg/kg weekly (after the initial 4 mg/kg loading dose).",patients stratified hormone receptor visceral disease status randomly assigned 1 1 ratio receive oral lapatinib 1 500 daily oral lapatinib 1 000 daily combination intravenous trastuzumab 2 mg/kg weekly initial 4 mg/kg loading dose,C0030705|C0205363|C0019932|C0597357|C0442045|C0012634|C0449438|G0000000|C1516050|G0000000|G0000000|C0456603|C1514756|C0442027|C1506770|G0000000|C1442061|C0332173|C0442027|C1506770|G0000000|C1442061|C0332173|C0205195|C0348016|C0728747|G0000000|C0439272|C0332174|C0205265|G0000000|C0439272|C1708715|C0178602
The median OS time in the study was 51.6 weeks in patients receiving lapatinib plus trastuzumab compared with 39.0 weeks in patients receiving lapatinib monotherapy.,median os time study 51 6 weeks patients receiving lapatinib trastuzumab compared 39 0 weeks patients receiving lapatinib monotherapy,C0549183|C0229090|C0040223|C0557651|C0450371|G0000000|C0439230|C0030705|C1514756|C1506770|C0728747|C1707455|C0450371|G0000000|C0439230|C0030705|C1514756|C1506770|G0000000
Enalapril and carvedilol doses were titrated upward as tolerated during the first 4 weeks after diagnosis and then remained unchanged throughout the remainder of the 6-month study period.,enalapril carvedilol doses titrated upward tolerated 4 weeks diagnosis remained unchanged remainder 6-month study period,C0014025|C0054836|C0178602|C1883350|C1282911|G0000000|G0000000|C0439230|C0011900|G0000000|C0442739|G0000000|C0332177|C0557651|C0439531
Furosemide dose was decreased as indicated according to clinical assessment during the 6-month study period.,furosemide dose decreased clinical assessment 6-month study period,C0016860|C0178602|C0205216|C0205210|C1261322|C0332177|C0557651|C0439531
Patients with an LVEF Ï½25% or LV thrombus received anticoagulation therapy with warfarin for 6 months.,patients lvef 25% lv thrombus received anticoagulation therapy warfarin 6 months,C0030705|C0428772|C0450371|C0023128|C0087086|C1514756|C0003281|C0039798|C0043031|G0000000|C0439231
The 10 patients randomized to standard therapy plus bromocriptine (PPCM-Br) received bromocriptine 2.5 twice daily for 2 weeks followed by 2.5 mg daily for 6 weeks in addition to standard heart failure therapy.,10 patients randomized standard therapy bromocriptine ppcm-br received bromocriptine 2 5 daily 2 weeks 2 5 daily 6 weeks addition standard heart failure therapy,C0450371|C0030705|C0034656|C1442989|C0039798|C0006230|C3828544|C1514756|C0006230|G0000000|G0000000|C0332173|G0000000|C0439230|G0000000|G0000000|C0332173|G0000000|C0439230|C0332287|C1442989|C0018787|C0231174|C0039798
Carvedilol was added after resolution of overt heart failure.,carvedilol resolution overt heart failure,C0054836|C1514893|G0000000|C0018787|C0231174
"One group was assigned 80 mg fluvastatin XL once daily, the other was assigned placebo.",assigned 80 fluvastatin xl daily assigned placebo,C1516050|C0450371|C0082608|C4053562|C0332173|C1516050|C0032042
"At day 30, open-label statin therapy was initiated in all patients; at the end of one-year follow-up, 75% of patients were treated with statin in the fluvastatin group and 78% in placebo group (ns.).",day 30 open-label statin therapy initiated patients one-year follow-up 75% patients treated statin fluvastatin 78% placebo ns,C0332173|C0450371|C1709323|C0360714|C0039798|C1548602|C0030705|C4082117|C0589120|C0450371|C0030705|C1522326|C0360714|C0082608|C0450371|C0032042|C0038944
"Following signed informed consent, blood samples were taken for examination of serum markers of inflammation and plaque instability (CRP, IL-6, and PAPP-A/proMBP) and patients were randomized to fluvastatin 80 mg or placebo immediately p.o.",signed informed consent blood samples examination serum markers inflammation plaque instability crp il-6 papp-a/prombp patients randomized fluvastatin 80 placebo,C1519316|C1522154|C1511481|C0005767|C0370003|G0000000|C0229671|C0005516|C0021368|C0011389|C1444783|C3890735|C0020898|C0032999|C0030705|C0034656|C0082608|C0450371|C0032042
The fetal blood sampling rate was 10.6% in the index compared with 20.4% in the control group (relative risk 0.52; 95% [CI] 0.46-0.59).,fetal blood sampling rate 10 6% compared 20 4% control relative risk 0 52 95% ci 0 46-0 59,C0015965|C0005767|C0441621|C0871208|C0450371|G0000000|C1707455|C0450371|G0000000|C0243148|C0080103|C0035647|G0000000|C0450371|C0450371|C0008107|G0000000|C0450371|C0450371
OBJECTIVE: To estimate the effectiveness of intrapar-tum fetal monitoring by cardiotocography plus ST analysis using a strict protocol for performance of fetal blood sampling.,objective estimate effectiveness intrapar-tum fetal monitoring cardiotocography st analysis strict protocol performance fetal blood sampling,C0018017|C0750572|C1280519|C0723950|C0015965|C0150369|C0007208|C0036056|C0002778|G0000000|C0442711|C0597198|C0015965|C0005767|C0441621
"In women assigned to the control group, a scalp electrode was applied to the fetal head and connected to a conventional fetal heart rate monitor.",women assigned control scalp electrode applied fetal head connected conventional fetal heart rate monitor,C0043210|C1516050|C0243148|C0036270|C0013812|C4048755|C0015965|C0018670|C2986575|C0439858|C0015965|C0018787|C0871208|C0030695
METHODS: We performed a multicenter randomized trial among laboring women with a high-risk singleton pregnancy in cephalic presentation beyond 36 weeks of gestation.,methods performed multicenter randomized trial laboring women high-risk singleton pregnancy cephalic presentation 36 weeks gestation,C0025663|C0884358|C0439743|C0034656|C0008976|C0022864|C0043210|C0332167|C0481462|C0032961|C0205096|C0449450|C0450371|C0439230|C0032961
"After women had given written informed consent, they were randomized on a 1:1 basis through a web-based computer-generated randomization sequence with variable block size to either monitoring by cardiotocography plus ST analysis of the fetal ECG (index group) or cardiotocography alone (control group).",women written informed consent randomized 1 1 basis web-based computer-generated randomization sequence variable block size monitoring cardiotocography st analysis fetal ecg cardiotocography control,C0043210|C0043266|C1522154|C1511481|C0034656|G0000000|G0000000|C1527178|C0282111|C0009622|C0034656|C0004793|C0439828|C0028778|C0456389|C0150369|C0007208|C0036056|C0002778|C0015965|C1623258|C0007208|C0243148
"The drug was repeated every 4 h until regular uterine contractions or a Bishop's score of 8 or active labour had begun, or the cervix was suitable for amniotomy or a maximum up to 200 mg of dose.",drug repeated 4 regular uterine contractions bishops score 8 active labour begun cervix suitable amniotomy maximum 200 dose,C0013227|C0205341|G0000000|C0205272|C0042149|C1140999|C0649610|C0449820|G0000000|C0205177|C0022864|C0439659|C0007874|C3900053|G0000000|C0806909|C1442061|C0178602
"The commonest indication for LSCS in the oral group was nonprogress of labour (5/10, 50% vs 4/11, 36.36%; p Â¼ 0.588) and in the vaginal group it was non-reassuring fetal heart rate (3/10, 54.54% vs 6/11, 30%; p Â¼ 0.398).",commonest indication lscs oral nonprogress labour 5/10 50% 4/11 36 36% 0 588 vaginal non-reassuring fetal heart rate 3/10 54 54% 6/11 30% 0 398,C0205214|C0392360|C1332110|C0442027|G0000000|C0022864|C0450371|C0450371|C0450371|C0450371|C0450371|G0000000|C1442061|C0042232|C1518422|C0015965|C0018787|C0871208|C0450371|C0450371|C0450371|C0450371|C0450371|G0000000|C1442061
"Of 128 women enrolled, 68 (53.1%) received 50 mg of misoprostol vaginally (Group I) and 60 (46.9%) received the same dose orally (Group II).",128 women enrolled 68 53 1% received 50 misoprostol vaginally 60 46 9% received dose orally ii,C1442061|C0043210|G0000000|C0450371|C0450371|G0000000|C1514756|C0450371|C0085174|G0000000|C0450371|C0450371|G0000000|C1514756|C0178602|C0442027|G0000000
"Oxytocin augmentation was needed in 21.6% cases (13/60) in the oral group, as compared with 19.11% cases (13/68) in the vaginal group (p Â¼ 0.720).",oxytocin augmentation 21 6% 13/60 oral compared 19 11% 13/68 vaginal 0 720,C0030095|C1293122|C0450371|G0000000|C0450371|C0442027|C1707455|C0450371|C0450371|C0450371|C0042232|G0000000|C1442061
There were 2/68 (2.9%) cases of failed induction in the oral group in the present study.,2/68 2 9% failed induction oral study,C0450371|G0000000|G0000000|C0231175|C0205263|C0442027|C0557651
"Median duration of follow-up in the clopidogrel group was 364 days (minimum-maximum: 1-598), and 364 days (2-598) in the placebo group.",median duration follow-up clopidogrel 364 days minimum-maximum 1-598 364 days 2-598 placebo,C0549183|C0449238|C0589120|C0070166|C1442061|C0439228|C1524031|C1442061|C1442061|C0439228|C1442061|C0032042
"Methods: Patients undergoing unilateral, below-knee bypass graft for atherosclerotic peripheral arterial disease (PAD) were enrolled 2 to 4 days after surgery and were randomly assigned to clopidogrel 75 mg/day plus ASA 75 to 100 mg/day or placebo plus ASA 75 to 100 mg/day for 6 to 24 months.",methods patients undergoing unilateral below-knee bypass graft atherosclerotic peripheral arterial disease pad enrolled 2 4 days surgery randomly assigned clopidogrel 75 mg/day asa 75 100 mg/day placebo asa 75 100 mg/day 6 24 months,C0025663|C0030705|G0000000|C0205092|C0542339|C0741847|C0181074|C0333482|C0205100|C0003842|C0012634|C0182158|G0000000|G0000000|G0000000|C0439228|C0038894|G0000000|C1516050|C0070166|C0450371|C0439422|C0004057|C0450371|C1442061|C0439422|C0032042|C0004057|C0450371|C1442061|C0439422|G0000000|C0450371|C0439231
"Results: In the overall population, the primary endpoint occurred in 149 of 425 patients in the clopidogrel group vs 151 of 426 patients in the placebo (plus ASA) group (hazard ratio [HR], 0.98; 95% confidence interval [CI], 0.78-1.23).",population primary endpoint occurred 149 425 patients clopidogrel 151 426 patients placebo asa hazard ratio hr 0 98 95% confidence interval ci 0 78-1 23,C0032659|C0205225|C2349179|C1709305|C1442061|C1442061|C0030705|C0070166|C1442061|C1442061|C0030705|C0032042|C0004057|C0598697|C0456603|G0000000|G0000000|C0450371|C0450371|C0237529|C1272706|C0008107|G0000000|C0450371|C0450371
Treatment was permanently discontinued by 88 patients (21.0%) in the placebo group and 107 patients (25.2%) in the clopidogrel group.,treatment permanently discontinued 88 patients 21 0% placebo 107 patients 25 2% clopidogrel,C0039798|G0000000|C1444662|C0450371|C0030705|C0450371|G0000000|C0032042|C1442061|C0030705|C0450371|G0000000|C0070166
"Therefore, we conducted a randomized controlled trial comparing aspirin plus clopidogrel with aspirin alone in CABG patients revascularized with at least 1 saphenous vein.",conducted randomized controlled trial comparing aspirin clopidogrel aspirin cabg patients revascularized 1 saphenous vein,C0004927|C0034656|C2587213|C0008976|C1707455|C0004057|C0070166|C0004057|C0010055|C0030705|G0000000|G0000000|G0000000|C0042449
Objectives We sought to evaluate the effect of aspirin plus clopidogrel versus aspirin alone on saphenous vein graft occlu-sion at 3 months after coronary artery bypass grafting (CABG).,objectives sought evaluate aspirin clopidogrel versus aspirin saphenous vein graft occlu-sion 3 months coronary artery bypass grafting cabg,C0018017|G0000000|C0220825|C0004057|C0070166|G0000000|C0004057|G0000000|C0042449|C0181074|C1518532|G0000000|C0439231|C0018787|C0003842|C0741847|C0332835|C0010055
"The primary endpoint-improvement of myocardial viability-was defined as a gain of at least 2/17 viable segments 3 months after STEMI, assessed by resting 4 h thallium-201-gated-SPECT.",primary endpoint-improvement myocardial viability-was defined gain 2/17 viable segments 3 months stemi assessed resting 4 thallium-201-gated-spect,C0205225|C2349179|C0027061|C0443348|C1704788|C1517378|C0450371|C0443348|C0441635|G0000000|C0439231|C3538872|C1516048|C0035253|G0000000|C0039738
"To analyse the primary endpoint of improvement of myocardial viability (Figure 2A), SPECT images were obtained from 43 and 47 patients in the control and BMC groups, respectively.",analyse primary endpoint improvement myocardial viability figure 2a spect images 43 47 patients control bmc,G0000000|C0205225|C2349179|C2986411|C0027061|C0443348|G0000000|C1420849|C0040399|C1704254|C0450371|C0450371|C0030705|C0243148|C0065839
"In a multivariate logistic regression analysis (Figure 3), including CV risk factors, time to PCI and the presence of microvascular obstruction on MRI, BMC infusion was significantly associated with improvement of myocardial viability (P Â¼ 0.03).",multivariate logistic regression analysis figure 3 including cv risk factors time pci presence microvascular obstruction mri bmc infusion improvement myocardial viability 0 03,G0000000|C0242415|C0684320|C0002778|G0000000|G0000000|C0332257|C3538987|C0035647|C1521761|C0040223|C4049621|C0150312|C0443258|C0028778|C0024485|C0065839|C0574032|C2986411|C0027061|C0443348|G0000000|C0450371
"In the BMC group, two patients were excluded before bone marrow aspiration because of a transient ischaemic attack and a randomization error; one patient did not have bone marrow aspiration because of thrombopenia induced by a GP2b3a inhibitor.",bmc patients excluded bone marrow aspiration transient ischaemic attack randomization error patient bone marrow aspiration thrombopenia induced gp2b3a inhibitor,C0065839|C0030705|C1554077|C0262950|C0086590|C0220787|C0040704|C0475224|C0277793|C0034656|C0743559|C0030705|C0262950|C0086590|C0220787|C0040034|C0205263|G0000000|C1999216
"We have chosen the change in regional systolic myocardial function measured by MRI as our primary endpoint, based on the assumption that regional function is more sensitive than global LV function for the evaluation of cell therapy.",chosen change regional systolic myocardial function measured mri primary endpoint based assumption regional function sensitive global lv function evaluation cell therapy,C1707391|C0392747|C0205147|C0039155|C0027061|C0031843|C0444706|C0024485|C0205225|C2349179|C1527178|G0000000|C0205147|C0031843|C0020517|C0205246|C0023128|C0031843|C0220825|C0007634|C0039798
"For the comparison of changes in MRI variables between groups, analysis of covariance was used including treatment group as the main factor Intracoronary cell infusion was performed between 3 and 8 days after PCI with a median of 6 days in the BM group and 5 days in the peripheral blood group.",comparison mri variables analysis covariance including treatment main factor intracoronary cell infusion performed 3 8 days pci median 6 days bm 5 days peripheral blood,C1707455|C0024485|C0439828|C0002778|G0000000|C0332257|C0039798|C0205225|C1521761|C0595454|C0007634|C0574032|C0884358|G0000000|G0000000|C0439228|C4049621|C0549183|G0000000|C0439228|C0006416|G0000000|C0439228|C0205100|C0005767
"In all samples derived from the selection procedure, cell viability was measured with propidium iodide staining by flow cytometry.",samples derived selection procedure cell viability measured propidium iodide staining flow cytometry,C0370003|C1441547|C0036576|C0184661|C0007634|C0443348|C0444706|C0033468|C0021966|C0487602|C0806140|C0814048
"Cardiac dynamic PET images were obtained at the same time as the mean 20-s administration under resting conditions of an intravenous injection of [ 13 N]ammonia diluted in 10 ml of saline solution, with a mean activity of 707 MBq (9.25 MBq/kg).",cardiac dynamic pet images time 20-s administration resting conditions intravenous injection 13 nammonia diluted 10 saline solution activity 707 mbq 9 25 mbq/kg,C0018787|C0729333|C0031268|C1704254|C0040223|C0450371|C0001554|C0035253|C0012634|C0348016|C0021485|C0450371|G0000000|C1720119|C0450371|C0036082|C0037633|C0205177|C1442061|C0556640|G0000000|C0450371|C2346983
"The cells were produced in a class B room under a class A biosafety cabinet, with a closed automated system (Miltenyi CliniMACS System; Miltenyi Biotec, Bergisch Gladbach, Germany) being used to select the cells immunomagnetically, which were then resuspended in 10 ml (AE2) of normal saline solution (0.9% NaCl) with 10% human serum albumin.",cells produced class class biosafety cabinet closed automated system miltenyi clinimacs system miltenyi biotec bergisch gladbach germany select cells immunomagnetically resuspended 10 ae2 normal saline solution 0 9% nacl 10% human serum albumin,C0007634|G0000000|C0456387|C0456387|G0000000|C0179481|C0587267|C0205554|C0449913|G0000000|G0000000|C0449913|G0000000|G0000000|G0000000|G0000000|C0017480|C1707391|C0007634|G0000000|G0000000|C0450371|C1970109|C0205307|C0036082|C0037633|G0000000|G0000000|C0037494|C0450371|C0086418|C0229671|C0001924
Patients with HER2 negative tumors were included in arm C without further randomization and received letrozole 2.5 mg once daily until progression of disease.,patients her2 negative tumors included arm randomization received letrozole 2 5 daily progression disease,C0030705|G0000000|C0205160|C0027651|C0332257|C0446516|C0034656|C1514756|C0246421|G0000000|G0000000|C0332173|C0242656|C0012634
"Patients with HER2 and HR positive MBC or LABC were randomized to either letrozole alone (arm A, n Â¼ 31) or letrozole plus trastuzumab (arm B, n Â¼ 26) as first-line treatment.",patients her2 hr positive mbc labc randomized letrozole arm 31 letrozole trastuzumab arm 26 first-line treatment,C0030705|G0000000|G0000000|C0439178|C0065839|G0000000|C0034656|C0246421|C0446516|C0450371|C0246421|C0728747|C0446516|C0450371|C0205435|C0039798
The secondary outcome measures were the time interval from the first dose of misoprostol to vaginal delivery; the percentage of women who delivered vaginally within 12 hours and 24 hours after beginning labor induction; the incidence of tachysystole or nonreassuring FHR pattern; rate of women given oxytocin; the percentage of cesarean deliveries performed; and poor neonatal outcomes defined as low Apgar score (less than 7 at 1 or 5 minutes) and admission to the neonatal intensive care unit.,secondary outcome measures time interval dose misoprostol vaginal delivery percentage women delivered vaginally 12 hours 24 hours labor induction incidence tachysystole nonreassuring fhr pattern rate women oxytocin percentage cesarean deliveries performed poor neonatal outcomes defined low apgar score 7 1 5 minutes admission neonatal intensive care unit,C0027627|C1274040|C0079809|C0040223|C1272706|C0178602|C0085174|C0042232|C0011209|C0439165|C0043210|C1705822|G0000000|C0450371|C0439227|C0450371|C0439227|C0022864|C0205263|C0021149|C2985339|G0000000|G0000000|C0449774|C0871208|C0043210|C0030095|C0439165|C3841297|C0011209|C0884358|C0032854|C1552240|C1274040|C1704788|C0205251|C0741195|C0449820|G0000000|G0000000|G0000000|C0439232|C0184666|C1552240|C0162425|C1947933|C0439148
"If a favorable cervix or adequate uterine contractions were not achieved after the first 4 doses, the dose was doubled to 40 Î¼g administered every hour and was prepared by dissolving 1 tablet in 100 mL of tap water (40 Î¼g/20 mL).",favorable cervix adequate uterine contractions achieved 4 doses dose doubled 40 administered hour prepared dissolving 1 tablet 100 tap water 40 g/20,C3640814|C0007874|C0205410|C0042149|C1140999|G0000000|G0000000|C0178602|C0178602|C0205173|C0450371|C1521801|C0439227|C4082130|C1549535|G0000000|C0039225|C1442061|C0034115|C0043047|C0450371|C0439267
"For the titrated group, 1 tablet was dissolved in 200 mL of tap water in a medicine bottle by an administrative nurse not involved in patient care.",titrated 1 tablet dissolved 200 tap water medicine bottle administrative nurse involved patient care,C1883350|G0000000|C0039225|C1549535|C1442061|C0034115|C0043047|C0013227|C0179376|C1292785|C0028661|C1314939|C0030705|C1947933
"For the rehabilitation group, the researcher checked the patient's progress, encouraged adherence to exercise, and helped solve problems that had arisen using the manual.",rehabilitation researcher checked patients progress encouraged adherence exercise helped solve arisen manual,C0034991|C0035173|C1283174|C0030705|C1272688|G0000000|C1510802|C0015259|C1269765|G0000000|G0000000|C0024763
"The usual care group received instructions on taking medications, information leaflets about cardiac risk factors, a healthy diet, and smoking cessation, and a follow-up appointment.",usual care received instructions medications leaflets cardiac risk factors healthy diet smoking cessation follow-up appointment,C3538928|C1947933|C1514756|C0302828|C0013227|C1708664|C0018787|C0035647|C1521761|C3898900|C0012155|C0037369|C1880019|C0589120|C0003629
The rehabilitation group received the manual and the introductory session in addition to usual care.,rehabilitation received manual introductory session addition usual care,C0034991|C1514756|C0024763|G0000000|C1883016|C0332287|C3538928|C1947933
Participants in both groups received a blinded pedometer (Yamax Digiwalker NL-2000) as well as instructions about how to wear the pedometer correctly during 7 consecutive days from morning to bedtime.,participants received blinded pedometer yamax digiwalker nl-2000 instructions wear pedometer correctly 7 consecutive days morning bedtime,C0679646|C1514756|C0150108|C2709220|G0000000|G0000000|C0027778|C0302828|G0000000|C2709220|G0000000|G0000000|C1707491|C0439228|C0332170|C0521112
"Nevertheless, participants in the intervention group did use 1 pedometer blinded (Yamax Digiwalker NL-2000) and used a second one to monitor their daily steps (Yamax Digiwalker SW-200) since discharge.",participants intervention 1 pedometer blinded yamax digiwalker nl-2000 monitor daily steps yamax digiwalker sw-200 discharge,C0679646|C0886296|G0000000|C2709220|C0150108|G0000000|G0000000|C0027778|C0030695|C0332173|C1261552|G0000000|G0000000|C0038995|C0012621
Subjects in both groups received usual medical follow-up by their own physicians (cardiologist and family physician).,subjects received usual medical follow-up physicians cardiologist family physician,C0681850|C1514756|C3538928|C0199168|C0589120|C0031831|C0175906|C0015576|C0031831
"Exercise training was the largest component, typically occupying half of the available time including warm up and cool down, and used exercise equipment in physiotherapy gyms.",exercise training largest component typically occupying half time including warm cool exercise equipment physiotherapy gyms,C0015259|C0040607|C0443228|C0449432|G0000000|G0000000|C2825407|C0040223|C0332257|C0184348|C1548792|C0015259|C0014672|C0949766|G0000000
"All patients in the trial (and in the 'elective hospitals' comparison) had similar care in all respects other than referral to cardiac rehabilitation, receiving available explanatory booklets, being advised to see their general practitioner (GP) and attend routine outpatient follow-up, with referral for further cardiac investigations or interventions as appropriate.",patients trial elective hospitals comparison care respects referral cardiac rehabilitation receiving explanatory booklets advised practitioner gp attend routine outpatient follow-up referral cardiac investigations interventions,C0030705|C0008976|C0206058|C0019994|C1707455|C1947933|C0679133|C0034927|C0018787|C0034991|C1514756|C0681841|C0030258|G0000000|C1709627|C3811116|C1999232|C0205547|C0029921|C0589120|C0034927|C0018787|C1261322|C0886296
They took place weekly or bi-weekly and averaged 20 h over 6e8 weeks.,weekly bi-weekly averaged 20 6e8 weeks,C0332174|C0332174|C1510992|C0450371|G0000000|C0439230
"In the operating room, an 18 G intravenous cannula was inserted in an appropriate antecubital vein and ringer's solution was started, at 10 ml/kg per h throughout the study period.",operating 18 intravenous cannula inserted antecubital vein ringers solution started 10 ml/kg study period,C3242339|C0450371|C0348016|C0520453|C0441587|C1549091|C0042449|C1875730|C0037633|C1272689|C0450371|C1300574|C0557651|C0439531
"After preoxygenation, anaesthesia was induced with thiopental 5 mg/kg, fentanyl 3 Âµg/kg and atracurium 0.5 mg/kg.",preoxygenation anaesthesia induced thiopental 5 mg/kg fentanyl 3 g/kg atracurium 0 5 mg/kg,C0412792|C0002903|C0205263|C0039925|G0000000|C0439272|C0015846|G0000000|C1300563|C0004234|G0000000|G0000000|C0439272
"The patients were randomly allocated to one of three groups according to the agents to be used before the induction of anaesthesia: Control group received oral placebo (n = 32, Group P), patients who received 800 mg of gabapentin (n = 32, Group G), and those patients who received 0.3 mg of clonidine (n = 32, Group C) 90 minutes prior to surgery.",patients randomly allocated agents induction anaesthesia control received oral placebo = 32 patients received 800 gabapentin = 32 patients received 0 3 clonidine = 32 90 minutes prior surgery,C0030705|G0000000|G0000000|C0450442|C0205263|C0002903|C0243148|C1514756|C0442027|C0032042|G0000000|C0450371|C0030705|C1514756|C1442061|C0060926|G0000000|C0450371|C0030705|C1514756|G0000000|G0000000|C0009014|G0000000|C0450371|C0450371|C0439232|C0332152|C0038894
"Methods: The authors assigned 378 mild hypertensive outpatients in sinus rhythm, but with â¥2 episodes of AF in the previous 6 months, to 1 of 2 groups.",methods authors assigned 378 mild hypertensive outpatients sinus rhythm 2 episodes af previous 6 months 1 2,C0025663|C3812881|C1516050|C1442061|C2945599|C0857121|C0029921|C0016169|C0871269|G0000000|C0332189|C0344434|C0205156|G0000000|C0439231|G0000000|G0000000
The secondary endpoint was the time to a first ECG-documented recurrence of AF.,secondary endpoint time ecg-documented recurrence af,C0027627|C2349179|C0040223|C1623258|C0034897|C0344434
"In both groups, patients were randomly treated with telmisartan or amlodipine for 1 year.",patients randomly treated telmisartan amlodipine 1,C0030705|G0000000|C1522326|C0248719|C0051696|G0000000
The primary endpoint of the study was to assess the efficacy of telmisartan as compared with amlodipine with regard to cumulative number of patients relapsing into documented AF.,primary endpoint study assess efficacy telmisartan compared amlodipine regard cumulative patients relapsing documented af,C0205225|C2349179|C0557651|C1516048|C1280519|C0248719|C1707455|C0051696|G0000000|C1511559|C0030705|C0035020|C1301725|C0344434
The primary end point was assessment of whether the addition of clopidogrel to aspirin increases the number of patients fully responding to platelet inhibition after off-pump CABG.,primary assessment addition clopidogrel aspirin increases patients responding platelet inhibition off-pump cabg,C0205225|C1261322|C0332287|C0070166|C0004057|C0205217|C0030705|G0000000|C0005821|C0021467|C1518543|C0010055
Antiplatelet drugs were administered when postoperative chest tube drainage was <50 ml/h for two consecutive hours and were continued daily for 12 months.,antiplatelet drugs administered postoperative chest tube drainage <50 ml/h consecutive hours continued daily 12 months,G0000000|C0013227|C1521801|C0032790|C0817096|C0175730|C0012621|C0450371|C0439391|C1707491|C0439227|C0549178|C0332173|C0450371|C0439231
All patients underwent off-pump CABG through a median sternotomy.,patients underwent off-pump cabg median sternotomy,C0030705|G0000000|C1518543|C0010055|C0549183|C0185792
"In our opinion, the daily dose of clopidogrel 75 mg plus aspirin 100 mg was, perhaps, the best compromise between antithrombotic effectiveness and safety in our patients.",opinion daily dose clopidogrel 75 aspirin 100 compromise antithrombotic effectiveness safety patients,C0871010|C0332173|C0178602|C0070166|C0450371|C0004057|C1442061|C2945640|G0000000|C1280519|C0036043|C0030705
"METHODS Study Design This was a 42-week, single-center, randomized, controlled , double-blind study.",methods study design 42-week single-center randomized controlled double-blind study,C0025663|C0557651|C1707689|C0450371|C0037179|C0034656|C2587213|C0013072|C0557651
"Overall, 125 postmenopausal hypertensive women (age, 61.4AE6 years; systolic blood pressure â diastolic blood pressure [SBP â DBP], 158AE11 â 92AE9 mm Hg) were randomized to valsartan 320 mgAEhydrochlorothiazide (HCTZ) (n=63) or amlodipine 10 mgAEHCTZ (n=62).",125 postmenopausal hypertensive women age 61 4ae6 systolic blood pressure diastolic blood pressure sbp dbp 158ae11 92ae9 mm hg randomized valsartan 320 mgaehydrochlorothiazide hctz n=63 amlodipine 10 mgaehctz n=62,C1442061|C0232970|C0857121|C0043210|C0001779|C0450371|G0000000|C0039155|C0005767|C0033095|C0012000|C0005767|C0033095|G0000000|C0536221|G0000000|G0000000|G0000000|C0025424|C0034656|C0216784|C1442061|G0000000|C0020261|C0369718|C0051696|C0450371|G0000000|C0369718
"The present study comprised (1) a 4-week screening period (a 2-week wash-out period and a 2-week placebo run-in phase), and (2) a 38-week double-blind treatment period.",study comprised 1 4-week screening period 2-week wash-out period 2-week placebo run-in phase 2 38-week double-blind treatment period,C0557651|C2700400|G0000000|C0332174|C0220908|C0439531|C0332174|C0441648|C0439531|C0332174|C0032042|C3274438|C0205390|G0000000|C0450371|C0013072|C0039798|C0439531
"All eligible patients were randomized (1:1) to receive valsartan 160 mg or amlodipine 5 mg. After 4 weeks of treatment , patients were force-titrated to valsartan 320 mg and amlodipine 10 mg until the end of the study.",eligible patients randomized 1 1 receive valsartan 160 amlodipine 5 4 weeks treatment patients force-titrated valsartan 320 amlodipine 10 study,C1548635|C0030705|C0034656|G0000000|G0000000|C1514756|C0216784|C1442061|C0051696|G0000000|G0000000|C0439230|C0039798|C0030705|C0441722|C0216784|C1442061|C0051696|C0450371|C0557651
"The 17-segment model for regional wall motion analysis of LV and LVEF was evaluated before, and 1 and 6 months after intracoronary infusion of bone marrow cells.",17-segment model regional wall motion analysis lv lvef evaluated 1 6 months intracoronary infusion bone marrow cells,C0450371|C3161035|C0205147|C0677535|C0026597|C0002778|C0023128|C0428772|C0220825|G0000000|G0000000|C0439231|C0595454|C0574032|C0262950|C0086590|C0007634
Selective coronary and left ventricular (LV) angiography were carried out according to the standard Seldinger method.,selective coronary left ventricular lv angiography carried standard seldinger method,C0036576|C0018787|C0205091|C0018827|C0023128|C0002978|C0206243|C1442989|G0000000|C0025663
